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Abstract 
West Nile virus (WNV) is one of the most widely spread emerging neurotropic 
flaviviruses. It is found in Asia, Africa and Europe and is closely related to Japanese 
encephalitis (JE), Murray Valley encephalitis (MVE) and Saint Louis encephalitis (SLE) 
viruses. Recently, this virus received world attention due to epidemic outbreaks in the 
new world, including USA, Europe and Russia associated with some 10% mortality on 
each occasion. Although pathogenesis of WNV encephalitis has been studied to some 
extent, still very little is known. Such studies have used neonatal or young mice as a 
model. These do not accurately reflect the pathogenesis of disease in adult mice due to 
immaturity of the immune system which facilitates severe encephalitis. Therefore, an 
adult model using a systemic route of WNV inoculation was developed in this project to 
understand better the mechanisms of pathogenesis of WNV encephalitis. This model 
exhibits similar histopathological and clinical features of human disease. Since IFN -y is 
critical for resolution of many viral infections, its role in WNV encephalitis was 
investigated using IFN-y-deficient (B6.IFN-y-/-) mice compared to the corresponding 
wildtype (B6.WT) mice. 
Survival studies after intraperitoneal (i.p.) inoculation (i.p. model) showed that more than 
twice the number of B6.IFN-y-/- mice survived compared to B6.WT mice. Upon 
rechallenged with a 50-fold higher dose of WNV surviving mice were completely 
protected. Using immunoperoxidase labelling and plaque assay techniques, WNV antigen 
(Ag) was detected from day 6 post infection (p.i.) in the brain but was undetectable after 
day 11 p.i. Replicating WNV was only detectable between day 6 and 10 p.i. in both 
groups. The maximum virus titres were 2.23 log10 pfu/gm in B6.WT and 2.22 log10 
pfu/gm in B6.IFN-y-/- mice on day 8 p.i. WNV Ag was confined to the neurones and 
their dendrites. The kinetics of infection of WNV was similar in both groups, however, 
twice the number of B6.IFN-y-/- brains showed neuronal infection from day 6-11 (p.i.). 
There was no significant difference in the number of infected neurones and the virus 
titres between the groups. 
Leukocyte migration into the CNS is a hallmark feature of viral encephalitis. Using 
hematoxylin and eosin (H and E) staining in paraffin sections, infiltration of leukocytes 
v 
into the brain parenchyma was determined and quantitated. In both groups, leukocyte 
infiltration was evident from day 5 p.i. consisting of both mononuclear and 
polymorphonuclear leukocytes with perivascular cuffing. In B6.WT, leukocyte 
infiltration was significantly (p=<0.001) increased from day 7 p.i., compared to day 5 and 
6 and significantly decreased by day 9 p.i. (p=<0.001) compared to day 7 p.i. In 
B6.IFN-y-/- mice, leukocyte infiltration peaked on day 8, decreased by day 9 p.i. 
However, in both groups of mice, the number of infiltrating leukocytes returned nearly to 
baseline values by day 15 p.i and leukocytes were undetectable by day 30 p.i. Although 
the kinetics of leukocyte infiltration were similar between the groups, approximately 
4-fold higher numbers of leukocytes were observed in the brain parenchyma of B6.WT 
compared to B6.IFN-y-/- mice on day 7 p.i. 
Expression of intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1) in the neurovascular endothelial cells is required to facilitate the 
transmigration of leukocytes into the CNS. Using immunoperoxidase labelling, 
expression of these adhesion molecules in the neurovascular endothelium was determined 
and the number of blood vessels positive for these molecules was quantitated. There was 
no constitutive expression of ICAM-1 in the neurovascular vessels in B6.WT mice. It 
was expressed at low levels initially at day 3 p.i., increased by day 6 p.i., and was 
maximal on day 9 p.i. In B6.IFN-y-/- mice, ICAM-1 was constitutively expressed in the 
vessels, upregulated by day 3 p.i., numbers peaking on days 8 and 10 p.i. The number of 
ICAM-1 positive vessels was significantly higher (p=<0.001 on each day) in B6.IFN-y-/-
mice from day 6 onwards compared to B6.WT mice. In both groups of mice, the number 
of vessels expressing ICAM-1 returned to nearly baseline values by day 15 p.i. In 
addition to this, ICAM-1 was also expressed on the microglia in B6.IFN-y-/- mice from 
day 6 p.i., but not on those from B6.WT mice at any timepoint. More than 85% mice 
were postive for microglial ICAM-1 expression. The number of microglia expressing 
ICAM-1 was quantitated. The number of ICAM-1-positive vessels increased at least 24h 
before ICAM-1-positive microglia. Microglia and vessels thus expressed increased 
ICAM-1 with different kinetics in B6.IFN-y-/- mice. Microglia expressed ICAM-1 earlier 
than activation detected by GS-lectin. Significantly higher numbers of microglia were 
expressing ICAM-1 (p=<0.05) on day 6-8 compared to activated microglia, however on 
day 9-10 p.i. the numbers of cells positive for both were nearly equal and both returned to 
nearly baseline levels on day 15 p.i. 
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Unlike ICAM-1, VCAM-1 was not constitutively expressed in either group and increased 
significantly after infection with similar kinetics. In B6.WT mice, VCAM-1 was 
expressed from day 5 p.i., and was maximal on day 9, whereas in B6.IFN-y-/- mice, 
VCAM-1 was expressed from day 3 p.i., peaking on day 9 p.i. approximately 3-fold 
higher (p=<0.001) than in B6.WT. However, in both groups, the number of vessels 
positive for VCAM-1 declined nearly to baseline values from day 15 p.i. Despite 
significantly increased CAM levels, significantly less leukocyte infiltration was observed 
in the brain parenchyma of B6.IFN-y-/- mice. 
Microglia and astrocytes are immunocompetent cells of the CNS. Expression of glial 
fibrillary acidic protein (GFAP) and isolectin-B4 derived from Griffonia simplicifolia 
(GS-lectin) were used as markers of astrocyte and microglial activation, respectively, and 
the number of activated glial cells were quantitated. In both groups of mice, astrocytes 
were extremely rarely activated. Thus the presence or absence of IFN-y did not influence 
astrocyte activation. In contrast, microglia were highly activated in both groups of mice, 
independently of IFN-y, from day 7 p.i. onwards. Microglial activation was associated 
with various altered morphologies as well as nodule formation. Microglial activation was 
observed after 24h of neuronal infection in both groups. In B6.WT mice, activation of 
microglia was significantly increased on days 7-11 (p=<0.001), peaking on day 10 p.i. 
whereas in B6.IFN-y-/- mice, the number of activated microglia was significantly 
increased on days 8-11 (p=<0.001), peaking on day 9 p.i. However, in both groups of 
mice, the number of activated microglia and their activated morphology, returned to 
nearly baseline values and their normal state, respectively, from day 15 p.i., after WNV 
Ag was undetectable. These values returned completely to baseline values at day 30 p.i. 
Although the kinetics of activation was similar between the groups, significantly higher 
(p=<0.001) numbers of microglia were activated in B6.IFN-y-/- compared to B6.WT 
mice on day 9 p.i. Microglial nodules were observed from day 7 p.i. in both groups. In 
B6.WT, the number of nodules peaked on day 10 and 11 p.i. whereas in B6.IFN-y-/- mice 
they were maximal on day 9 p.i. However, in both groups, the number of nodules had 
decreased by day 15 p.i., concurrent with the return to normal resting microglial 
morphology. Despite the significant numbers of nodules formed, neuronal death occurred 
in <1% infected neurones that had microglial nodules around them. Since microglia are 
regarded as antigen presenting cells (APC) of the CNS, immunoperoxidase labelling was 
also used to detect MHC-II expression in activated microglia. Microglia expressed 
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increased levels of MHC-11 from day 7 p.i., independently of IFN-y in WNV encephalitis. 
Despite a high degree of activation, as detected by lectin histochemistry, significantly 
fewer (p=<O.OOI) microglia expressed MHC-II at any timepoint from day 7-10 p.i. from 
either group. 
The pathogenesis and outcome of disease is often linked to the route of virus inoculation 
in the host. Therefore, the pathogenesis and role of IFN -y was also evaluated in WNV 
encephalitis using intranasal (i.n.) WNV inoculation (i.n. model) in both B6.WT and 
B6.IFN-y-/- mice. Both groups of mice were highly susceptible to i.n. inoculation with 
100% mortality by day 7 p.i. with nearly 5-fold higher virus titres in the brain at the time 
of death, compared to the peak virus titres detected in both groups of mice in the i.p. 
model. At the time of death, extremely high neuronal infection was observed throughout 
the brain, although not in the cerebellum. Leukocyte infiltration was observed from day 5 
p.i. It was maximal at the time of death but concentrated only in the olfactory bulb (OB) 
in the i.n. model. Although microglial activation was observed concurrently with 
neuronal infection from day 3 p.i., significantly fewer numbers of microglia were 
activated compared to numbers of infected neurones at the time of death in the i.n. model. 
The portal of CNS invasion by neurotropic viruses also depends upon the route of 
inoculation. In the i.p. model, WNV Ag was first detected in the cervical spinal cord 
motor neurones 24h before it was detectable in the brain. After 24h WNV Ag was 
detected in the brainstem for the first time and was then detectable in other parts of the 
brain, however, at no point was the OB found to be infected. Extremely rare 
neurovascular endothelium infection and blood brain barrier damage suggests that WNV 
gains access to the CNS via retrograde axonal migration along the spinal cord in the i.p. 
model. In contrast, in the i.n. model, WNV Ag was first detected in the outermost layer of 
the OB on day 3 p.i. and nowhere else in the brain. After day 3 p.i. WNV Ag was 
detected in other parts of the OB and brain proper, spreading rostral-to-caudal, indicating 
that WNV gains access to the brain via the olfactory route in i.n. infection. 
Antibody is important in controlling many neurotropic viral infections. Therefore, 
preliminary experiments were undertaken to evaluate its role in WNV using passive 
transfer of HI serum both in the i.p. and i.n. model in B6.WT mice. Passive transfer of HI 
serum i.p. 24h before and 48h after infection completely abrogated encephalitis in the i.p. 
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model. Moreover, the preliminary studies on B cell-deficient (B6.J.!MT-/-) mice showed 
100% mortality by day 9 p.i. with extensive brain and cervical spinal cord infection, 
compared to the corresponding B6.WT mice in the i.p. model, further confirming the 
importance of Ab in controlling WNV. However, the passive transfer of the same dose of 
HI seum was unable to protect mice from lethal WNV encephalitis in the i.n. model. 
Although passive transfer of 750-fold higher dose of HI serum than the original dose 
extended the survival time of mice in the i.n. model, only 13% of mice survived until day 
14 p.i. Moreover, adoptive transfer of splenocytes (5x107 splenocytes per mouse) from HI 
mice 24h before i.n. infection to naive mice also failed to protect mice in this model. 
Interestingly, surviving mice from low-dose i.n. WNV infection were completely 
protected when rechallenged i.n. with a 600-fold higher dose of WNV than the original 
dose. 
This thesis presents the significant results of a study of the pathogenesis of WNV 
encephalitis in adult mice. In short, IFN-y does not play an important role in survival 
against WNV infection or development of secondary anti-WNV immunity. Leukocyte 
recruitment is significantly reduced in the absence of IFN-y. The induction of ICAM-1 
and VCAM-1 in the CNS is IFN-y-independent and is not sufficient to facilitate 
transmigration of a compensatory number of leukocytes into the brain parenchyma during 
infection. WNV clearance is also independent of IFN-y. Microglia are activated in 
response to neuronal infection and activation is independent of IFN-y. These cells may be 
involved in WNV clearance. The route of inoculation of WNV determines the disease 
profile and severity of disease. Passive protection against WNV infection occurs reliably 
only in the i.p. model, but not in the i.n. model. 
Finally, these results clearly indicate that effective WNV clearance and generation of 
immunological memory can occur in the absence of IFN-y. However, most importantly, it 
suggests that IFN-y is involved in exacerbating disease. The mechanism by which it 
exerts this action within the CNS is unresolved. 
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Chapter-1 
General introduction 
1.1. Viral Encephalitis: one of the severe and devastating human diseases 
Encephalitis is an inflammation of the brain parenchyma and is almost always accompanied 
by inflammation of the adjacent meninges. It can occur at any age in any part of the world 
and has a high mortality rate. The reported incidence of encephalitis is 7.4/100,000 per year 
across the total population (Encephalitis Support Group 2001). Many aetio1ogical agents 
may cause encephalitis, including viruses, bacteria, parasites, fungi, rickettsia, etc.,. 
However, viruses are the most common cause. Indeed, encephalitis may be caused by more 
than 100 different neurotrophic viruses (Gutierrez & Prober 1998). 
Viral infections are the major cause of human morbidity and mortality throughout the world 
(Whitton & Oldstone 1996). Viral infections of the central nervous system (CNS) are one of 
the most severe and devastating human diseases. They can produce a wide range of 
neurological diseases including encephalitis, meningitis, myelitis and several demyelinating 
and degenerative syndromes (Griffin et al. 1992). The severity and the nature of clinical 
disease depends upon the virulence of the infecting virus and the quality of the host immune 
response to the infecting viruses (Weiner & Fleming 1999). In order to cause encephalitis, 
virus should have both neurovirulence and neuroinvasive properties. Neurovirulence is 
defined as the ability of neurotropic virus to infect CNS tissue, to replicate in some of its 
cells and injure them. Neuroinvasiveness is defined as ability of virus to invade the CNS by 
a peripheral route. Therefore, a neurovirulent virus necessarily does not cause encephalitis 
unless it is also neuroinvasive and absence of neuroinvasiveness makes a highly 
neurovirulent virus non-encephalitic (Halevy et al. 1994). Similarly, host responses also 
vary from one virus to another, depending upon the route of virus entry and spread within 
the CNS as well as tropism of the virus for specific CNS cells (Weiner & Fleming 1999). In 
most viral infections, neurones are the primary cells infected in the CNS (Griffin & 
Hardwick 1999). 
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Experimental studies on animal models show that invasion of CNS generally follows initial 
viral replication in various peripheral sites and a period of viremia (Albrecht 1968). 
Different neurotropic viruses use different anatomical sites and different mechanisms to 
invade the CNS (Johnson 1982). Some viruses use the neural route, where they replicate 
within nerves and are moved towards the brain parenchyma via the axonal transport system 
of neurones (Tang et al. 1999; Nathanson et al. 1961; Carbone et al. 1987). Virus 
movement rates have been estimated 2.4 and 3 mm/hour for rabies and poliovirus 
respectively (Nathanson and Cole, 1970). Other viruses use the haematogenous route 
(Johnson 1964; Dallasta et al. 1999). In this manner, they can infect brain capillary 
endothelial cells (Soilu-Hanninen et al. 1994), or use the transport system through brain 
endothelial cells without replication (Coffin et al. 1957; Liou & Hsu 1998), cross the 
choroid plexus with subsequent infection of the ependymal lining of the ventricles 
(Nathanson & Cole 1970) or use the olfactory route (Andrews et al. 1999; Monath et al. 
1983). Independent of the routes of neuroinvasion, disease can occur only if virus spreads 
within the CNS, replicates extensively within the susceptible resident cells and induces 
changes in those cells. Within the CNS, viral spread may take place either from cell to cell, 
often along dendritic or axonal processes, or extracel!ularly (Johnson 1987). Viruses that 
enter into the brain via the haematogenous route cause widely scattered pathology 
throughout the brain whereas those using the neural pathway tend to cause more localized 
and contiguous pathology (Albrecht 1968). 
Viral encephalitis manifests as either acute encephalitis or postinfectious encephalomyelitis 
(also known as acute disseminated encephalomyelitis) depending on cause and 
pathogenesis. Acute viral encephalitis is caused by direct viral infection of neural cells with 
associated perivascular inflammation and destruction of brain tissue, including grey matter. 
In contrast, postinfectious encephalomyelitis occurs a few days or weeks after the 
appearance of systemic symptoms of viral infection with perivenular inflammation and 
demyelination of brain tissue, including white matter (Gutierrez & Prober 1998; Johnson 
1987). Although acute encephalitis may be caused by many different groups of viruses, fatal 
cases are reported predominantly due to either arthropod-borne viruses or herpes simplex 
virus (HSV) (Johnson 1987). 
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1.1.1. Arboviral encephalitis: a global health problem 
Arthropod-borne viruses, hence the name arboviruses, are one of the commonest causes of 
viral encephalitis. They have been reported to cause 10% of all cases of sporadic 
encephalitis and up to 50% of all cases in epidemic years (Gutierrez & Prober 1998). 
Arboviral infections occur worldwide. The highest incidence of arboviral disease occurs in 
tropical and subtropical regions (Halley eta/. 2000). As the name arbovirus implies, these 
viruses are transmitted by arthropods but they replicate in both the arthropods and vertebrate 
host. Therefore, these viruses are usually maintained in a reservoir cycle that consists of 
both arthropods and vertebrate hosts, both being needed to maintain the virus in nature. 
Groups of arthropods involved in the transmission of arbovirus include mosquitoes, ticks, 
sandflies and midges (Shope & Meegan 1993). Arboviruses that cause human encephalitis 
are members of three families, the Togaviridiae, Flaviviridiae and Bunyaviridae. 
1.1.2. Flaviviral encephalitis: the most common arboviral encephalitis 
Flaviviruses are enveloped, single-stranded plus sense, positive stranded RNA viruses, the 
genome of which consists of approximately 11, 000 bases. They are genetically quite stable 
compared to other RNA viruses. The name flavivirus derived from the latin word flavus, 
meaning yellow from the jaundice associated with yellow fever, caused by yellow fever 
virus (Rice 1996). 
Japanese encephalitis (JE), dengue, yellow fever (YF), tick borne encephalitis (TBE), 
Murray Valley encephalitis (MVE), Saint Louis encephalitis (SLE) and West Nile viruses 
are the most important flaviviruses to cause regional endemic and epidemic disease 
throughout the world (Rice 1996). The large majority of incidents of flaviviral encephalitis 
are inferred from case reports, hospital case lists and reports of presumed outbreaks of the 
infectious disease. Thorough investigation of the aetiology and risk factors of encephalitis in 
well-defined populations is still lacking. The epidemiology of some of the flaviviral 
infections throughout the world is summarised in table 1.1. Flaviviruses produce a wide 
spectrum of infection and disease depending upon the virus dose, age and other factors 
which affect the host response. Usually, one of 3 different patterns of disease occur in 
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Table 1.1 Summary of important flaviviruses causing disease in humans 
Viruses Geographic Vectors Mortality Disease 
repon(s) rate pattern 
Dengue Southeast Asia Mosquito- 10-40% Endemic and 
Aedes aegypti epidemic 
Japanese Orient, China, Mosquito - Culex 30-40% Endemic and 
encephalitis 1 apan, India, tritaeniorhynchus epidemic 
Korea, other culicines 
Australia 
Murray Valley Australia Mosquito- 10% Epidemic, 
encephalitis Culex annulirostris sporadic over 
wide areas 
Saint Louis Southern, central Mosquito- 5-15% Endemic and 
encephalitis and western states Culex pipens epidemic 
of America and others 
Tick borne Russia and Ticks- 5-20% Endemic in 
encephalitis Northern Europe Ixodos ricinus forested 
and others regions 
Yell ow fever New world and Mosquito- 3-20% Endemic and 
Africa Aedes aegypti epidemic 
West Nile Asia, Africa, Mosquito- 5-10% Endemic and 
Europe, Middle Culex pipens epidemic 
East and others 
Derived from Centre for Disease Control 2000; Morbidity and Mortality Weekly Report 1999; 
Dumpis et al. 1999; Monath 1994; Shope & Meegan 1993; Russell & Dwyer 2000. 
infected individuals. These viruses may thus cause fatal encephalitis, subclinical 
encephalitis or there may be clinically inapparent infection (Monath 1986). 
1.1.3. West Nile Yirus: one of the deadly flavivirus 
1.1.3.1. History and Epidemiology 
West Nile virus (WNV) belongs to the family flaviviridae which comprises approximately 
70 viruses, nearly 40 of which cause human disease (Monath & Heinz 1996; Leyssen et al. 
2000). Serologically, WNV is a member of Japanese encephalitis virus complex that 
includes JE, SLE, Kunj in and MVE viruses (Calisher et al. 1989). WNV was first isolated 
from the blood of a febrile woman in the West Nile province of Uganda in 1937 (Smithbum 
et al. 1940) and since then has been found subsequently in west and central Asia, Africa, 
Middle East, Europe and America. It causes serious epidemics outside these areas and can 
infect a wide range of vertebrates such as humans, animals and birds with significant 
morbidity and mortality (Sampson et al. 2000; Steele et al. 2000; Ben-Nathan et al. 1996; 
Smithbum et al. 1940). The reported WNV outbreaks throughout the world are presented in 
table 1.2. 
Table 1.2. Summary of WNV outbreaks throughout the world 
Country Year outbreaks 
Israel 1951-1954, 1957 
France 1962 
South Africa 1974 
Western Ukraine 1985 
Algeria 1994 
Romania 1996 
Italy 1998 
Democratic Republic of the Congo 1998 
Russia 1999 
United State 1999 
France 2000 
Israel 2000 
Derived from Hubalek 2000; Roehrig 2001; Tsai et al. 1998 
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In humans, WNV infection is usually asymptomatic or presents with mild febrile disease, 
but during epidemics, 10% or more of reported cases show severe or fatal encephalitic 
infection (MMWR 1999; Briese et al. 1999, Ceausu et al. 1997). Typically, the disease is 
characterized by high fever, severe headache, lymphadenopathy and maculopopular rash, 
(George et al. 1984; Flatau et al. 1981), variably associated with other manifestations, such 
as diffuse muscular pain, nausea, vomiting and conjunctivitis (Sampson et al. 2000). 
Encephalitis is a common complication of WNV infection (Katz et al. 1989), other 
complications occur rarely but include myocarditis, hepatitis and pancreatitis (Georges et al. 
1987; Perelman & Stern 1974; Albagalic 1959). Recently, WNV has been isolated from a 
patient with human immunodeficiency virus (HIV) (Szilak & Minamoto 2000). 
1.1.3.2. Mode of WNV transmission 
Wild birds, especially wetland and terrestrial avian species, are the principal hosts of WNV 
(Hubalek & Halouzka 1999). Mosquitoes, largely bird-feeding species, especially Culex 
species (43 species), are the principal vector for WNV (Hubalek & Halouzka 1999). 
Mosquitoes become infected after feeding on infected birds. WNV then replicates in the 
cells of the midgut epithelium, circulates in their blood and is transferred to the salivary 
gland via haemocytes. This cycle takes approximately 10 to 14 days and once complete, 
mosquitoes can transmit WNV to human or animal hosts, secreting virus in the saliva during 
a blood meal (Kettle 1995). Mosquitoes may remain infected and able to transmit virus for 
many weeks or months (Shope & Meegan 1993). 
Humans and domestic animals are usually regarded as incidental or "dead-end" hosts. They 
are generally thought not to participate in the WNV transmission cycle due to the low levels 
of viremia (Halley et al. 2000). The transmission cycle of WNV in the ecosystem is 
presented in figure l.l. Although the natural foci of WNV infections mainly occur in 
wetland ecosystems and are characterized by repeated bird-mosquito cycles, sometimes 
ticks may serve as a substitute vector (bird-tick cycle) in some warm and dry habitats in the 
absence of mosquitoes (Hubalek & Halouzka 1999). 
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Figure: 1.1 Transmission cycle of WNV. 
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1.1.3.3. Organization of WNV genome 
All flaviviruses, including WNV share a common size of 40-60nm, and can be readily 
visualized under the electron microscope. WNV consists of an isometric ribonucleoprotein 
core of about 35 nm surrounded by a lipid envelope. Transmission electron micrograph of 
WNV on a vera cell monolayer is shown in figure 1.2. The viral genome consists of 
infectious positive, single-stranded 42S RNA. This functions, via a long open reading frame 
containing 10,290 nucleotides, as mRNA for the synthesis of all structural and non-
structural viral proteins in vivo (Castle et al. 1985). In the flaviviral genome, the structural 
proteins consist of nucleocapsid protein, envelope glycoprotein and precursor membrane 
glycoprotein. The non structural (NS) proteins are NSl, NS2A, NS2B, NS3, NS4A, NS4B 
and NS5. The exact functions of NS 1 protein in virus replication has not been defined (Rice 
1996), however, it has been suggested that it plays a role in early RNA replication (Leyssen 
et al. 2000). NS3 and NS5 are believed to be enzymatic components required for RNA 
replication (Rice 1996). NS2B acts as a cofactor for NS3 protein. The functions of NS2A, 
NS4A and NS4B are still unknown (Leyssen et al. 2000; Rice 1996). The schematic 
representation of organization of flaviviral genome is presented in figure 1.3. In vitro 
experiments have shown the presence of large amounts of WNV structural and 
nonstructural proteins incorporated into cellular membranes in vera cells (Castle et al. 
1986). 
1.1.3.4. Characteristics of WNV 
WNV can infect a wide range of vertebrates (Sampson et al. 2000; Steele et al. 2000; 
Ben-Nathan et al. 1996; Pogodina et al. 1983). The requirement to replicate alternately in 
both mosquitoes and vertebrate hosts under very different cellular conditions may explain 
the highly conserved genome of WNV, relatively unusual in an RNA virus. Genetic drift 
and/or recombination, thought to be an immune evasion survival strategy in other viruses, is 
thus not an option for WNV. Therefore this makes mechanistic interaction with the 
vertebrate host immune system more likely as a possible survival strategy. WNV infection 
of a wide variety of vertebrate cells from different species results variously in the increased 
expression of the critical immune recognition molecules, class I and II major 
histocompatibility complex (MHC-I and MHC-II) antigens (Bao et al. 1992; Argall et al. 
1991; King et al. 1989; Liu et al. 1989; King & Kesson 1988) intercellular adhesion 
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Figure: 1.2 Electron micrograph of WNV in vero cell culture infected with WNV. Adapted 
from Centre for Disease Control 2001. 
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Figure: 1.3 Schematic diagram of organization of flaviviraJ genome. Abbreviation: C, core or 
nucleocapsid protein, E, envelope glycoprotein, NS, non-structural protein, prM, precursor 
membrane glycoprotein. Drawings taken from Roehrig et al. 2000. 
molecule-! (ICAM-1; CD54), (Shen et al. 1995), vascular cellular adhesion molecule-! 
(VCAM-1; CD106), endothelial-selectin, (E-selectin; CD62E) (Shen et al. 1997) and B7-1 
(CD80) (Johnston et al. 1996). Changes in MHC and ICAM-1 occur independently of 
interferons, since this effect is seen in cells unable to produce type I interferon and type I 
interferon-specific antibody does not abrogate this effect. Increased cell surface molecule 
expression is also functional; thus increased susceptibility to both WNV- and MHC-specific 
cytotoxic T lymphocyte lysis is clearly demonstrable (Kesson & King 2001; Douglas et al. 
1994; King et al. 1993). This apparently paradoxical enhancement of the efficacy of the 
host antiviral cellular immune response by WNV may, at least in part, be responsible for the 
involvement of the immune system in the generation of pathology, particularly encephalitis. 
1.2. Divisions of the Nervous system 
The nervous system is an internal communication network that enables animals to adjust 
minutely to changes in the environment. It is divided into the CNS and the peripheral 
nervous system (PNS). The CNS consists of the brain and spinal cord, located in the cranial 
cavity and spinal cavity, respectively. The PNS consists of cranial and spinal nerves (both 
motor and sensory), various ganglia (collections of nerve cells outside the CNS) and 
receptors such as motor nerve and sensory nerve endings (Burkitt 1993). The cranial and 
spinal nerves serve as "telephone wires" that carry messages to and from every receptor and 
effector in the body. 
1.2.1. Cellular organization of the central nervous system 
The brain and spinal cord are covered by 3 layers of supporting tissue namely: dura, 
arachnoid and pia mater, collectively known as the meninges. There is no conventional 
lymphatic drainage in the CNS, however, it has been shown that blood fluids pass out from 
the capillaries and seep through the neural tissue towards the brain surface and ventricles 
(Albrecht 1968). As well, various proteins, such as ovalbumin, drain from the brain into the 
deep cervical lymph nodes (reviewed in Matyszak 1998). 
The brain is an extremely complicated organ, consisting of 3 principal parts, the cerebellum, 
brainstem and cerebrum. The cerebrum directs and coordinates hearing, sight, touch, 
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thinking, use of language, emotions and learning. The brainstem is connected to the spinal 
cord. It relays information from the sense organs and regulates autonomic functions, such as 
balance, blood pressure, breathing and heart rate. The cerebellum helps to maintain 
gravitational balance while coordinating muscular movements with sensory information 
(Stevens 2001). 
The spinal cord is a long cylindrical structure that is directly continuous with the brain, 
essentially serving as a neuronal cable. Near the muscle cells, the axons of spinal cord 
motor neurones divide into numerous branches that form the neuromuscular junctions with 
the muscle cell (Carpenter 1991 ). The function of the spinal cord is critical. It contains 
afferent pathways that carry sensory information from most parts of the body to the brain 
and descending efferent pathways that relay commands from the brain to the motor 
neurones. It also contains fibre systems and neurones that mediate segmental reflexes and 
provide autonomic innervation (Carpenter 1991; Stevens 2001). 
Despite extensive protection, the CNS can be invaded and damaged by variety of 
microorganisms. Resident cells of the CNS, such as microglia and astrocytes, and 
haematogenous cells that can invade the CNS from the vasculature are involved in the 
defence against such infections (Marten et al. 2001; Kreutzberg 1996; Mucke & Eddleston 
1993). In order to illustrate how these components are integrated, it is first necessary to 
review the normal cellular components of the CNS and the immune response. 
1.2.1.1. Neurone: the functional unit of the nervous system 
The CNS controls and coordinates the activities of the entire nervous system by means of 
two principle types of cells, neurones and glial cells. Schematic diagrams of the CNS 
resident cells are presented in figure 1.4. The neurones are specialized to receive stimuli and 
conduct electrical impulses to other parts of the system and are arranged as an integrated 
communication network. The glial cells are nonconducting. They are in intimate physical 
contact with the neurones, providing physical and metabolic support to these cells as well as 
electrical insulation for neuronal cell bodies and processes. The neurone consists of a 
nucleus surrounded by cytoplasm and processes such as axons and dendrites. Axons are the 
neuronal processes that transmit stimuli to other neurones or to effector cells; dendrites 
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Figure: 1.4 Schematic diagram of CNS resident cells. Adapted from Afifi & Bergman 1998; Burkitt et al. 1993. 
receive stimuli from other nerve cells or from the environment. Neurones are terminally 
differentiated cells, which do not divide (Burkitt 1993). Synapses are highly specialized 
intercellular junctions that link the neurones of each nervous pathway. They facilitate the 
transmission of impulses from one neurone to another, and from neurone to effector cells 
such as muscle fibres, where motor neurones synapse with skeletal muscle at the 
neuromuscular junction (Afifi & Bergman 1998; Burkitt 1993). The neuromuscular junction 
is shown in figure 1.5 and figure 1.6. 
1.2.1.2. Glial cells: supporting cells of the central nervous system 
Glial cells play a central role in maintaining neuronal function and viability by providing 
both mechanical and metabolic support for neurones. The glial cells constitute almost half 
the volume of CNS. They are highly branched cells that occupy the space between 
neurones. They are classified into astrocytes, microglia, oligodendrocytes and ependymal 
cells (Afifi & Bergman 1998; Dong & Benveniste 2001). 
• Astrocytes: providing nourishment for neurones 
Astrocytes are the predominant glial cell type in the CNS. They can be identified by their 
characteristic star shaped morphology (hence their name) and expression of glial fibrillary 
acidic protein (GFAP) in the cytoplasm (Martin & O'Callaghan 1995). They provide 
physical support for neurones, holding them in place by forming a matrix. The end feet of 
astrocytes are in close proximity to the microvessels. These facilitate the exchange of 
metabolites and waste to and from neurones and regulate the ionic concentration in the 
intercellular compartment, thus maintaining the microenvironment of the neurones. As well, 
they are involved in the formation and maintenance of the blood-brain barrier (Dong & 
Benveniste 2001; Burkitt 1993). They also affect the function of neurones in normal CNS 
physiology by guiding neuronal development, synthesizing essential neurotrophic factors, 
removing neurotransmitters, specifically glutamate, and buffering potassium ions (Dong & 
Benveniste 2001; reviewed in Schoneboom et al. 1999). Recently astrocytes have become 
recognised as imunocompetent cells of the CNS, involved in both immunological and 
inflammatory events occurring in the brain. Upon stimulation, astrocytes can secrete various 
cytokines, chemokines and cytotoxic metabolites. As well, they can express increased levels 
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hematoxylin stain showing the neuromuscular junction or motor end plate. Adapted from 
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Figure: 1.6 Schematic ultrastructural diagram of the neuromuscular junction (NMJ). NMJ is 
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synaptic gap between the nerve and muscle is 50pm. when a motor neuron is activated, the 
nerve impulses reache the axon terminal and communicate with the muscle fibre by 
discharging acetylcholine, present in the axon terminal, into the gap between pre and 
postsynaptic membranes. Adapted from Burkitt et al. 1993. 
of various molecules critically involved in cellular immune recognition interactions, 
including ICAM-1, MHC-I and MHC-II molecules (Dallasta et al. 2000; Glabinski et al. 
1999; Brodie et al. 1997; Grzybicki et al. 1997; Benveniste 1992). This will be discussed in 
more detail in section 1.5. 
• Oligodendocytes: myelin synthesizing cells 
Oligodendrocytes can be identified by the characteristic expression of myelin specific 
protein such as myelin basic protein and myelin glycolipid such as galactocerebroside 
(Benveniste 1992). They provide support for neurones by producing the myelin sheath that 
electrically insulates axons (Adams et al. 1994). In the grey matter, oligodendrocytes 
closely aggregate around neuronal cell bodies and are also known as perineuronal satellite 
cells. In the white matter, they are lined up between myelinated fibres and referred to as 
interfascicular glia (Adams et al. 1994). 
• Ependyma: CSF synthesizing cells 
Ependymal cells are the epithelial lining of the ventricles of the brain and spinal cord, and 
have morphologic and physiological characteristics of fluid-transporting cells. In many 
areas of the brain, they are modified to produce CSF by transport and secretion of materials 
derived from adjacent capillary loops in the CNS. The modified ependymal cells and 
associated capillaries are known as the choroid plexus (Burkitt 1993; Afifi & Bergman 
1998). CSF is produced constantly by these cells and effectively forms a bath in which the 
CNS is suspended, acting as a shock absorber (Burkitt 1993). 
• Microglia: CNS defence cells 
Microglia are the smallest glial cells and comprise up to 20% of the total glial cell 
population in the brain (Lawson et al. 1990), belonging to the mononuclear phagocyte 
system (Davis et al. 1994; Ling & Wong, 1993). They are present in nearly equal numbers 
in the grey and white matter (Kreutzberg 1996; Dickson et al. 1991). The cellular form of 
microglia present in the normal adult brain displays a ramified morphology with small 
somata and long thin branched processes. Expression of immune molecules, such as MHC, 
10 
ICAM-I, cytokines and chemokines, is low or absent (Sudo et al. 1998; Banati et al. 1993). 
They respond to the slightest alteration in their microenvironment (Greenfield 1997; 
Matyszak 1998). Once activated, they can produce several different kinds of secretory 
products as well as other immune molecules. These include cytokines, chemokines, 
cytotoxic metabolites, neurotrophic growth factors as well as increased expression of cell 
surface receptors like Fe receptor (FeR), complement receptor type 3 (CR3), a-D-
galactoside residues and other marker molecules such as ICAM-1, MHC-I and MHC-II 
(Nakajima & Kohsaka 1998; Banati et al. 1993; Benveniste, 1992). Microglial activation is 
critical in the defence of the neural parenchyma against infectious diseases, inflammation, 
trauma, ischaemia, brain tumors and neurodegeneration (Kreutzberg 1996). This will be 
discussed in more detail in section 1.5 and chapter 4. 
1.2.2. Olfactory system 
The olfactory system, which senses and processes odors, is one of the oldest and most vital 
parts of the brain and plays an important role in the survival of many animals. Lower 
vertebrates and many mammals rely heavily on the sense of smell for information about 
their environment. Olfaction is a basic or even primary mode of communication and is 
fundamental to vital functions such as detection and location of food sources and/or 
predators, as well as social and sexual behaviour (Carpenter 1991; Switzer et al. 1985). The 
olfactory system consists of the olfactory epithelium, bulb and tracts, together with the 
cerebral olfactory areas and their projections to other centres. The relationship between the 
nasal cavity and the olfactory bulb (OB) is shown in figure 1.7. In the olfactory system, the 
axons of the olfactory receptor neurones (also known as olfactory neuroepithelial cells) in 
the epithelium lining the nasal cavity, project to the OB, located at the anterior or rostral end 
of the cerebrum, where they synapse on the dendrites of second-order neurones within 
glomeruli (Barr & Kiernan 1983) as shown in figure 1.8. 
1.2.3. Blood-brain barrier: a specialized vessel wall in the central nervous system 
The proper function of all neurones of the CNS is dependent on the maintenance of a 
physical and chemical milieu within certain narrow limits. The system that regulates the 
exchange of water and solutes between the blood, the CSF, and the brain involves 
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Figure: 1.7 Sagittal section through the skull of a rodent shows the relationship of the nasal 
cavity with the olfactory bulb and the cortex (cerebrum). Adapted from Puche 2001. 
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Adapted from Carpenter 1991. 
membranes with selective permeability and specific carrier-mediated transport systems 
which form barriers (Carpenter 1991). This is collectively known as blood-brain barrier. 
The blood-brain barrier (BBB) is a series of interfaces between blood, CSF and neural 
tissue, formed mainly by microvascular capillary endothelial cells, a continuous 
homogeneous basement membrane and numerous astrocytic processes (de Boer & Breimer 
1998; Carpenter 1991). Capillaries within the CNS contain a continuous inner layer of 
unfenestrated endothelial cells connected by a high density of continuous, high-resistance 
tight junctions, derived totally or partially from the neuroectoderm (Andjelkovic & Pachter 
1998; Carpenter, 1991). The basement membrane surrounding the endothelial cells has 
approximately 85% of its surface covered by astrocytic end feet (Hurwitz et al. 1994; 
Carpenter 1991), which thus contribute to the maintenance of structural integrity of the 
BBB (Benveniste 1992). Besides astrocytes, microglia also extend their processes into the 
perivascular basement membrane where they may be in direct contact with endothelial cells. 
In addition to these, perivascular macrophages and pericytes are also present in tight 
apposition to endothelial cells (Andjelkovic & Pachter 1998). All these structural and 
cytologic properties of cells contribute to maintain BBB integrity, which is a critical 
regulator of CNS homeostasis and function. However, the BBB in the CNS is not complete 
everywhere. The circumventricular organs, including the postrema, median eminence, 
pineal gland, and choroid plexus are devoid of BBB. Here capillary endothelium with tight 
junctions is replaced by capillaries with fenestrated endothelium (Banks et al. 1995; 
Carpenter 1991). 
The BBB is critically important not only to maintain the physiochemical composition of the 
microenvironment of the CNS, but also to prevent the entry of circulating leukocytes and 
pathogens into the CNS (Hurwitz et al. 1994). Excepting activated T cells, immune cells 
normally do not pass through the intact BBB, unless there is an enhanced expression of 
endothelial adhesion molecules (Hickey et a/. 1991). However, during inflammatory 
diseases of the CNS, the disruption of BBB can occur facilitating the entry of inflammatory 
cells as well as infectious pathogens (Petito & Cash 1992; Andersen et al. 1991). Thus, 
breakdown of the BBB can facilitate infection of the brain parenchyma and has been 
reported in many viral encephalitides (Dallasta et al. 1999; Eralinna et al. 1996; Andersen et 
al. 1991). 
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1.3. Cross talk between the central nervous system and the immune 
system 
The nervous system and the immune system are both designed to receive and respond to 
minute changes in physical or chemical stimuli generated within or outside of the body. 
Traditionally. it was thought that there was no communication between the CNS and the 
immune system, with both acting separately (Neumann & Wekerle 1998). However, recent 
studies have demonstrated that the immune system can interfere with CNS function and the 
CNS can also influence the activity of the immune system (Aarali 1983; Becher et al. 2000). 
The communication between the CNS and the immune system occurs via the coordinate use 
of surface molecules, as ligands and receptors in cell adhesion, and soluble mediators such 
as cytokines, chemokines, nitric oxide (NO), neuropeptides, neurohormones, synaptic 
transmitters and neurotrophic factors (Neumann & Wekerle 1998; Black 1994; Benveniste 
1998). The occurrence of neurotransmitter receptors on lymphocytes, as well as cytokine 
receptors on neurones and glial cells (Gebicke-Haerter et al. 2001; Zhao & Schwartz 1998; 
Yamada & Yamanaka 1995), further support the notion that a bi-directional communication 
exists between the CNS and the immune system (Black 1994). 
Previously, the CNS was thought to be an "immune privileged" site due to the presence of 
the BBB, which prevented the entry of leukocytes, plasma proteins and cytokines. The 
evident lack of professional antigen presenting cells (APC), such as B cells, dendritic cells, 
and macrophages, and low expression or absence of MHC-I and II molecules (Benveniste 
1992; Neumann 2001) in the CNS cells further promoted this idea. Although access of 
immune cells to the CNS is restricted (Fontana 1987; Cserr et al. 1992) a small number of 
activated T lymphocytes, irrespective of their antigen receptor specificity, do pass through 
the BBB (Hickey et al. 1991 ), but do not seem to interact much with the cells of the CNS 
(Neumann & Wekerle 1998), presumably due to the absence or low expression of MHC 
molecules which are required for the initiation and propagation of antigen-specific immune 
responses (Neumann 2001). However, several recent studies have demonstrated that in 
response to invasion by microorganisms, resident cells of the CNS such as astrocytes and 
microglia can mount a significant response, with the production of many different kinds of 
cytokines and chemokines, as well as the upregulation of MHC-I and II molecules (Renno 
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et al. 1995; Acarin et al. 2000; Cross & Woodroofe 2001; Banati et al. 1993). These cells 
can also actively participate in integrative communication pathways between resident 
immune cells of the CNS and those of the periphery (Aarali 1983). In addition to this, the 
influx of massive number of inflammatory leukocytes also occurs in the CNS parenchyma 
during infection or injury (Chan et al. 1989; Nansen et al. 1998; Ferber et al. 1996). Thus, 
despite important differences between the CNS and periphery, they can no longer be 
regarded as independent or isolated from one another, either anatomically or functionally. 
1.4. Immunity: a host defence mechanism 
The outcome of viral infection is determined by a race between the replicating agent and the 
host defences. Several experiments on immune-deficient mice or mice treated with 
immunosuppressive drugs have proven the crucial role of the immune response in 
controlling viral infections (Camenga & Nathanson 1974; Nathanson & Cole 1970; Beland 
et al. 1999; Pasparakis et al. 1996; Ben-Nathan et al. 1996; Ferber et al. 1996; Liu & 
Chamber 2001; Planz et al. 1997). In neurotropic viral infections, significant depression of 
immune reactivity is associated with enhanced virus-mediated morbidity and mortality from 
encephalitis, characterized by prolonged viremia, elevated virus levels in the CNS and other 
peripheral tissues, and a reduced or undetectable antibody response (Nathanson & Cole 
1970; Ben-Nathan et al. 1996; Liu & Chambers 2001). 
Immunity, the state of protection from infectious disease and injury results from the ability 
to generate an enormous variety of effector cells and molecules that are capable of 
specifically recognizing and eliminating many different types of microorganisms. The 
immune response consists of innate and adaptive immune components (Kuby 1994). The 
innate immune system allows recognition of foreign substance (antigen) via germ-line 
encoded pattern recognition receptors, and thus, are responsible for immediate action 
against antigen (Ag). In contrast to innate immunity, adaptive or acquired immunity enables 
Ag recognition via specific Ag-receptors generated by somatic recombination, and 
demonstrate plasticity and memory (De Leo & Yezierski 2001; Becher et al. 2000). The 
mechanism of host defence against infections or injury is a symphony of many innate and 
adaptive immunologic components, both working together to effectively eliminate foreign 
invaders (Janeway et al. 2001). 
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1.4.1. Innate immunity: the vanguard of host defence 
Innate (non-specific) immunity is regarded as a pre-existing or rapidly inducible host 
effector system for the control of infection, against which the host has not been previously 
immunized (Welsh et al. 1997). Innate resistance mechanisms are important barriers to 
pathogens, particularly in controlling virus multiplication at the onset of infections, prior to 
the development of an adaptive immune response. They enable the host to "knock down" 
the immediate accumulation of viruses that could otherwise be lethal prior to the generation 
of the specific immune response (Baron et al. 2000). Innate immunity includes a series of 
anatomical and physiological barriers, as well as non-specific cellular responses with 
antimicrobial activity. Besides these, apoptosis, i.e., programmed cell death is also 
considered to be part of the innate immune reponse, induced to counteract viral infection 
(Everett & Mcfadden 1999). 
1.4.1.1. Anatomic and physiological barriers 
Anatomic barriers that tend to prevent the entry of pathogens are regarded as the first line of 
defence of the host. Skin and mucous membranes are included in this category. When intact, 
the skin is impermeable to most pathogens and the low pH also inhibits their growth (Kuby 
1994 ). The mucous membranes, lining the inner surfaces of the body, also act as a 
protective barrier. They block the adherence of pathogens by means of various secretions 
such as mucus, tears, saliva, etc., that contain antimicrobial compounds, eg., lysozyme in 
tears. Physiological barriers further include temperature, pH, oxygen tension, and various 
soluble factors (Janeway et al. 2001). Body fluids such as gastric juice contain acid that 
prevents microbial colonization in the intestine, since very few ingested microorganisms 
can survive the low pH of the stomach. Basic responses of the body to infection such as 
hyperthermia also have an inhibitory effect on virus replication and may alter the outcome 
of infection (Nathanson & Cole 1970). Elevated body temperature reduces the replication or 
increases the inactivation of some flaviviruses and may convert a lethal infection into a 
sublethal one (Monath 1986). 
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1.4.1.2. Cells of the innate immune system: role in antiviral defence 
Cellular components of innate immunity include natural killer (NK) cells, macrophages, and 
granulocytes. These cells act directly to reduce the impact of infection in the earliest stages. 
However, these cells also play a key role in the initiation and subsequent direction of the 
adaptive immune response, as well as participating in the removal of pathogens that have 
been targeted by the adaptive immune response. 
• Granulocytes 
Granulocytes are phagocytic cells. They include neutrophils, eosinophils and basophils. 
Neutrophils are predominant among the leukocyte population in the blood and are a major 
cell type that plays an important role in early host defence. The ability of neutrophils to 
restrict bacterial and fungal infections has long been recognised, however, its role in 
antiviral defence has been little studied. Recent studies have shown the role of neutrophils 
in controlling the viral infections (Milligan et at. 2001; Watanabe et al. 1999; Srivastava et 
al. 1999; Van Strijp et al. 1990; Tsuru et al. 1987). It has been proposed that neutrophils 
produce antiviral cytokines such as tumor necrosis factor (TNF) (Maatta et al. 1998) and 
NO (Andrews et al. 1999) which may contribute to the control of viral infection (Rossol-
Voth et al. 1991, Guidotti et al. 2000). They can degrade the phagocytosed virion proteins 
by generating reactive oxygen species, as has been seen in JE virus (Srivastava et al. 1999) 
and HSV (Van Strijp et al. 1990) infections. Reactive oxygen species play an important role 
in antiviral defence (Skulachev 1998). The role of basophils and eosinophils in antiviral 
immunity is also poorly understood. Recently, it has been shown that eosinophils may be 
directly involved in controlling viral infection by secreting an antiviral component, 
ribonuclease (Domachowske et al. 2000). 
• Macrophages 
Macrophages are professional phagocytes that reside in many different organs and tissues. 
They mature continuously from circulating monocytes and migrate into the tissues 
throughout the body, and are widely distributed within the host organs. Their ability to 
phagocytose and destroy pathogens, including virus particles, allows them to act in the front 
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line of host defence against initiation and dissemination of viral infections (Janeway et al. 
2001). Besides phagocytosis, macrophages are also involved in controlling viral infections 
directly, by producing antiviral cytokines such as interferon-a/j3 (IFN-a/j3), TNF and NO 
(MacMicking et al. 1997; Abbas et al. 1997) or indirectly, by modulating several 
immunoregulatory functions (Guidotti & Chi sari 2001 ). Activated macrophages also 
produce chemokines that not only facilitate the recruitment of inflammatory cells to the site 
of infection, but also exert antiviral function by themselves (Aikhatib et al. 1996; Deng et 
al. 1996; Yang et al. 1997). Several animal models of viral encephalitis have demonstrated 
the crucial role of macrophages in early antiviral defence (Ben-Nathan et al. 1996; Zisman 
et al. 1971). In a study by Ben-Nathan et al. (1996), depletion of macrophages by 
dichloromethylene diphosphonate in WNV infection resulted in an extended viraemia with 
higher blood virus levels which was associated with accelerated development of 
encephalitis and death. Moreover, depletion of macrophages also enhanced the 
neuroinvasion of noninvasive (attenuated) virus and increased mortality by 70-75%, 
compared to control mice. 
• Natural killer cells 
NK cells are large granular lymphocytes that make up 5-10% of the recirculating 
lymphocytes (Kuby 1994). NK cells play an important role in eliminating virus-infected 
cells via cytolysis and are a critical component of the innate immune system (Biron et al. 
1999). NK cells recognise virus-infected cells before the upregulation of MHC-I expression, 
suggesting that the NK cell response is important especially for those viral infections, in 
which downregulated MHC-I expression is a dominant feature as a strategy to escape the 
adaptive immune response (Ghiasi et al. 2000; Guidotti & Chisari 2001). In addition to the 
cytolytic function, NK cells are also involved in noncytolytic antiviral effector functions, 
producing antiviral cytokines like IFN-y and chemokines (Ghiasi et al. 2000; Karupiah et 
al. 1990; Fehniger et al. 1998). Adler et al. (1999) have demonstrated that in the absence of 
T cells, NK cells can protect mice from HSV -1 encephalitis. 
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• Soluble factors 
In addition to the cellular components, various soluble molecules secreted by leukocytes are 
involved in innate immunity. These include the type I interferons, complement and natural 
antibodies. 
Interferons (IFN) are potent antiviral cytokines. They are classified into type I and type II 
IFN. Type I IFN includes IFN-a and IFN-~, produced by virus-infected cells and thus 
involved in the first line of antiviral defence. Type II IFN includes IFN-y, which is produced 
by T cells recognizing cognate Ag and is thus not directly induced on infected cells by viral 
infection. IFN -a/~ makes several contributions to host defence against viral infection. Both 
inhibit viral replication directly (Kurane et al. 1990; Schijns et al. 1991; Grieder & Vogel 
1999), inducing resistance to viral replication in uninfected cells. They also activate NK 
cells which can kill virus-infected cells selectively and which also produce IFN-y. 
Rokutanda (1969) has demonstrated that circulating IFN-a/~ reduced viraemia in JE virus 
infection. Several studies on IFN-a/~ or IFN-a/~ receptor gene knock out mice have 
shown the importance of these cytokines in early antiviral defence (Muller et al. 1994; 
Durbin et al. 2000). Type I IFN may also markedly influence the adaptive immune response 
(Janeway et al. 2001; Tilg & Kaser 1999). 
Complement is another first line of host defence against viral infections. Complement 
functions as a modulator of the humoral immune response and can control viral infection in 
several ways: by neutralizing virus infectivity, by contributing to the inflammatory 
response, by opsonization of viral Ag and by lysis of virus-infected cells via the membrane 
attack complex (Lachmann et al. 1997; Kuby 1994). Ochsenbein et al. (1999) have shown 
the important role of complement in antiviral immunity, using an animal model of vesicular 
stomatitis virus (VSV) infection. 
Like complement, natural antibodies (Ab) are also an essential part of the innate immunity. 
Indeed, these two components effectively work together. Spontaneously occurring 
immunoglobulins in the normal host in the absence of apparent Ag stimulation are known as 
natural Ab. They belong to the immunoglobulin M class of Ab produced by peritoneal B-1 
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cells (Ochsenbein et al. 1999). Natural Ab is involved in early viral defence by facilitating 
Ag uptake, processing, and presentation to B lymphocytes via complement and Fe receptors 
(Ochsenbein et al. 1999). Recently, it has been shown that natural Ab plays a key role in 
preventing the spread of viruses, such as VSV, lymphocyte choriomeningitis virus (LCMV) 
and vaccinia virus, to vital organs. It also improves immunogenicity through enhanced Ag-
trapping in the secondary lymphoid organs (Ochsenbein et al. 1999). 
1.4.1.3. Apoptosis: an innate host defence strategy against viral infection 
Apoptosis is thought to play an important role in viral infection for the elimination of 
virus-infected cells, prior to the development of adaptive immunity. Thus, apoptosis may be 
considered as part of the innate immune response to viral infection (Everett & McFadden 
1999; Griffin & Hardwick 1997). Apoptosis may result via a default mechanism, where the 
cell commits suicide to prevent viral replication and spread to adjacent cells (Razvi & 
Welsh 1995). This view is further supported by findings that many viruses encode genes 
which can inhibit apoptosis (Griffin & Hardwick 1997). However, although it is an 
important host defence strategy, apoptosis of crucial and nonreplaceble cells, like neurones, 
result in long term functional defects of CNS or death (Griffin et al. 1994, Griffin & 
Hardwick 1999). 
Apoptosis is a normal cell response required for the tissue remodeling that occurs during 
development and metamorphosis, as well as in healing in all multicellular animals. A 
hallmark of apoptosis is the fragmentation of nuclear DNA into 200 base pair pieces 
through the activation of endogeneous nucleases (Janeway et al. 2001). Apoptosis is 
different from that of necrotic cell death. Many different stimuli can induce apoptosis. 
These include cytokines, steroids, growth factor withdrawal and DNA-damaging agents. In 
the case of B and T cells, Ag-receptor engagement can also induced apoptosis. In contrast to 
apoptosis, necrosis is induced by those agents which affect membrane integrity, generalized 
protein synthesis or energy metabolism (Razvi & Welsh 1995). 
Some viruses induce apoptosis of infected cells (Despres et al. 1998; Lewis et al. 1996) by 
triggering cellular sensors that initiate cell death, presumably to assist virus dissemination 
(Everett & McFadden 1999). Alternatively, some viruses actively prevent the apoptosis of 
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infected cells (Aleman et al. 2001) by inducing bcl-2 gene expression or by using homologs 
of the bcl-2 gene contained in the viral genome (Akbar et al. 1994). The bcl-2 molecule is 
an anti-apoptotic transmembrane cellular protein that inhibits the apoptosis normally 
induced by a variety of insults. Increased levels of bcl-2 can significantly decrease apoptosis 
(Akbar et al.1994). Geiger et al. (1995) observed that upregulation of bcl-2 expression in 
the brains of transgenic mice was correlated with markedly decreased neuronal apoptosis 
and increased survival in HSV infection. Moreover, Levine et al. (1996) observed an 
antiviral property of bcl-2 involved in preventing viral replication as well as apoptosis in the 
CNS. This protected mice from lethal Sindbis virus (SBV) encephalitis. However, Liao et 
al. (1997) showed that enforced expression of bcl-2 was unable to protect many cell types 
from JE virus-induced apoptosis in vitro. Moreover, CTL, NK cells and cytotoxic cytokines 
all can eliminate virus-infected target cells via apoptosis (Razvi & Welsh 1995, DeLuca et 
al. 1999), regardless of bcl-2levels in these cells. 
Apoptosis can also occur in non-infected cells in the CNS during viral encephalitis 
(McQuaid et al. 1997) as an indirect consequence of viral infection (DeLuca et al. 1999). 
Just as recruitment of inflammatory cells are important for the control of infection, 
termination of inflammatory reactions are also equally important to protect the CNS from 
continuing immune-mediated damage such as that seen in lymphocytic choriomeningitis 
and MS (Pender & Rist 2001; Bauer et at. 1998; Zinkernagel 1992). Thus, all infiltrating 
inflammatory cells, including T cells, B cells and macrophages may undergo apoptosis in 
the CNS and are cleared by microglia through phagocytosis (Magnus et al. 2001). 
1.4.1.4. Inflammatory cells in viral infections 
Disease occurs when an infectious pathogen succeeds in invading or overwhelming the 
innate host defences to establish a local site of infection and replication that allows its 
further dissemination. Virus spread is often countered by an inflammatory response that 
results in the influx of more effector molecules from local blood vessels. The hallmark of 
the inflammatory response is the infiltration and/or migration of cells to the sites of injury 
(De Leo & Yeziersk 2001). 
20 
Inflammation is a physiological response to stimuli such as microbial infection and tissue 
injury. It is characterized by redness, heat, swelling and pain at the local site. Inflammation 
is thus classically associated with localized increased vascular permeability, accompanied 
by an infiltration of 'inflammatory' leukocytes. It is usually initiated within minutes at the 
site of infection or injury (Janeway et al. 2001). Local tissue macrophages respond 
immediately to counter infecting pathogens and help to set up a state of inflammation in the 
tissue at the site of infection (Matyszak 1998). Local blood vessels increase in diameter to 
increase local blood flow. They activate endothelial cells lining the blood vessels to express 
adhesion molecules which then arrest leukocytes attracted by soluble mediators. Blood flow 
is then reduced and this facilitates the transmigration of inflammatory cells into the site of 
infection (Janeway et al. 2001; Kuby 1994). Neutrophils are the first cells that migrate to 
the inflammatory site, followed by monocytes, which differentiate into tissue macrophages, 
and then NK cells. In the later stages of inflammation, lymphocytes (T lymphocytes and B 
lymphocytes) and eosinophils enter into the inflammatory sites, where they participate in 
resolution of infections and tissue repair (Janeway et al. 2001). Besides these, increased 
vascular permeability leads to leakage of fluid and proteins from the blood into the tissue. 
This results in tissue swelling, oedema and pain. The accumulation of plasma proteins, 
including those of complement and natural Ab in the tissue further act in host defence and 
trigger a continuing inflammatory cascade. All these changes are initiated by 
proinflammatory cytokines such as TNF, interlukin-1 (IL-l) and chemokines produced by 
macrophages, in response to the infectious pathogens (Janeway et al. 2001; Kuby 1994) and 
are aimed at preventing infection from becoming established. If they fail to control the 
infection, activated macrophages and other cells from the early innate response help to 
initiate the development of an adaptive immune response. 
1.4.1.5. Cellular adhesion molecules: role in inflammatory response 
Leukocyte recruitment to the sites of inflammation is central to the normal progression of 
the inflammatory response, which is mediated by chemokines produced by activated 
macrophages. However, other mechanisms are involved in arresting circulating leukocytes 
and supporting their transmigration from the blood into adjacent inflammatory sites. This is 
mediated through the interaction between leukocytes and endothelium (Imhof & Dunon 
1995; Janeway et al. 2001). This interaction is enabled via a number of different cell surface 
glycoproteins known as cellular adhesion molecules (CAM). In the absence of CAM 
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expression, the adhesive forces between leukocytes and the vascular endothelium are very 
weak. This effectively disables leukocyte tethering and extravasation and prevents 
development of inflammatory responses in these tissues resulting in more severe infection 
(Dallasta et al. 2000; Meager 1999). Thus adhesion molecules are pivotal to 
leukocyte/endothelial interactions in the inflammatory response, and hence, in host defence 
mechanisms (Andjelkovic & Pachter 1998). A stepwise schematic diagram of leukocyte 
extravasation during inflammation is presented in figure 1.9. 
CAM were initially discovered as cell surface structures mediating cell-cell and 
cell-extracellular matrix interactions (Lee & Benveniste 1999). CAM involved in the 
immune response have been classified into 3 families on the basis of different molecular 
structure. These are the selectins, which are prominent in initial leukocyte interactions with 
vascular endothelium, the integrins, which regulate adhesion and migration, and the 
immunoglobulin superfamily, whose many members also include the Ag-specific receptors 
ofT and B cells (Springer 1990). 
• Selectins 
Selectins are a family of adhesive receptors found on leukocytes, platelets and endothelial 
cells. They are involved in the initial attachment and rolling of leukocytes on the vascular 
endothelium (Ley & Tedder 1995) before extravasation (Meager 1999). The selectin family 
is comprised of three proteins, namely leukocyte-selectin (L-selectin, CD62L), platelet-
selectin (P-selectin, CD62P) and endothelial-selectin (E-selectin, CD62E) (Carlos & Harlan 
1994). L-selectin is constitutively expressed by all circulating leukocytes, whereas 
P-selectin serves as a receptor found on endothelial cells and platelets for molecules 
expressed by both neutrophils and macrophages. Expression of P-selectin on the 
endothelium initiates the earliest phase of leukocyte migration into the inflammatory site 
whereas its expression on platelets initiates recruitment of leukocytes to thrombi to induce 
production of fibrin during haemostasis (Imhof & Dunon 1995). E-selectin is present 
exclusively in endothelial cells and is expressed only upon stimulation by cytokines such as 
TNF and IL-l (Bernardes-Silva et al. 2001; Meager 1999). E-selectin is responsible for the 
initial capture of leukocytes by the endothelium, including neutrophils, monocytes and T 
cell subsets from the circulation by setting them rolling on a path towards interaction with 
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Figure: 1.9 Diagrammatic representation of adhesive interactions during leukocyte emigration to the site of inflammation. During the process of 
blood flow , leukocytes first roll along endothelium adjacent to the extravascular site of inflammation. Subsequently, some of the rolling 
leukocytes adhere firmly and diapedese between endothelial cells with the help of different cell adhesion molecules that are expressed by 
activated vascular endothelium, and then migrate into subendothelial tissue. Modified from Carlos & Harlan 1994. 
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ICAM-1 and VCAM-1 before diapedesis into the site of inflammation (Andjelkovic & 
Pachter 1998). 
• Integrins 
Integrins are adhesion molecules expressed constitutively on the surface of leukocytes. 
They serve as receptors for members of the immunoglobulin superfamily expressed on 
activated vascular endothelium. Integrins provide a versatile mechanism for the arrest and 
tight adhesion of circulating leukocytes on vascular endothelium. This is rapidly followed 
by intermediate adhesion during transendothelial migration and finally deadhesion at 
extravasation (Imhof & Dunon 1995). Different populations of leukocytes express different 
integrins, among them leukocyte function-related antigen (LFA-1, CD 11 a/ CD 18), Mac-! 
(CDllb/CD18) and very late antigen-4 (VLA-4/CD49d) are the most important integrins as 
regards cell adhesion. 
LFA-1 is expressed on the surface of all leukocytes that interact with ICAM-1, Mac-! is 
expressed on macrophages, granulocytes, and dendritic cells whereas VLA-4 is expressed 
only on lymphocytes and monocytes (Carlos & Harlan 1994; Fischer and Reichmann 2001). 
Besides their role in leukocyte endothelial interactions, integrins also participate in other 
cell-cell interactions. These include T cell activation by APC, killing of virus-infected cells 
by cytotoxic T lymphocytes (Albelda & Buck 1990; Imhof & Dunon 1995), as well as the 
modulation of growth and differention of many connective tissues and nervous system cells 
(Springer 1990). 
• Immunoglobulin superfamily 
CAM of the immunoglobulin superfamily are involved in cell-cell adhesion and are 
especially important during inflammatory responses, wound healing and embryogenesis 
(Albelda & Buck 1990). Five members of this family are involved in leukocyte/endothelium 
interactions: ICAM-1, ICAM-2, VCAM-1, platelet-endothelial cell adhesion molecule-1 
(PECAM-1) and the mucosal addresin cell adhesion molecule-1 (MAdCAM-1) (Carlos & 
Harlan 1994). Among them, ICAM-1 and VCAM-1 have been extensively studied in viral 
encephalitis (Dallasta et al. 2000; Lewandowski & Hobbs 1998; Sasseville et at. 1992; 
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Nansen et al. 1998; Sobel et al. 1990; Irani & Griffin 1996). This will be discussed in more 
detail in chapter 5. 
In the process of cell adhesion, ICAM-1 binds to LFA-1 as a prelude to leukocyte adhesion 
and migration (Wong & Dorovini-Zis 1995). ICAM-1 is present at very low levels on many 
cell types, including all haematopoietic cells, epithelial cells and endothelial cells. These 
cells can be induced to express high levels of ICAM-1 by the proinflammatory cytokines, 
TNF, IL-l and IFN-y (Dobbie et al. 1999; Lee et al. 1999; Fabry et al. 1992). This 
upregulation of ICAM-1 enables both leukocyte-leukocyte and leukocyte-endothelial cell 
interactions. ICAM-1 also serves as an accessory protein for Ag receptor activation on B 
and T cells (Lee & Benveniste 1999), as well as being the major receptor for rhinoviruses 
(Sethi et al.l997). VCAM-1 is a ligand for VLA-4 and plays an important role in leukocyte 
extravasation. Since VLA-4 is not expressed on the surface of granulocytes, VCAM-1 is 
involved only in the extravasation of mononuclear cells i.e., lymphocytes and monocytes. 
VCAM-1 is not expressed constitutively, but can be induced by TNF, IL-l and IFN-y 
stimulator (Barten & Ruddle 1994; De Jong et al. 1996). Therefore, VCAM-1 was 
originally identified as a cytokine-inducible adhesion molecule (Imhof & Dunon 1995). In 
addition to this, VCAM-1 is also involved in the initiation of T cell activation and 
proliferation (Lee & Benveniste 1999). 
1.4.2. Adaptive immunity; the second line of defence 
As previously mentioned, the host defence against viral infections is prosecuted by a 
symphony of many innate and adaptive immunologic components. These may act alone or 
in cooperation, depending upon the nature of infecting viral Ag. Adaptive (specific) 
immunity reflects the presence of a functional immune system capable of specifically 
recognizing and selectively eliminating Ags. Unlike innate immunity, adaptive immunity 
displays specificity, diversity, memory, and self/nonself recognition. Humoral and 
cell-mediated (cellular) immunity represents the two principal arms of adaptive immunity. 
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1.4.2.1. Humoral immunity: a long term defensive strategy against viral infections 
The humoral branch of immunity involves the interaction of B cells with Ag and their 
subsequent proliferation and differentiation into Ab-secreting plasma cells. Body fluids 
were once known as humors, therefore, immunity mediated by Ab is known as humoral 
immunity (Janeway et al. 2001). Ab is produced either in a membrane-bound form by B 
(bursal, thymic-independent) lymphocytes or in a secreted form by plasma cells that 
represent the terminal differentiation of B cells upon antigenic stimulation (Abbas et al. 
1997). Secreted Ab circulate in the blood (also known as circulating antibody) to function as 
the effectors of humoral immunity. They bind to Ag and neutralize it or facilitate the 
elimination of Ag by complementing macrophage activity. Membrane-bound Ab subserves 
the recognition phase of humoral immunity and denotes the antigenic specificity of B cells 
(Kuby 1994). 
Antibody have an immunoglobulin (lg) structure. The basic functional unit consists of 2 
heavy chains and 2 light chains linked by disulphide bonds. On the basis of enzyme 
digestion, this structure is further divided into Fab portions with two Ag binding sites and 
Fe portion. The Fab portion consists of both heavy and light chain components whereas the 
Fe portion consists of only heavy chain components (Winkelhake 1978). On the basis of 
individual differences in structure and function, five Ab isotypes are recognised: IgM, IgG, 
lgA, IgE and IgD. Among them, IgM, lgG, IgA are important in viral infections (Weiner & 
Fleming 1984). 
IgM is produced during the "initial phase' Ab response, which appears in primary infection. 
It is expressed before isotype switching, i.e., before the B cell undergoes somatic 
hypermutation, and is short-lived. The individual binding sites of lgM are generally of low 
affinity, it has high avidity due to its pentameric structure, which effectively gives it 10 Ag-
binding sites. lgM plays a crucial role in controlling bloodstream infection via the efficient 
activation of the complement system (Janeway et al. 2001). IgG constitutes the major 
source of specific Ab both in the blood and extracellular fluid and persists for life. lgG 
neutralizes viral Ag, opsonizes Ag for phagocytosis, and activates complement. IgA 
represents secretory Ab and is involved in mucosal immunity (Ogra et al. 1975). lgE is 
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found in the blood and extracellular fluid at low levels. It is bound by receptors on mast 
cells and basophils (Winkelhake 1978). It is involved in immediate hypersensitivity 
reactions. lgD is involved in the activation of B cells by an Ag but its functions are 
incompletely understood (Janeway et al. 2001). 
1.4.2.1.1. Role of antibody in viral encephalitis 
Circulating Ab, acquired as a result of natural infection or passive transfer of specific Ab, 
plays an extremely important role in limiting viral infections by terminating the primary 
infection, limiting the spread of viraemia and preventing disease, as well as preventing 
reinfection. Several animal models of viral encephalitis have demonstrated the importance 
of Ab in viral infections although most of this research is based on passive transfer of either 
monoclonal or polyclonal Ab. 
Levine et al. (1991) for the first time proposed that passive transfer of hyper immune serum 
(polyclonal Ab) can clear Sindbis virus (SBV) from neurones by non-cytolytic mechanisms. 
Such mechanisms precipitate prolonged presence of viral RNA in the neurones (Levine & 
Griffin 1992). Similarly, Wright and Buchmeier (1991) showed that pre-existing Ab, 
passively transferred, can prevent T-cell-mediated immunopathology in LCMV infection. 
Moreover, passive transfer of specific monoclonal Ab to SBV-infected IFN-deficient mice, 
which are extremely susceptible to SBV, resulted in complete clearance of virus and 
survival (Byrnes et al. 2000), suggesting that Ab can control viral infection even in the 
complete absence of IFN. Ab has been found to be involved in preventing the spread of 
virus in the CNS (McKendall et al. 1979; Levine et al. 1991) as well as in restricting viral 
gene expression in the CNS (Dietzschold et al. 1992). Studies on B-cell-deficient mice 
further provides evidence for the role of Ab in viral encephalitis. Liu & Chambers (2001) 
showed that B-cell-deficient mice have increased susceptibility to YF virus infection, 
compared to the wild type mice. This is supported by the findings of Beland et al. (1999) in 
HSV -1 infection. Similarly, mice with B cell suppression showed increased neuronal 
infection and increased incidence of latent infection with HSV compared to control mice 
(Simmons & Nash 1987; Kapoor et al. 1982). 
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1.4.2.2. Cell-mediated immunity: a major antiviral defence mechanism 
The cellular branch of the immune system involves interaction of T lymphocyte 
(thymus-dependent) with Ag and their subsequent proliferation and differentiation into 
memory T cells and various effector T cells. T cells express a unique Ag-binding receptor 
on their membranes, known as the T cell receptor (TCR), that recognises Ag only in 
association with MHC molecules. Each T cell expresses about 105 receptors/cell, all of 
which have an identical Ag specificity (Kuby 1994). Unlike the humoral immunity, which 
can be transferred by serum Ab, cell-mediated immunity can only be transferred by immune 
T cells. 
T helper (T H) cells and T cytotoxic (T c) cells are subsets of T cells, which can be 
distinguished on the basis of their cell surface glycoprotein expression. T cells displaying 
CD4 function as T H cells, whereas T cells displaying CDS function as Tc cells (Abbas et al. 
1997). In response to the recognition of an Ag-MHC-II complex by the TCR, TH cells are 
activated and become effector cells which secrete various cytokines. These play an 
important role in activating B cells, Tc cells, macrophages, and various other cells 
participating in the immune response, as well, they stimulate one another to proliferate and 
differentiate further (Kuby 1994 ). On the basis of secreted cytokines profile, T H cells are 
classified principally into THl and TH2 cells (Mosmann et al. 1986). THl cells produce 
pro inflammatory cytokines, such as IL-2, IFN -y and TNF, which acti vale macrophages and 
cytotoxic T lymphocytes. They are involved in cell-mediated immune responses that are 
particularly suitable for combating intracellular pathogens like viruses. In contrast, T H2 cells 
secrete IL-4, IL-5 and IL-l 0 but not IFN- y, and are more involved in humoral responses, 
contributing their help for strong Ab production, eosinophil activation, and inhibition of 
several macrophage functions, thus providing phagocyte-independent protective responses 
(Spellberg & Edward 2001; Zhao & Schwartz 1998). In addition THO cells produce a 
mixture of both THl and TH2 cytokines. They are regarded as uncommitted cells, prior to the 
decision to respond as THl or TH2 cells. 
Several factors influence the T H (CD4+) cell differentiation. These include the cytokine 
profile of "natural immunity" secreted by different effector cells, the nature of the peptide 
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ligands derived from the microorganisms, as well as the activity of costimulatory molecules 
and microenvironmentally secreted hormones (Romagnani 1999). The balance between 
these two populations is critically important for the recovery or progression of many disease 
conditions (Young & Hardy 1995). 
Under the influence of Twderived cytokines, Tc (CDS+) cells recognise an array of 
Ag-MHC-I complexes (Lobigs et al. 1996) on infected cells and/or APC. CDS+ T cells 
bearing cognate receptors for these complexes then proliferate and differentiate into 
cytotoxic T lymphocytes (CTL). This CTL play a key role in monitoring and eliminating 
cells infected with intracellular organisms. CTL kill their targets by programming them to 
undergo apoptosis. The cytoplasmic granules in CTL contain cytotoxic effector proteins 
such as perforin and granzymes that trigger apoptosis (Edwards et al. 1999). Moreover, 
these CTL also express Fas ligand which bind with Fas in the target cell membranes, which 
can also activate apoptosis by perforin-independent mechanisms (Razvi & Welsh 1995; 
Topham et al. 1997). Although, CDS+ T cells exhibit mainly cytotoxic activity, they also 
can control viral infections by non-cytotoxic mechanisms (Kimura & Griffin 2000). This 
occurs via the secretion of antiviral cytokines, like IFN-y and TNF (Ramshaw et al. 1997; 
Harty et al. 2000; Klavinskis et al. 19S9), as well as via secretion of chemokines that 
contribute to the recruitment of inflammatory cells with microbiocidal activities, including 
macrophages and neutrophils (Harty et al. 2000). 
• Role of major histocompatibility complex 
The effector mechanisms of both CD4+ and CDS+ T cells depend absolutely upon 
recognition of MHC molecules. After infection, infected cells display peptide fragments 
derived from the proteins of the pathogen on the cell surface in conjunction with host-cell 
MHC molecules (Klein 1979). Although MHC molecules do not possess specific peptide 
Ag-binding receptors like B and T cells, MHC molecules bind a broad spectrum of 
individual peptide molecules, in a cleft in the distal region of the MHC molecules. With the 
Ag thus bound, MHC molecules can be recognised by T lymphocytes bearing a T cell 
receptor of the correct specificity (Kuby 1994; Abbas et al. 1997). 
2S 
On the basis of function and structure, MHC molecules are classified as class I, II or III. 
Nearly all nucleated cells can express MHC-I molecules, always in association with a small 
stabilizing protein, J32-microglobulin (Kuby 1994). MHC-I molecules present 
endogeneously synthesized peptide fragments, such as those derived from viruses in 
infected cells, which are recognised by specific killer cells (Springer 1990). Cos+ T cells 
can recognise only MHC-I-associated Ag and thus, are known as class-I-restricted T cells 
(reviewed in Rothman et al. 1993). MHC-Il molecules are constitutively expressed by APC. 
They present phagocytosed, processed peptide Ag to helper T cells (Springer 1990). C04+ T 
cells can recognise only MHC-Il associated Ag, and thus are said to be MHC-Il restricted 
(Glimcher & Kara 1992). A relatively restricted range of cells constitutively express 
MHC-Il, but include macrophages/monocytes, B lymphocytes, dendritic cells, thymic 
dendritic cells, thymic epithelial cells, human vascular endothelial cells and Langerhans 
cells (Glimcher & Kara 1992). However, a wider range of cells can be induced to express 
MHC-II, including skin fibroblasts, neuroglial cells, pancreatic beta cells, thyroid epithelial 
cells and non human vascular endothelial cells (Kuby 1994; Mauerhoff et al. 19SS). 
MHC-III is not a membrane protein. It plays no role in Ag presentation to T lymphocytes 
(Kuby 1994) and thus will not be reviewed here. 
• Role ofT cells in viral encephalitis 
T cells are key players in antiviral immunity. They participate in the antiviral response both 
directly, by destroying viral infected cells (Edwards et al. 1999; Topham et al. 1997) and 
producing a range of antiviral cytokines (Ramshaw et al. 1997) that inhibit viral replication 
(Kundig et al. 1993; Schijns, 1991; Rossol-Voth et al. 1991), and indirectly, by providing 
help to B cells (Klein 1979). Several mouse models of viral encephalitis have shown the 
crucial role ofT cells for the control of viral infection in the CNS (Flory et al. 1993; Binder 
& Kundig 1991; Oomachowske et al. 2000). 
Williamson & Stahlman (1990) showed that both C04+ and COS+ T cells are required for 
the effective clearance of mouse hepatitis virus (MHV) from the CNS. Although clearance 
of MHV from the CNS was mediated mainly by COS+ T cells (Williamson & Stahlman 
1990), they required support from C04+ T cells. Without the help of C04+ cells, COS+ T 
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cells became apoptotic and were unable to clear the virus (Stohlman et al. 199S). Similarly 
in Borna disease, CDS+ T cells can control Borna disease virus infection in the CNS only in 
cooperation with CD4+ T cells (Noske et al. 199S). In contrast, in measles virus 
encephalitis, CD4+ T cells alone are protective in resistant mice, however, in partially 
resistant mice, these cells need help from CDS+ T cells to control infection (Weidinger et al. 
2000). In flaviviral encephalitis, role of T cells has not been studied in detail in animal 
models. Jacoby et al. (19SO) showed that adoptive transfer of immune spleen cells can 
protect na!ve mice from lethal flaviviral encephalitis. In JE virus, the adoptive transfer of JE 
virus specific CDS+ T cells via intracerebral (i.e.) route was found to be protective against 
lethal i.e. JE virus infection in adult mice only (Murali-Krishn & Manjunath 1996). Studies 
on T-cell-deficient as well as T-cell-suppressed mice further implicate the role ofT cells in 
control of viral encephalitis. Liu & Chambers (2001) have demonstrated that CD4+ 
T -cell-deficient mice are highly susceptible to YF viral encephalitis, compared to control 
mice. 
Similarly, CDS+ T cell-depleted mice are highly susceptible to coronavirus-induced 
encephalomyelitis (Flory et al. 1993) while CD4+ T cell depletion with monoclonal Ab 
results in death from severe CDS+ T cell-mediated immunopathology (Christensen et al. 
2001). Taken together, the balance between resistance and susceptibility to disease depends 
on the functional composition of the respective T cell subsets (Weidinger et al. 2000). Both 
subsets of T cells are important in combating the viral infection. Defects in or deletion of 
one of the subsets precipitate severe disease or death either from overwhelming viral 
infection or immunopathology. 
1.4.2.3. Cytokines: messengers of the immune system 
Cytokines are a low molecular weight (approximately S-SO kDa), soluble heterogeneous 
group of polypeptides that mediate intercellular communication. They are secreted by 
leukocytes, resident CNS cells and a wide variety of other cell types in the body in response 
to a number of stimuli. They act either in an autocrine or paracrine manner and thus 
contribute to a chemical signalling language in association with hormones and 
neurotransmitters to regulate development, tissue repair, haematopoiesis, inflammation and 
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immune responses (Balkwill 1997; Hopkins & Rothwell 1995). They have an extremely 
broad range of activities and may be synergistic or antagonistic, as well as having functional 
redundancy (Abbas et al. 1997). Cytokines exert their functions by binding to their specific 
receptors on the membrane of target cells. This sets off an intracellular signalling cascade 
leading to induction, enhancement or inhibition of a number of cytokine-regulated genes, 
with subsequent phenotypic changes in a variety of cells (Balkwill 1997; Miyajima et al. 
1992). 
Constitutive expression of most cytokines is low or undetectable. However, many increase 
massively in response to infection or injury, indicating a clear role in pathophysiological 
states (Hopkins & Rothwell 1995). The hallmark function of cytokines is the alteration of 
immune cells behaviour (Becher et al. 2000). They regulate the intensity and duration of the 
immune response, either by stimulating or inhibiting the activation, proliferation, and 
differentiation of various immune cells (Balkwill 1997). They also regulate secretion of Ab 
or cytokines from immune cells. In this manner they can activate the entire network of 
interacting cells of the immune system (Young & Hardy 1995; Balkwill 1997; Kuby 1994). 
Therefore, cytokines are also known as "messenger proteins" of the immune system (Kuby 
1994). IL, IFN, TNF, colony stimulating factors (CSF), chemokines, growth factors, 
neurotrophins and neuropoietins are all cytokines (Hopkins & Rothwell 1995) and can 
influence CNS functions. The major members of each cytokine family and their functions 
are summarised in table 1.3. Most studies have been carried out on inflammatory cytokines, 
especially on IFN-y and TNF. These contribute to CNS inflammation and antiviral 
responses, as well as to the generation of CNS pathology. Studies on cytokine/cytokine 
receptor-deficient mice, together with experiments blocking the functions of 
cytokine/cytokine receptor are allowing us to dissect out the role of these cytokines in 
inflammation and disease (Pasparakis et al. 1996; Huang et al. 1993 Dalton et al. 1993; 
Cantin et al. 1995). 
1.4.2.3.1. IFN-y: an immune interferon and antiviral cytokine 
IFN-y, or type II IFN, is a pleotropic, 17 kDa polypeptide cytokine. It plays a critical role in 
immune regulation. For this reason, it is also known as immune interferon (Popko et al. 
1997). IFN-y is produced by activated T lymphocytes (both CD4+, T H1 subset, and CDS+ T 
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Table: 1.3 Summary of major activities and features of cytokine families 
Family 
Chemokines 
Major members I Major activities and features 
MIP-laiP, RANTES, I Leukocyte chemotaxis and cellular activation 
MCAF/MCP-1, IL-8 
MGSA, NAP-1/2 
Colony stimulating I G-CSF, M- CSF, IL-3, I Colony cell formation in the bone marrow 
factors (CSF) GM-CSF and activation of mature leukocyte functions 
Growth 
(GF) 
factors I EGF, FGF, PDGF, I Cell growth and differentiation 
TGF- alP and ECGF 
Interleukins (IL) 
Interferons (IFN) 
Neurotropins 
Neuropoietins 
Tumor necrosis 
factors (TNF) 
IL-la, IL-lP, !Lira I Multiple tissue and immunoregulatory 
and IL-2 to IL-15 activities 
IFN - alP and IFN-y Inhibition of intracellular viral replication and 
cell growth regulation, IFN-y is primarily 
immu-noregulatory 
BDNF, NGF, NT-3 to I Growth and differentiation of neurons 
NT-6 and GDNF 
CNTF, OM and IL-6 Cytokines acting on the nervous system, and 
acting via related receptor complexes 
TNF and lymphotoxin I Similar to IL-l, in addition to tumor 
Cl. and 13 cytotoxicity 
Addapted from Hopkins & Rothwelll995. Abbreviations: BDNF, brain-derived neurotrophic 
factor, CNTF, ciliary neurotrophic factor, E & FGF, epidermal & fibroblast GF, ECGF, 
endothelial cell GF, GDNF, glial-derived neurotrophic factor, G, M & GM-CSF, granulocyte, 
macrophage & granulocyte/macrophage-CSF, IUra, IL-l receptor antagonist, MCAF, 
monocyte chemotactic and activating factor, MCP-1, monocyte chemotactic protein, MGSA, 
melanoma growth stimulatory activity, MIP-1 alP, macrophage inflammatory protein, NAP, 
neutrophil activating protein, NGF, nerve growth factor, NT, neurotrophin, OM, oncostatin 
M, PDGF, platelet-derived GF, RANTES, regulated upon activation normal T expressed and 
secreted, TGF- alj3, transforming GF-alp. 
cell), NK cells (Howard & Hardy et al. 1995) and macrophages (Gessani & Belardelli 
1998). It acts on cells which posses the IFN-y receptor (IFN-yR) and induce increased 
expression of several genes. Therefore, many organs and systems have been found to be 
affected by IFN-y since IFN-yR are present on virtually all cells of the body (Billiau 1996). 
IFN-y facilitates the differentiation of CD4+ T lymphocytes into the T H 1 subset involved in 
cell-mediated immunity. Cells from this subset in their turn also secrete IFN-y. In contrast, 
IFN-y inhibits the stimulation of TH2 cells, which are involved in humoral immunity 
(Young & Hardy 1995). Several studies have demonstrated that endogenous production of 
IFN-y is essential for host defence against virus infection (Huang et al. 1993; Bouley et al. 
1995; Karupiah et al. 1990). IFN-y is an antiviral cytokine that inhibits viral replication 
either directly (Ruby 1997), or indirectly by activating other effector cells of the immune 
system. Effector cells activated by this cytokine include CTL, NK cells and macrophages. 
These cells control viral replication by eliminating infected cells and themselves producing 
a variety of inflammatory cytokines, including IFN -y (Utermohlen et al. 1996; Billiau 
1996). IFN-y produced by NK cells is transient compared to IFN-y produced by T cells. 
Nevertheless, this brief response plays an important role in controlling pathogens during 
early stages of infection (Romani et al. 1997). 
IFN-y acts as a mediator of both innate and adaptive immunity. In innate immunity, it 
increases the antimicrobial capacity of macrophages by inducing increased production of 
reactive oxygen and nitrogen intermediates (Hz02, NO), increased expression of MHC 
molecules required to present Ag to lymphocyte, increased expression of FeR required for 
the opsonization of neutralized microbial pathogens (Loughlin et al. 1993; Kreil & Eibl 
1995) and increased production of indoleamine-2-3-dioxygenase (IDO) enzyme, required 
for the metabolism of tryptophan (Thomas et al. 1994) (see below). In adaptive immunity, 
IFN-y regulates Ab production via direct effects on B cells. IFN-y thus promotes switching 
of Ig into Ig02a and Ig03 subclasses, but inhibits switching to IgG 1 and IgE (Young & 
Hardy 1995). IFN-y also induces increased expression MHC-I and MHC-II molecules on a 
wide variety of cell types (Grau et al. 1997; Huynh & Dorovini-Zis 1993; Momburg et al. 
1986). It activates vascular endothelial cells to express high levels of cell surface CAM 
(Grau et al. 1997; Doukas & Pober 1990), which, with regulation of chemokine production 
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Table: 1.4 Summary of major activities and features of IFN-y on CNS cells 
Cell types Effect Functional response 
t ICAM-1, VCAM-1 Adhesion 
Astrocytes INO Astrogliosis 
t MHC-I T cell cytotoxicity 
t MHC-II Ag presentation 
t ICAM-1 Adhesion 
I Phagocytosis Damage 
Microglia 
INO,ROI Cytotoxicity 
t MHC-I/MHC-II T cell cytotoxicity I Ag 
presentation 
t ICAM-lNCAM-1 Differentiation 
Neurones IROI,NO Damage 
INO Differentiation 
t MHC-I Antigen presentation 
t ICAM-1 . Adhesion, death 
Oligodendrocytes 
INO Damage 
_I 
- -- --
Derived from Munoz-Fernandez & Frenso 1998. Abbreviations: Ag: antigen, ICAM-1: 
intercellular adhesion molecule-1, MHC: major histocompatibility complex, NO: nitric 
oxide, NGF: neurotrophic growth factor, ROI: reactive oxygen intermediates, VCAM-1: 
vascular cell adhesion molecule-1, I: upregulation 
by IFN-y (Tran et al. 2000), facilitates the recruitment of different subpopulations of 
leukocytes to the sites of inflammation (Issekutz et al. 1988; Sethna & Lampson 1991). 
IFN-y has multiple effects on CNS cells. It is involved both in normal functioning of the 
brain as well as in the development and differentiation of neurones there (Munoz-Fernandez 
& Frenso 1998). IFN-y may be either neuroprotective or neurotoxic depending upon the 
effects it may exert on different CNS resident cells. The major effects of IFN-y on CNS 
resident cells are summarised in table 1.4. 
• Nitric oxide: an antiviral radical gas 
NO is a small membrane-permeable gas that serves as a mediator of many physiological 
functions. These include regulation of blood pressure, organ blood flow distribution, 
inhibition of the adhesion and activation of platelets and polymorphonuclear granulocytes, 
neurotransmission, insulin release and many others (Southan & Szabo 1996).1t is water-and 
lipid-soluble and easily diffuses across the cell membrane. Thus, NO can exert its function 
not only in the cell where it is produced but can also interact with neighbouring cells and 
other molecules (Karupiah et al. 2000). It is produced by the oxidation of L-arginine by 
nitric oxide synthase (NOS) enzyme under both physiological and pathophysiological 
conditions, and converted into reactive nitrogen intermediates or other stable secondary 
products. Both forms are involved in normal tissue function and pathology (MacMicking et 
al. 1997). Many different cell types can be induced to produce NO (Boje & Arora 1992; 
MacMicking et al. 1997; Andrews et al. 1999; Komatsu et al. 1996), however, activated 
macrophages and neutrophils are the major source of NO (Karupiah et al. 2000). 
NOS has 3 isoforms. NOS 1 is expressed constitutively in neurones (Komatsu eta/. 1999). 
NOS3 is expressed constitutively in endothelial cells (Karupiah et al. 2000). These isoforms 
are involved in the normal physiology and regulation in these cells. In contrast, NOS2 is 
readily inducible by IFN-y, hence it is also known as inucible nitric oxide synthase (iNOS). 
It is typically associated with inflammatory and immune responses (Karupiah et al. 1998; 
Willenborg et al. 1999). The productions of NO is modalities used for controlling viral 
infections (Guidotti et al. 2000; Karupiah et al. 1993). Much evidence suggests that NO also 
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contributes to innate resistance against viral infections (Karupiah et al. 1998; Tucker et al. 
1996) and that it can inhibit viral replication at an early stage. This prevents viral spread and 
promotes viral clearance and earlier recovery from infection (Reiss & Komatsu 1998). 
Growing evidence from experiments using NOS gene-deficient mice, or neutralizing NOS 
with aminoguanidine or treating mice with an analog of arginine, Nw-nitro-L-arginine 
methyl ester (L-NAME), have shown the crucial requirement of NO in antiviral defence 
(Saxena et al. 2000; Komatsu et al. 1999; Karupiah et al. 1998; Tucker et al. 1996). 
The actual mechanism of antiviral action of NO is still not clear. They may be mediated by 
reaction with several possible cellular and viral targets. These include inhibition of 
ribonucleotide reductase, activation of cellular guanylate cyclase, modification of both 
cellular and viral transcription factors, inhibition of cellular metabolism (Mannick 1995; 
Komatsu et al. 1999) or inhibition of viral proteases (Saura et al. 1999). Although NO is 
important for early antiviral defence, its excessive production is harmful, leading to 
pathology in many neurotropic viral infections (Lane et al. 1999; Rose et al. 1998; Andrews 
et al. 1999; Fujii et al. 1999). 
• Indoleamine-2,3-dioxygenase: IFN-y inducible enzyme 
IDO is a monomeric haemoprotein that catalyzes the oxidation of tryptophan into 
N-formylkynurenine, the first and rate limiting step in this metabolic pathway. Although 
IDO can be induced by several other cytokines, IFN -y is the most potent inducer of IDO 
(Takikawa et al. 1990; Thomas et al. 1993). Yoshida et al. (1979) were the first to suggest 
the possible role of IDO in antiviral defence. Christen et al. (1990) have demonstrated the 
role of IDO as an antioxidant defence against viral pneumonia. Increased levels of IDO 
have been observed in viral encephalitides (Heyes 1992; Maloney 2000) and intracellular 
parasitic disease (Thomas et al. 1993). In addition to its antimicrobial properties, IDO also 
plays an important role in the development of fetus as demonstrated by Kamimura et al. 
(1991). Besides these functions, IDO may be involved in rejecting allografted tumors by 
damage to cells through tryptophan depletion (Takikawa et al. 1990). 
Quinolinic acid (QA) is an end product of tryptophan metabolism. It is a neurotoxic agonist 
of the N-methyl-D-aspartate (NMDA) type excitatory amino acid receptor family. It's 
34 
neurotoxicity is mediated by overactivation of NMDA receptors, oxidative stress and 
reactive oxygen species production (Santamaria et al. 2001). On the other hand, kynurenic 
acid which is also produced during tbis metabolism protects neurones from the toxic effects 
of QA (reviewed in Sanni et al. 1998; Heyes et al. 1992). Therefore balanced production of 
QA and kynurenic acid is required for the proper function of CNS. Overproduction of QA 
causes neurodegeneration (Heyes et al. 1992). 
1.4.2.3.2. TNF: a proinflammatory and antiviral cytokine 
TNF is one of the many cytokines that make up the complex network of biological response 
modifiers active in the host response to infectious diseases (Czarniecki 1993). It is produced 
primarily by activated immune cells. Although TNF is produced by T and B lymphocytes, 
NK cells and mast cells, macrophages are the major source of TNF which is produced by 
these cells in response to various stimuli. Therefore, TNF is also seen as a mediator of botb 
innate and adaptive immunity, and acts as an intermediate link between acute and adaptive 
inflammatory responses (Pasparakis et al. 1996, Abbas et al. 1997). In the CNS, it is 
produced by neurones, microglia and astrocytes upon stimulation (Acrain et al. 2000; Chen 
et al. 2000; Medana et al. 1997). TNF is produced predominantly as a secreted form, 
although it also exists as a transmembrane form on the surface of activated immune cells. 
Both forms are bioactive and bind to their receptors (Herbein & Brien 2000). This sets off 
an intracellular signaling cascade for the induction of many genes (Larrick & Wright 1990). 
TNF plays an important role in inflammation by promoting the transmigration of 
inflammatory leukocytes to the sites of inflammation. This is mediated by inducing 
expression and upregulation of CAM in the vascular endothelium (de Jong et al. 1996; 
Dobbie et al. 1999) and increasing the permeability of endothelial cells (Medana et al. 
2001). TNF also acts as an antiviral cytokine. It interferes with viral replication in several 
ways and thus plays an important role in many viral infections (Rossel-Voth eta! 1991; 
Schijns et al. 1991). Some of its actions include directly inhibiting viral replication by 
preventing viral entry into the cell, inducing apoptosis in virus-infected cells and exerting 
antiviral effects in association with IFN (Czarniecki 1993; Herbein & Brien 2000). TNF 
further plays an important role in controlling T cell activation and proliferation by 
regulating IL-2 receptor expression (Pimentel-Muinos et al. 1994), required for T cell 
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Table: 1.5 Summary of major activities and features of TNF on CNS cells 
Cell types Effect Functional response I 
t ICAM-1, VCAM-1 Adhesion 
INO Astrogliosis 
Astrocytes 
I Proliferation Astrogliosis 
t MHC-IIMHC-II T cell cytotoxicity/ Ag presentation 
INGF Nerve repair 
t ICAM-1 Adhesion, Ag presentation 
I Phagocytosis Adhesion 
Microglia 
INO,ROI Cytotoxicity 
t MHC-IIII Ag presentation 
t ICAM-lNCAM-1 Adhesion/differentiation 
Neurones IROI,NO Damage 
INO Adhesion/differentiation 
I Demyelination Damage I 
Oligodendrocytes t ICAM-1 Adhesion, death 
INO Damage 
-
-
-
' 
- -
Derived from Munoz-Fernandez & Frenso 1998. Abbreviations: Ag: antigen, ICAM-1: 
intercellular adhesion molecule-!, MHC: major histocompatibility complex, NO: nitric 
oxide, NGF: neurotrophic growth factor, ROI: reactive oxygen intermediates, VCAM-1: 
vascular cell adhesion molecule-!, I: upregulation 
activation (reviewed in Pimentel-Muinos et al. 1994 ). Besides these functions, TNF acts as 
a regulator of the humoral immune response and is required in the formation of primary 
lymphoid follicles and germinal centers in the spleen (Pasparakis et al. 1996). Like IFN-y, 
TNF exerts multiple effects in CNS cells. The summary of effects of TNF on CNS resident 
cells is presented in table 1.5. Although TNF is involved in antiviral defence, excessive 
production in the CNS is detrimental, and may exacerbate disease, resulting in death 
(Andrews et al. 1999; Choe et al. 1998). 
1.4.2.3.3. IL-10 and TGF -13: anti-inflammatory cytokines 
The anti-inflammatory cytokines are a series of immunoregulatory molecules which can 
modulate the proinflammatory cytokine response under pathophysiological conditions to 
limit the injurious effects of sustained or excess inflammatory reactions. Thus, a dynamic 
balance exists between proinflammatory and anti-inflammatory cytokines (Opal & Depalo 
2000). IL-10 and tumor growth factor-13 (TGF-13) are examples of anti-inflammatory 
cytokines that regulate the production of proinflammatory cytokines produced by activated 
THl CD4+ T cells and activated macrophages. Being anti-inflammatory in nature, these 
cytokines play a critical role in preventing uncontrolled T cell-mediated tissue destruction, 
and have thus become important therapeutic proteins for the treatment of organ-specific 
autoimmune diseases (Cua et al. 2001). 
IL-l 0 is an 18 kDa molecule produced by a variety of cell types such as T H2 T cells, B cells, 
macrophages, mast cells and glial cells (Chabot et al. 1999; Wagner et al. 1999) and is 
perhaps the most important anti-inflammatory cytokine found in the human immune 
response. It is a potent inhibitor of THl cytokines, IL-2 and IFN-y. Therefore IL-10 was 
previously known as cytokine synthesis inhibition factor (Opal & Depalo 2000). IL-l 0 
regulate the activities of macrophages by inhibiting cytokine secretion, like TNF, IL-l, 
IL-12 and chemokines, and by reducing MHC-II and costimulators (eg., B7-l and B7-2) to 
reduce T cell activation. In addition to this, IL-l 0 plays a crucial role in the proliferation of 
CD4+ T cells into THO-TH1-TH2, as well as in the differentiation of B cell, thymocytes and 
mast cells (reviewed in Sawada et al. 1999). Moreover, IL-l 0 is a unique and potent 
modulator of the CNS cytokine network that regulates the expression of both cytokines and 
cytokine receptors by CNS resident cells (Sawada et al. 1999; Szczepanik et al. 2001). CNS 
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expression of IL-10 was found to abrogate EAE. The i.e. inoculation of replication-deficient 
adenovirus expressing human IL-10 into mice with active EAE blocked the progression of 
EAE ( Cua et al. 2001) by reducing cell damage and enhancing lesion repair through the 
protection of oligodendrocytes and their progenitors (Molina-Holgado et al. 2001 ). 
However, intravenous (i.v.) inoculation of same vector was unable to protect the mice from 
EAE, despite high levels of circulating IL-10. 
TGF-~ is a group of cytokines (TGF-~1, TGF-~2 and TGF-~3) (Opal & Depalo 2000), 
produced by a variety of cells, including T cells, macrophages and glial cells (Abbas et al. 
1997; Lehrmann et al. 1998). These cytokines play important regulatory roles in 
angiogenesis, osteogenesis, reproduction, development, cell growth and differentiation, 
wound healing and immune responses (Benveniste 1998). Like IL-l 0, the TGF-~ cytokines 
are an important regulatory group that can shut off immune and proinflammatory responses. 
They can suppresses activation and proliferation of B and T cells and maturation of CTL. 
They inhibit production of proinflammatory cytokines (TNF, IL-l) from activated 
macrophages and can down-regulate MHC-II expression (Letterio 2000; Benveniste 1998). 
In the CNS, TGF-~ reduces the incidence of neuronal death induced by trophic factor 
removal, excitotoxicity and oxidative injury (Prehn et al. 1994). Although IL-10 and TGF-~ 
both are negative regulators of the immune response, their regulation of THl activity is 
different. IL-10 blocks the activity of THl T cell by suppressing macrophage activity, 
whereas TGF-~ directly acts upon THl T cells (Janeway et al. 2001). 
1.4.2.3.4. Chemokines: chemoattractant cytokines 
As previously mentioned (see the section on innate immunity, section 1.4.1.2.), neutrophils, 
macrophages, and NK cells, which are the effector cells of the innate immune response play 
important roles in neutralizing and clearing infectious pathogens before the development of 
adaptive immunity. Thus, migration of these cells into infectious sites and their subsequent 
activation is a critical step, enabling the host to achieve effective and efficient removal of 
pathogens. Among the cytokines released in the earliest phases of infection, are members of 
a family of chemoattractant cytokines known as chemokines. Chemokines are 
heparan-binding proteins that chemotactically guide the inflammatory cells in a 
unidirectional way through the microvascular cell wall (Ransohoff et al. 1996; De Groot & 
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Woodroofe 2000). They are secreted not only in response to infectious pathogens but also in 
response to a number of other different stimuli such as trauma, proinflammatory cytokines, 
and products of an activated immune response (McManus et al. 2000). On the basis of 
structural and genetic criteria, chemokines are generally classified into four subfamilies. 
This includes CC or ~-chemokines, CXC or a-chemokines, CX3C and C chemokines (De 
Groot & Woodroofe 2000). CXC chemokines are produced largely by activated 
macrophages as well as tissue cells such as endothelium and fibroblasts, and 
megakaryocytes. These chemokines are specific to neutroplils and act as a mediator of acute 
inflammation (Abbas et al. 1997). IL-8 was the first chemokine to be identified and belongs 
to the CXC family (Janeway et al. 2001). The CC chemokines are largely produced by 
activated T cells and act predominantly on T cells, monocytes, eosinophils and basophils, 
but not on neutrophils (Ransohoff et al. 1996). Macrophage inflammatory protein- Ia 
(MIP-la), regulated upon activation normal T expressed and secreted (RANTES), 
macrophage inflammatory protein-!~ (MIP-1~), monocyte chemotactic protein-! (MCP-1), 
etc., are the examples of CC group chemokines (Mahalingam & Karupiah 1999). 
Fractalkaline/neurotactin belongs to the CX,C family and acts on T lymphocytes, NK cells 
and monocytes, whereas lymphotactin belongs to C chemokine and is chemotactic only for 
T lymphocytes (Mahalingam & Karupiah 1999; De Groot & Woodroofe 2000). Like 
cytokines, chemokines exert their functions through the specific receptors (Rollins 1997) 
present in wide variety of cells (Jiang et al. 1998; Meucci et al. 2000). They elicit a 
signalling cascade to attract inflammatory cells from the circulation to the sites of 
inflammation (Siebert et al. 2000). Chemokines play a critical role in the perivascular 
transmigration and accumulation of specific subsets of leukocytes to the sites of 
inflammation (Asensio et al. 1999). 
Several studies on chemokine gene or chemokine receptor gene knock out mice in viral 
encephalitis have proven the importance of chemokine expression for the recruitment of 
inflammatory cells in the CNS (Liu et al. 2001; Salazar-Mather et al. 2000; Andrews et al. 
1999). Moreover, recent studies have demonstrated antiviral properties of chemokines. 
Chemokine receptor, CC receptor-S, CCR-5, may function as a co-receptor for viruses like 
HIV -1 (Alkhatib et al. 1996; Deng et al. 1996) and natural mutation of such a specific co-
receptor can confer resistance to the virus, and thus may have significant advantages in 
HIV-1 therapy (Yang et al. 1997). In addition to these, chemokines also have been found to 
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modulate different biological functions such as cell adhesion, phagocytosis, cytokine 
secretion, T cell activation, apoptosis, proliferation, angiogenesis, haematopoiesis and viral 
pathogenesis (Bacon & Harrison 2000; Rollins 1997). 
1.5. The immune response within the central nervous system 
As previously mentioned, the CNS has been considered to be an 'immune-privileged site" 
for many years due to the presence of the BBB which isolates the CNS from the peripheral 
immune system. This, coupled with lack of lymphatic drainage and low or absent 
expression of MHC molecules which effectively allow foreign Ag to hide from the immune 
system, helped to maintain this view. However, this has gradually changed due to 
recognition of the ability of activated T cells to pass across the BBB continuously to 
monitor the CNS (Hickey et al. 1991). More importantly, resident cells, such as microglia 
and astrocytes can themselves mount a potent response upon invasion by pathogens. Work 
from both animal models of virus-induced encephalitis, and in vitro culture systems have 
shown that both microglia and astrocytes can secrete numerous cytokines and chemokines, 
as well as express receptors that enable communication with the peripheral immune system 
(Chao et al. 1994; Merrill et al. 1996; Ransohoff et al. 1996; Dickson et al. 1993; Brodie et 
al. 1997; Schijns et al. 1991; Persidsky et al. 1999; Sauder et al. 2000; Asensio et a/.1999). 
Moreover, when activated, microglia and astrocytes can function as APC. They express 
high levels of cell surface MHC molecules (Bo et al. 1994; Weissenbock et al. 2000). 
Therefore, it is presently widely accepted that these cells actively collaborate with 
peripheral immune cells to generate an effective inflammatory response within the CNS. 
Interestingly, Neuman & Wekerle (1998) suggested that neurones, particularly 
physiologically active neurones, are the main player in regulating immune responses within 
the CNS by suppressing MHC-II inducibility and cytokine production in microglia and 
astrocytes through their electrical activity. This prevents unwanted immune-mediated 
damage of neurones. Under stress, however, neurones activate immunologically relevant 
molecules in these glial cells to enable them to become competent for interaction with 
infiltrating leukocytes (Neuman 2001). 
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1.5.1. CNS cells: factories for cytokines 
Several studies, both in vivo and in vitro, have shown that CNS resident cells are the 
endogenous source of cytokines that act as the intercellular messengers in neurone-glia 
interactions, microglial-astroglial crosstalk, as well as in glial-T cell interactions during 
infection or injury (Acarin et al. 2000; Nohava et al. 1992; Streit et al. 1999). 
From studies by Knoblach et al. (1999) and Acrain et al. (2000), it is likely that neurones 
are involved in initiation and propagation of inflammation through their production of TNF 
and IL-6 in response to injury. Moreover, neurones can regulate the activities of 
microglia!macrophages, leading to local expansion and enhanced function, in CNS 
inflammatory diseases. This occurs via production of macrophage-colony stimulating factor 
(M-CSF) (Nohava et al. 1992) (CSF-1 in mouse) (Kreutzberg 1996) which is mitogenic for 
microglia (Lodge & Sriram 1996). Lack of CSF-1 in mice results in an abnormal microglial 
response and increased neuronal vulnerability to injury (Berezovaskaya et al. 1995). Several 
in vitro studies have shown the ability of astrocytes to produce cytokines such as IL-6 and 
TNF upon stimulation (Chen et al. 2000; Schoneboom et a/.!999). Acrain et al. (2000) have 
shown that astrocytes can also produce these cytokines within the CNS in vivo and actively 
pariticipate in the initiation of immune responses and inflammation within the CNS. 
Although, neurones and astrocytes can produce cytokines, activated microglia are the most 
abundant source. During neuronal stress these cells may become virtual factories for 
cytokines in the CNS (Graeber 1993). 
In in vitro culture systems, microglia have been shown to express of IL-l (Giulian et al. 
1986; Giulian et al. 1994), TNF (Renno et al., 1995; Medana et al. 1997), IL-12 (Lodge & 
Sriram 1996), IL-18 (Prinz & Hanisch 1999) and IL-Ia and IL-6 (Mitrasinovic et al. 2001). 
Similarly, in vivo animal models have shown that upon stimulation, microglia can produce 
cytokines within the CNS, including IFN-la (Yamada et al. 1994), IL-la (Zhao et al. 
2001), IL-lf:l and TNF (Acrain et al. 2000). These in turn induce upregulated CAM 
(Zielasek et al. 1993; Shen et al. 1997) and chemokine induction (McManus et al. 1998) 
which promotes recruitment of leukocytes across the BBB and may enhance inflammation 
in the CNS. Microglial production of IL-l f3 is also involved in remyelination via induction 
of growth-promoting factors, such as insulin-like growth factor-!, during pathological insult 
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within the CNS (Mason et al. 2001). Microglia have been found to express many cytokine 
receptors constitutively. These include receptors for IFN-la (Yamada & Yamanaka 1995), 
M-CSF (Mitrasinovic et al. 2001), IL-12 (Taoufik et al. 2001), IL-l, TGF, GM-CSF and 
IFN-y (Morris & Esiri 1998). 
It is known that glial cells play a critical role in CNS inflammation, thus contributing to 
defence in the CNS against infection. However, several studies suggest that activated glial 
cells are involved in brain damage by secreting proinflammatory cytokines and neurotoxic 
metabolites (Choe et al. 1998; Gonzalez-Scarano & Baltuch 2000; Banati et al. 1993; Boje 
& Arora 1992). Therefore, perhaps not surprisingly, these glial cells can also release potent 
anti-inflammatory cytokines such as IL-10 and TGF-[3 (Wagner et al. 1999; Pratt & 
McPherson 1997) which inhibit the local production of inflammatory mediators as an 
emergency mechanism in circumstances of brain inflammation (Hu et al. 1999). These 
cytokines function as negative regulators in the CNS cytokine network, mainly by 
suppressing microglial function (Sawada et al. 1999; Lodge & Sriram 1996), including 
chemokine production (Hu et al. 1999), production of proinflammatory cytokines (Lodge & 
Sriram 1996) and neurotoxic metabolites, such as NO and reactive oxygen intermediates 
(Molina-Holgado et al. 2001; Chao et al. 1995; Ledeboer et al. 2000), and thus limit or 
prevent brain damage. IL-10 is not constitutively expressed in the CNS, whereas TGF-[3 is 
constitutively expressed in microglia at low levels contributing to CNS homeostasis 
(reviewed in Hu et al. 1999; Morris & Esiri 1998). 
1.5.2. CNS cells: a source of chemokines 
Experiments in vivo and in vitro have demonstrated that cells of the CNS can express 
chemokines and their receptors. This is likely to result in the chemoattraction of 
inflammatory cells to the sites of viral infections in the CNS. This notion is supported by 
Persidsky et al. (1999). His group has shown that both microglia and astrocytes can produce 
f3-chemokines, including MIP-1a, MIP-1[3, MCP-1 and RANTES, in HIV-1 infection in an 
in vitro culture system. Using SCID mice as an in vivo model, they found that [3-chemokines 
secreted by glial cells play an important role in the transmigration of monocytes from 
circulation into the CNS. Similarly, Palm and Kim (2001) also observed secretion of 
f3-chemokines such as RANTES, IP-10, MIP-1 a and MIP-1 f3from glial cells, including 
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astrocytes, microglia and oligodendrocytes in Theiler's virus infection. Moreover, in a study 
carried out by Sauder et al (2000), glial cells, especially astrocytes, can express 
~-chemokines gene IP-10 and RANTES in the absence of inflammation in Borna disease. 
Chemokines are not only chemotactic for inflammatory leukocytes, but also chemotactic for 
microglia (Peterson et al. 1997). Both human microglia (Peterson et al. 1997) and rodent 
microglia (Johnstone et al. 1999) have been demonstrated to migrate in response to 
~-chemokines, secreted by glial cells in a concentration-dependent manner. Besides 
chemokine synthesis, astrocytes and microglia can express several different types of 
chemokine receptors, including CX3CR1, CCR1, CCR5, CCR2, etc., (Dorf et al. 2000; 
Gebicke-Haerter et al. 2001; Jiang et al. 1998). In addition to the traditional role of 
leukocyte attraction, several studies have shown a role for chemokines in normal CNS 
functions. For example, neurones can express chemokine receptor, CX3CR1, the receptor 
for fractalkine, a chemokine that can directly modulate neuronal activities like synaptic 
transmission and neuronal survival (Meucci et al. 2000). This chemokine is produced by 
neurones themselves (Tong et al. 2000). 
1.5.3. CNS cells: a source of nitric oxide 
NO in the CNS has highly pleiotropic biological characteristics. It influences many aspects 
of CNS physiology, including synaptic plasticity, neuronal development and behavioural 
responses and reduces leukocyte extravasation (Munoz-Fernandez & Frenso 1998). The 
expression of NOS, which produces NO, has been characterized in numerous cell types of 
the CNS, either as a constitutive function or as a response to stimuli. NO can act as a 
physiological neurotransmitter in the CNS and has been found to inhibit viral replication in 
neurones. It is produced constitutively by neuronal constitutive NOS (NOS1) in neurones 
(Komatsu et al. 1999). Several in vivo and in vitro culture systems have shown that both 
microglia and astrocytes can be induced to express NOS2 for the production of NO upon 
immune stimulation (Grzybicki et al. 1997; Zhao et al. 1998; Hemmer et al. 2001; Banati et 
al. 1993; Boje & Arora 1992; Lane et al. 1999). Besides these cells, oligodendrocytes can 
also express NOS2 upon LPS and IFN-y stimulation and thus can produce NO (Molina-
Holgado et al. 2001). 
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According to Lane et al. (1999), generation of NO by NOS2 accelerates demyelination in 
MHV -infected animals by upregulating chemokines, such as MCP-1. In contrast, Okuda et 
al. (1997) have shown that excessive production of NO from NOS2 plays an important role 
in the control of demyelination in EAE through the elimination of inflammatory cells from 
the CNS, possibly via apoptosis. In conclusion, NO produced by CNS resident cells exerts 
variety of functions. These may be antiviral, anti-inflammatory, neuronal death-inducing or 
demyelinating, depending upon the nature of the stimulus. 
1.5.4. CNS cells: an antigen presenting cells 
It is now clear that glial cells, especially astrocytes and microglia, play a critical role in 
orchestrating the immune response in the CNS. Besides their physiological roles in CNS 
homeostasis, both can function as APC in association with MHC I and II on their surfaces. 
These molecules are inducible and regulated by cytokines, neurotransmitters and 
neuropeptides (Neumann & Wekerle 1998; Dong & Benveniste 2001). They enable the 
presentation of Ag to infiltrating lymphocytes (Raivich et al. 1999). Much evidence 
suggests that activated microglia and astrocytes can express increased levels of MHC-I and 
MHC-II molecules in viral encephalitis (Weissenbock et al. 2000; Bi et al. 1995), 
experimental allergic encephalomyelitis (EAE) (Gehrmann et al. 1993), Toxoplasma 
encephalitis (Deckert-Schluter et al. 1999), and ischaemia (Morioka et al. 1992). Similarly, 
several studies have shown the induction of MHC-I and MHC-II in astrocytes (Caplazi & 
Ehrensperge 1998; Liu et al. 1989; Mauerhoff et al. 1988). Although both microglia and 
astrocytes can present Ag and stimulate T cell proliferation in the CNS, recent evidence 
suggests that microglia are more efficient APC than astrocytes (Alsoi et al. 1998). In 
addition to this, Argall et al. (1991) have shown that Schwann cells of the PNS also can 
express MHC-I and MHC-II molecules upon viral infection. 
In contrast to the glial cells, MHC-I inducibility is strictly regulated in the neurones 
(Neumann & Wekerle 1998) via their electrical activity (Neumann 2001), presumably 
because neurones are highly susceptible to the cytotoxic effect of CDS+ T cells (Medana et 
al. 2000). Kimura & Griffin (2000) showed upregulation of MHC-I mRNA in the neurones 
in SBV infection, but they were unable to detect its surface expression. This may be due to a 
posttranscriptional block, mediated by neurones themselves. Recently, it has been found 
43 
that neurones are induced to express MHC-1 molecules upon IFN-y stimulation in in vitro 
culture systems (Neumann et al. 1997), however, this induction is limited only to those 
neurones which lack electric activity (Neumann & Wekerle 1998) or have been paralysed 
before stimulation by the neurotoxin, tetrodotoxin, which blocks sodium channels and 
neuronal electrical activity (Medana et al. 2000; Neumann et al. 1997). This has potentially 
important implications for the clearance of sick neurones in inflammatory responses in the 
CNS. 
1.6. Immunopathology: the result of an uncontrolled immune response 
The outcome of viral infection depends upon the balance between the ability of virus to 
replicate inside the host and the capability of host to generate and maintain an effective 
immune response. Although CNS resident cells can produce several different kinds of 
cytokines and chemokines (Benveniste 1992), the CNS requires help from the peripheral 
immune cells for the effective control of viral replication and clearance (Planz et al. 1997; 
Williamson & Stohlman 1990). During infection, the CNS microvascular endothelium is 
activated, with increased expression of CAM (Nansen et al. 1998). This facilitates the 
transmigration of inflammatory leukocytes through the BBB (Dopp et al. 1994) and thus 
creates a localized inflammatory reaction within the CNS parenchyma (Matyszak 1998). 
These inflammatory cells produce several different types of effectors, including 
proinflammatory cytokines, chemokines, neutralizing Ab and CTL which function to 
combat viral infection (Munoz-Fernandez & Frenso 1998; Hatalski et al. 1998; Noske et al. 
1998) as well as enhance the activation of glial cells (Alsoi et al. 1998; Sedgwick et al. 
1998). These glial cells then secrete more inflammatory cytokines as well as neurotrophic 
growth factors (Nakajima & Kohsaka. 1998; Benveniste 1992) and thus cooperate with the 
activities of infiltrating leukocytes (Alsoi et al. 1998). 
Therefore, entry of inflammatory cells into the CNS and their retention and activation there, 
are crucial steps in the host immune response to neurotropic viral infection. However, 
occasionally, in the process of eliminating infected or dying cells, inflammatory reactions 
get out of hand, with the massive production of active mediators, including 
proinflammatory cytokines, which further increase the activation of inflammatory cells that 
can contribute to pathology in the CNS (Marten et al. 2001; Munoz-Fernandez & Fresno 
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1998) Moreover, activation of CNS resident cells, like microglia, is further enhanced and 
these cells then produce excessive amounts of many cytokines, as well as toxic metabolites 
such as reactive oxygen and nitrogen species, that can contribute to the lethal clinical 
manifestations of encephalitis and neurodegeneration (de Leo & Yezierski, 2001; Banati et 
al. 1993). For examples: several animal models of viral encephalitis have shown the 
importance of IFN and TNF in controlling the viral infections within the CNS (Brooks & 
Phillpotts 1999; Tishon et al. 1995; Rossel-Voth et al 1991), however, exaggerated 
production of these cytokines has been also implicated in the pathology of CNS viral 
infections, brain injury and neurodegenerative disorders (Munoz-Fernandez & Frenso 1998; 
Dickson et al. 1993; Ruddle et al. 1990). 
Maloney et al. (2000) showed that excessive induction of IDO induced by IFN-y is 
asoociated with immunopathology, by significantly decreasing the level of tryptophan 
within the CNS in human T celllymphotropic virus type-1. Tryptophan is highly correlated 
with serotonin, which is an important neurotransmitter (reviewed in Kamimura et al. 1991 ). 
Decreased tryptophan reduces the level of serotonin, alters CNS function and causes 
neuronal death (Maloney et al. 2000). Similarly, NOS2 induced by IFN-y (Karupiah et al. 
1993) leads to excessive production of NO which precipitates pathology in viral 
encephalitis eg., in HSV-1-induced encephalitis (Fujii et al. 1999). Andrews et al. (1999) 
have demonstrated the immunopathological role of TNF in MVE virus-induced 
encephalitis. In this model, increased production of TNF upregulates both microvascular 
CAM and neutrophil-specific chemokines N51/KC. This facilitates increased recruitment of 
neutrophils into the CNS parenchyma, which produces more inflammatory mediators, 
including NO, that disturb CNS homeostasis and neuronal function, leading to death. 
Initiation of EAE (Ruddle et al. 1990) and death from cerebral malaria (Medana et al. 1997) 
further illustrate the immunopathological role of TNF in the CNS. Akwa et al. ( 1998) have 
demonstrated that transgenic mice with CNS expression of IFN-a had significantly 
enhanced survival after i.e. inoculated LCMV infection. However, overproduction of IFN-a 
resulted in progressive inflammatory encephalopathy, with marked calcium mineralization, 
meningoencephalitis, gliosis and neurodegeneration (Campbell et al. 1999; Akwa et al. 
1998). 
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Similarly, IL-l has been found to produce immunopathology in the CNS. This cytokine is 
secreted by activated microglia (Giulian et al. 1994 ). It acts as a mitogen for astrocytes and 
these proliferate during embryonic development and injury in the brain (Giulian et al. 
1986). Activated astrocytes enhance neuronal survival through the production of various 
neurotrophic growth factors and removal of neurotoxins (Mucke & Eddleston 1993). In a 
study of Giulian et al. ( 1994 ), increased production of IL-l by microglia was observed in 
HIV -1 infection. This activated astrocytes produce excessive amounts of NOS2, leading to 
overproduction of NO and neuronal death (Zhao et al. 2001). Finally, in addition to the 
cytokines, B cells may also be associated with demyelination, resulting in 
immunopathology via the production of myelin-specific Ab (Cross et al. 2001). 
1.7. Aims of this project 
Most of the previous work on WNV encephalitis has been done in the young mouse model. 
We have therefore, developed an adult mouse model to understand better the mechanisms of 
pathogenesis and recovery from WNV encephalitis. Infection of IFN-y-deficient mice with 
several different viruses has illustrated the importance of this cytokine for controlling virus 
infection. Therefore, IFN -y-deficient mice were compared to wild types to evaluate the role 
of this cytokine in WNV encephalitis. The overall aim of this thesis is to evaluate the role of 
IFN-y in WNV encephalitis in this model as well as the disease profiles of WNV 
encephalitis that result from different routes of virus inoculation. The following 
experimental approaches have been used: 
1) To compare the susceptibility and disease profile of wild type and IFN-y-deficient 
mice to WNV in the intraperitoneal (i.p.) route of WNV inoculation, specifically: 
• To relate these to the development of CNS histopathology, kinetics of WNV 
replication and, clearance of WNV from the brain parenchyma. 
• To compare the expression and upregulation of cell adhesion molecules in 
the CNS microvascular endothelium in the i.p. model and to relate these to 
the level of leukocyte infiltration in the brain parenchyma. 
46 
• To determine the activation of glial cells, especially microglia and astrocytes, 
and to relate these to the WNV clearance from the brain parenchyma in the 
i.p. model. 
2) To compare the susceptibility and disease profile in the i.p. and intranasal route of WNV 
inoculation, specifically to relate these to the possible route of entry of WNV into the CNS 
and WNV replication in the brain parenchyma. 
3) To evaluate the role of antibody in WNV encephalitis in both i.p. and i.n. models in wild 
type mice. 
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Chapter-2 
General Materials and Methods 
2.1. West Nile Virus: production and titre estimation 
West Nile Virus (Sarafend strain) was passaged alternately in suckling mouse brain and 
cultured in vero cells. Working stocks consisted of culture supernatants from vero cells 
infected with brain-derived WNV. 
2.1.1. Production of WNY 
Frozen vero cells, derived from green monkey kidney, were thawed quickly in a 37°C water 
bath, washed in 10 ml complete medium (CM), i.e., Dulbecco's modified eagles medium 
(DMEM) (JRH Biosciences, Lenexa, USA) supplemented with 10% fetal calf serum (FCS), 
by centrifuging at 450 xg at 20°C for 5 mins. The supernatant was discarded and the cell 
pellet was resuspended gently in 25 mls of CM, transferred into 175 em' tissue culture flask 
and incubated at 37°C in a humidified atmosphere of 5% C02 in air for 24h. The vero cells 
were passaged and when they were confluent they were infected with mouse brain derived-
WNV stock, provided by Dr. Nicholas J.C. King, University of Sydney. 
The frozen brain virus (109 pfu/ml) was thawed at room temperature (RT0 ), mixed well in a 
vortex mixer and diluted 1:10 in CM. One ml of diluted brain (108 pfu/ml) virus was added 
into the vero cell culture flasks and incubated at 3rC in a humidified atmosphere of 5% 
C02 in air for 1h. The flasks were tilted every 10 mins for 1h to ensure even adsorption of 
virus. After 1h, the inoculum was removed by washing with DMEM and the cultures were 
incubated in 8 ml CM for 40h at 37°C. After 40h incubation, the culture medium was 
harvested and clarified by centrifugation at 480 xg for 20 mins at 4 oc. The supernatants 
were pooled, aliquoted and stored at -70°C until required. This stock was titrated and used 
to infect mice and vero cells. The flasks with infected vero cells were then frozen at -70°C 
overnight and, thawed to release intracellular virus. One ml sterile PBS was added to the 
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flasks, contents were pooled and centrifuged as described before. The supernatant was 
aliquoted and stored at -70°C until required. This virus stock was used to coat ELISA plates. 
2.1.2. Detection of virus titre: plaque assay 
Virus concentration was determined by enumeration of antibody-labelled viral plaques in 
semiconfluent vero cell monolayers grown on glass coverslips. A sterile coverslip, 13 mm 
in diameter, was added in each well in a 24 well plate. One ml CM was added into each 
well, gently allowing the coverslips to settle to the bottom of the well. About 0.2 x 106 
cells/ml was added in each well and incubated at 37°C for 24h. After 24h incubation, the 
vero cells were infected with IOOJ!l of serially diluted vero grown WNV and incubated for 
1h at 37°C, rocking the plate at 15 min intervals. After 1h adsorption of virus, the inoculum 
was removed by washing with DMEM and the culture was incubated in 2 ml CM for 24h at 
37°C. 
After 24h incubation, coverslips were washed 3 times in Tris-buffer (see appendix) and 
fixed in absolute ethanol at -20°C for 20 mins. Endogeneous peroxidase activity was then 
blocked with 0.3% H20 2 in methanol for 5 minutes. Coverslips were incubated with 10% 
normal goat serum (Gibco BRL, USA) at RT0 for 30 mins followed by polyclonal rat anti-
WNV antibody (Ab) (1:100 dilution). All subsequent incubations were done at RT0 • 
Coverslips were then incubated with biotinylated anti-rat IgG, 1:200 dilution (BA-4000, 
Vector Laboratories, Burlingame, CA) for 30 minutes and then with horseradish peroxidase 
complex, 1:100 dilution (PK-4000, Vector Laboratories, Burlingame, CA) according to the 
manufacturer's instructions. The HRP was visualized using 3' 3 diaminobenzidine 
tetrahydrochloride (DAB, 980681, ICN Biomedicals, Australia) and H,02 for approximately 
2 mins. Preparations were counter-stained with hematoxylin, mounted in DPX, and 
examined under transmitted light microscopy. Contiguous groups of labelled cells were 
counted as infected plaques and titres were calculated from the dilutions as pfu!ml. This 
technique is different from, and has considerable advantage over, previous techniques 
described by Taylor and Marshall (1975), for titrating WNV in that it takes only 24h, does 
not rely on plaques denoting cell death and uses single step kinetics. 
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2.1.3. Production of Rat anti-WNV antibody 
Polyclonal anti-WNY Ab was made in a rat and was used for the detection of WNV Ag. 
Five rats were anesthesised with isoflorane (Lypards, Australia) in a rat chamber and were 
inoculated with lOOJ!l of brain virus, containing 2xl05 pfu, via the intraperitoneal (i.p.) 
route. The rats were watched carefully for 14 days for any development of clinical 
symptoms and after 14 days post infection (p.i.), they were rechallenged again with a 
10-fold higher dose of brain virus, 2x106 pfu/rat. Seven days after rechallenge, blood was 
collected from cardiac puncture and pooled. The blood was kept at 4 oc overnight to 
facilitate clot retraction and then centrifuged at 1851 xg for 20 mins at 4 °C. Serum was 
collected, treated with 0.1% sodium azide (Ajax Chemicals, Sydney), aliquoted and kept 
frozen at -70°C until required. 
2.1.4. Avertin anaesthetic 
A vertin (Aldrich Chemical Co. Inc., Milwaukee, WI) was made by combining 2,2,2 
tribromoethanol (lgm), 2- methyl-2 butanol (lml) and dissolving in 50 mls boiled tap water. 
A vertin was ali quoted and kept at -20°C until required. The recommended dose for a mouse 
is 0.012 ml/grnlmouse, i.e. 250-300J!llmouse. 
2.2. Experimental WNV -induced encephalitis models 
In this thesis, pathogenesis of WNV encephalitis was studied in mice using the i.p. route of 
WNV inoculation (i.p. model) and intranasal (i.n.) route of WNY inoculation (i.n. model). 
2.2.1. Mice 
Eight-week-old Female C57BL/6 wild type (B6.WT), gamma interferon deficient 
(B6.IFN-y-/-) mice backcrossed to C57BL/6 and 3-week-old female B6.WT were obtained 
from the Blackburn animal breeding establishment, The University of Sydney. Eight-week-
old Female B cell-deficient mice backcrossed to C57BL/6 were obtained from John Curtin 
School, The Australian National University, Canberra, a kind gift from Dr. Gunasegaran 
Karupiah. During the experiments, all animals were housed under class II biohazard 
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conditions in hepa filter-top cages. The protocols for all animal experiments were approved 
by The Animal Care and Ethics Committee, The University of Sydney. 
2.2.2. Virus infection of mice 
2.2.2.1. Survival study and development of model 
• Titration of WNV in wild type mice 
After titration of vero-grown stock virus, groups of B6.WT mice were infected with serially 
diluted WNV to evaluate the development of disease and the survival rate in order to select 
an appropriate dose for the development of this model. Five different groups of mice (10 
mice/group) were inoculated i.p. with lOO~tl of serially diluted WNV, from 3x106 to 6x103 
pfu/mouse. The culture medium as well as diluent was CM. Therefore, supernatant from 
uninfected vero cells was used to mock-infect 10 mice for the control. Mice were monitored 
3 times per day until day 30 p.i. Clinical symptoms and death were recorded in detail. Mice 
were sacrificed if they became moribund and were regarded as having succumbed to disease 
for statistical purposes. 
• B6.WT and B6. IFN-y -/-mice: i.p. model 
After a series of titrations, 6x 104 pfu/mouse was chosen as the dose of WNV for the study 
of pathogenesis. Groups of 36 mice of B6.WT and B6.IFN-y-/- strains were inoculated i.p. 
with 6x104 pfu/mouse. Mice from each group were mock-infected as controls with the 
supernatant from uninfected vero cells. Mice were monitored 3 times per day until day 30 
p.i. The clinical symptoms and death were recorded in detail. Mice were sacrificed if they 
became moribund and were regarded as having succumbed to disease for statistical 
purposes. 
• B6.WT and B6. IFN-y -/- mice: i.n. model 
Groups of 20 mice of B6.WT and and B6.IFN-y-/- strains were inoculated with lO~tl via i.n. 
route of inoculation, containing 6x 104 pfu. Mice from each group were mock-infected as 
controls with supernatant from uninfected vero cells. Mice were monitored 3 times per day 
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until 7 days p.i. The clinical symptoms and death were recorded in detail. Mice were 
sacrificed if they became moribund and were regarded as having succumbed to disease for 
statistical purposes. 
2.2.2.2. Time course experiment: Virus infection and tissue preparation 
To determine the role of IFN-y in the development of CNS histopathology and viral 
clearance, a time course experiment was performed. For the time course experiment 
described in the i.p. model, groups of 120 mice each of B6.1FN-y-/- and B6.WT strains, 
respectively, were inoculated i.p., as described above and allocated randomly to groups 
representing timepoints. At least 7 mice were therefore in each group and were removed at 
the indicated timepoints from day 1 to 11 p.i. Groups of 3 mice were chosen for 
investigation on days 15 and 30 p.i. Mice were deeply anaesthesized i.p with avertin and 
perfused via the left ventricle with 10 ml PBS followed by 10 ml 2% paraformaldehyde in 
PBS, pH 7.5. In the i.n. model, groups of 21 mice, each of B6.1FN-y-/- and B6.WT strains, 
respectively, were inoculated i.n., as described above. Groups of 3 mice were allocated to 
each timepoint from day 1 to 7 p.i. 
Brains were removed with intact olfactory bulbs and post-fixed in 4% paraformaldehyde for 
24h at 4 °C. Cervical spinal cords were also collected from both groups at each timepoint in 
both i.p. and i.n. models and post-fixed with 4% paraformaldehyde. Brains were divided 
sagitally down the mid-line. Half of the brains were processed and embedded in paraffin. 
Spinal cords were cut into 3 pieces, processed and embedded in paraffin. Seven-micron 
sections of brains and spinal cords were cut, mounted onto slides precoated with 3-
aminopropyltriethoxysilane (APTES, ICN Biomedicals, Australia) and used for histology 
and immunohistochemistry. The remaining halves of brains were washed twice in PBS and 
then cryopreserved in 30% sucrose (w/v) in PBS, pH 7.5 overnight at 4°C. Sucrose-
infiltrated brains were then immersed in O.C.T medium (BDH Laboratories Supplies, 
England) and snap frozen using isopentane (BDH Laboratories Supplies, England), 
precooled in liquid nitrogen and then stored at -70°C until cryosectioning. Eight-micron 
sagital sections were cut, mounted onto slides precoated with APTES, air-dried overnight 
and stored at -70°C until they were used for immunohistochemistry. The flow chart of the 
time course experiment is presented in figure 2.1. 
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Methods: Time course experiment 
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Figure: 2.1 Flow chart of steps used in time course experiment. Protocol in A was used to 
collect brain tissues for plaque assay and matched immunohistochemistry. Protocol in B was 
used to collect brain tissues for immunohistochemistry only. 
A separate animal experiment was carried out to determine WNV brain titres. In tbe i.p. 
model, groups of 64 mice, each of B6.1FN-y-/- and B6.WT strain, respectively, were 
inoculated i.p. as described above. At least 4 mice from each group were removed at the 
indicated timepoints from day 1 to 11 p.i. Mice were deeply anaesthesized i.p with avertin 
and perfused via the left ventricle with 20 ml PBS only. Brains were removed with intact 
olfactory bulbs and divided sagitally down the mid-line. Half of the brains were weighed 
and kept in eppendorf tubes with 50jll CM and stored at -70°C until they were used for 
plaque assays and the remaining halves of brains were processed and embedded in paraffin 
for matched immunohistochemistry. Similarly in the i.n. model, groups of 21 mice, each of 
B6.1FN-y-/- and B6.WT strain, respectively, were inoculated i.n. as described above. 
Groups of 3 mice from each strain were removed at the indicated timepoints from day 1 to 7 
p.i. Mice were perfused and brains were processed as described before in the i.p. model. 
The techniques used in this thesis are summarized in table 2.1. 
2.2.3. Histology and immunohistochemistry 
Paraffin sections were used for histology. Routine hematoxylin and eosin (H and E) staining 
was used to study histopathological changes occurring during encephalitis in both groups. 
Both paraffin and frozen sections were used for immunohistochemistry (IHC). 
Paraffin sections were dewaxed in xylene, taken through graded (100-70%) ethanol and 
then fully rehydrated in water. Antigen was retrieved either by digestion of sections with 
enzymes or microwaved with citrate buffer (see appendix). The sections were washed once 
with Tris-buffer and endogeneous peroxidase activity was blocked with 0.3% H20 2 in 
methanol for 30 mins. The sections were washed 3 times for 10 mins with Tris-buffer, 
incubated with 100jll of 10% normal goat serum (Gibco BRL, USA) at RT0 for 30 mins, for 
non-specific blocking, and incubated with IOOJ!l of primary Ab. The incubation period for 
each Ag and isotype control used in this thesis are summarized in table 2.2. The sections 
were washed again with Tris-buffer 3 times for I 0 mins and incubated with 1:200 dilution 
of lOOjll secondary Ab for 30 mins at RT0 • The sections were washed again with Tris-buffer 
3 times for 10 mins and incubated with lOOJ!l of horseradish peroxidase complex, 1:100 
dilution (PK-4000, Vector Laboratories, Burlingame, CA) for 30 mins. The HRP was 
visualized using 3'3 diaminobenzidine tetrahydrochloride (DAB, 980681, ICN Biomedicals, 
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Australia) and H20 2 for approximately 5 mins. The sections were counter-stained with 
hematoxylin, mounted in DPX, and examined under transmitted light microscopy. Frozen 
sections were thawed out at RT0 , air dried for 30 mins and rehydrated in Tris-buffer for 5 
mins. After rehydration, all subsequent procedures were identical to those described for 
paraffin section. 
2.2.4. TUNEL labelling 
Paraffin brain sections were subjected to TUNEL staining to determine the incidence of 
neuronal death in the brain. This was achieved using the Apoptag® peroxidase In situ 
Apoptosis detection kit (Intergen Company). The labelling protocol followed was exactly 
according to the manufacturer's instructions. 
2.3. Quantification of cell numbers in histological sections 
Numbers of infected neurones were determined on anti-WNV -stained sections of brain 
parenchyma from both groups. To evaluate whether there were significant differences in 
WNV antigen-positive neurones between groups, the number of WNV-positive neurones 
were quantified as follows. The number of neurones positive for viral Ag was counted in 12 
defined areas of brain as shown in figure 2.2. These areas included brain stem, cerebellum, 
superior colliculus, pyriform cortex (front cortex), cortex retrosplenalis (back cortex), 
hippocampus, thalamus, base of brain, olfactory bulb, base of olfactory bulb, corpus 
striatum and base of cerebellum. At least 5 high-power fields were counted in each area for 
each sample. Thus each mouse brain was evaluated on 60 high power fields. Numbers of 
infiltrating leukocytes, activated microglia, ICAM-1 and VCAM-1-expressing blood vessels 
were also quantified in this way. 
2.4. Detection of hyper-immune serum efficiency and passive transfer 
2.4.1. Production of hyper-immune serum and immune splenocytes 
Hyper-immune (HI) serum was made in wild type mice and was used for passive serum 
transfer experiments. A group of 20 mice was infected i.p. with 6xl04 pfu/mouse and 
carefully watched for 14 days for any development of clinical symptoms or death. After 14 
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Figure: 2.2 Schematic diagram of sagittal brain section. Different numbers in the brain section show different areas of the brain 
used for counting as described above. 1, brainstem, 2, cerebellum, 3 , base of cerebellum, 4, superior colliculus, 5, thalamus, 6, hip-
pocampus, 7, base of the brain, 8, cortex retrosplenalis, 9, pyriform cortex, 10, corpus striatum, 11, base of olfactory bulb, 12, 
olfactory bulb 
days, they were rechallenged with a 50-fold higher dose of virus, i.e., 3x106 pfu/mouse. 
Seven days after rechallenge, they were again rechallenged with 3x106 pfu/mouse. Blood 
and spleens were collected after this 3"' challenge i.e., 28 days after the first inoculation, by 
exsanquination under anaesthesia. The blood was kept at 4 oc overnight to facilitate clot 
retraction and centrifuged at 1851 xg for 20 mins at 4 °C. Serum was collected, a1iquoted 
and stored at -70°C until required. The neutralizing capacity of hyper-immune serum was 
assessed before passive transfer into naive mice. Spleens from hyper-immune mice were 
kept in a small petri dish containing CM and processed immediately for adoptive transfer of 
splenocytes into naive mice (see below). 
2.4.2. Direct ELISA 
Direct, enzyme linked immunosorbent assay (direct ELISA) was performed to determine 
IgG titre in hyper-immune serum. Intracellular virus, as described in section 2.1.1, was used 
to coat the plate. It was diluted at a 1:5 dilution in a carbonate buffer (see appendix). Diluted 
WNV, 50!-!1, was added in each well of the ELISA plate using a multichannel pipette. Some 
wells were coated only with carbonate buffer as a negative control for WNV Ag. The plate 
was sealed with plastic film (glad wrap) and incubated overnight at 4°C, and then wells 
were washed 5 times with PBS/Tween-20 (PBS with 0.5% Tween-20) to remove unbound 
WNV Ag. Fifty microlitres of serially diluted immune and normal serum samples were 
added to the coated plate (serially diluted with PBS-T20 in a separate 96 well plate before 
adding to ELISA plate). Then the plate was incubated at RT0 for 2h and rinsed 5 times with 
PBS/T20. Duplicate samples were used for each dilution. Fiffty microlitres of HRP-
conjugated 1:3000 diluted secondary Ab, rabbit anti-IgG (P0406, DAKO) was added to 
each well and incubated at RT0 for 1h. After rinsing the plate 5 times with PBS/T20, 50!-!1 
of TMB one step substrate (Sl600, DAKO) was added to each well for visualization of the 
reaction product, and incubated at RT in the dark for 15 minutes. Blue to sky blue colour 
developed, depending upon the concentration of IgG. The colour intensity was measured 
using a 650 nm filter in the ELISA plate reader. 
2.4.3 Plaque reduction neutralization test 
A plaque reduction neutralization test (PRNT) was performed in a 6 well plate, containing 
vero cell monolayers on 22 mm diameter round coverslips. The vero cell monolayer was 
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grown in the sterile coverslips as described above, one day before PRNT. The number of 
vero cells required to give a semiconfluent growth was 0.3x106 cells/mi. Stock WNV was 
diluted in CM to give 100 pfu in 1001-11. Serum was serially diluted in CM and 1001-11 of 
diluted seum was incubated with 1001-11 of diluted virus containing 100 pfu in an eppendorf 
tube for 30 mins at 37°C. Vero cell monolayers were infected with WNV preincubated with 
the serially diluted immune sera and incubated for lh at 37°C. After lh adsorption, the 
mixed inoculum was removed, washed with CM and the cells incubated with 2 ml CM for 
24h at 37°C. The following day WNV titres were determined using the Ab-labelling method 
as decribed above and the number of infected cells was counted on the whole coverslip. The 
dilution of serum required for 50% plaque reduction was determined as described 
previously by Reed and Muench (1938) and was defined as the 50% neutralization titre 
(NT 50). Undiluted normal serum was used as a negative control whereas undiluted immune 
serum was used as a positive control for the neutralization of WNV. 
2.4.4. In vitro efficiency of neutralizing antibodies 
To test whether neutralizing Ab could influence the release of virus in vitro, presence of 
WNV in the vero cell culture supernatant was assessed in 12 well plates. Vero cell 
monolayers were grown on coverslips as described above, infected with 6x 104 pfu/coverslip 
and incubated for 1h at 37°C. Both immune and normal serum was serially diluted in CM. 
Virus inoculum was removed after lh adsorption and 2 ml CM and 3001-11 of serially diluted 
serum was added to each well. The plate was incubated at 37°C for 48h. After 48h of 
infection, culture supernatants of infected vero cells were harvested and diluted 1:10-1:50. 
Fresh vero cell monolayers were infected (2001-11) with this diluted culture supernatant. The 
plate was incubated for 1h at 37°C, supernatant was removed and 2 ml fresh CM was added. 
The plate was incubated for 24h at 37°C. The following day WNV plaques were determined 
using the Ab-labelling method as decribed above and the number of plaques was counted as 
described above. The number of plaques were counted for each dilution and compared. 
2.4.5. Passive transfer of hyper-immune serum 
Passive transfer of HI serum was performed only in B6.WT mice. Hyper-immune or normal 
sera, 2001-11 of 1:3 diluted was transferred i.p. to 8-week-old B6.WT mice, 24h before 
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infection. In both i.p. and i.n. models, groups of 30 mice, 10 mice/subgroup were used, i.e. 3 
groups of mice were used in each model. In both models, one group received 200JLI HI 
serum/mouse, the second group received normal serum and third group was left untreated. 
After 24h, all groups of mice were inoculated with 6xl04 pfu/mouse, either i.p. or i.n. and 
were monitored 3 times per day until day 14 p.i. The clinical symptoms and death were 
recorded. Mice were sacrificed if they became moribund and were regarded as having 
succumbed to disease for statistical purposes. 
2.5. Preparation of splenocytes and adoptive transfer 
2.5.1. Pn~paration of splenocytes 
As described earlier in section 2.4.1, spleens were collected from hyper-immune mice and 
immediately placed in a small petri dish containing 5 ml CM. Spleens were washed once 
with 70% ethanol and twice in PBS and were transferred into clean petri dish containing 
CM and a small piece of filter gauze. Spleens were placed on the top of filter gauze and 
very gently, using a syringe plunger, strained into the CM. The splenocytes were then 
transferred into a falcon tube using a pipette and centrifuged at 450 xg at RT0 for 5 mins. 
Supernatant was discarded and the pellet was resuspended in 2 ml RBC lysis buffer (see 
appendix) for 1 min to allow lysis of RBC and then 2 ml CM was added to stop the process. 
The suspension was centrifuged at 450 xg at RT0 for 5 mins. The supernatant was 
discarded, the pellet was resuspended in 10 ml PBS and splenocytes were counted using a 
haemocytometer and trypan blue. The number of splenocytes need to transferred was 5xl07 
cells/mouse. The volume was adjusted to 200j.tl PBS and the cells injected i.p. Splenocytes 
from normal or pre-immune mice were processed similarly as the control. 
2.5.2. Adoptive transfer of sulenocytes 
Adoptive transfer of splenocytes was performed only in B6.WT mice. Two hundred 
microlitres of cell suspension containing 5xl07 splenocytes were adoptively transferred i.p. 
to 8-week-old B6.WT mice using a 28 gauge needle, 24h before infection. In this 
experiment groups of 30 mice, 10 mice/subgroup were used, i.e., 3 groups of mice were 
used. One group received 5x I 0 7 immune splenocytes/mouse, the second group received 
5xl07 normal splenocytes/mouse and third group was left untreated. After 24h, all groups of 
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mice were inoculated i.n. with 6x104 pfu/mouse and were monitored 3 times per day until 
day 7 p.i. The clinical symptoms and death were recorded. Mice were sacrificed if they 
became moribund and were regarded as having succumbed to disease for statistical 
purposes. 
2.6. Data analysis 
All data derived from immunohistochemistry and lectin histochemistry shown in the figures 
are mean values ± SEM for the total number of fields examined from the indicated number 
of mice, n. Data were analysed using unpaired two-tailed Student's t test for single 
comparisons, or by ANOV A, where multiple comparisons were required. The Fisher exact 
probability test was used for survival analysis. Data were considered significant if p = 
<0.05. 
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Table 2.1 Summary of techniques described in this thesis. 
Techniques Parameters detected 
Hematoxylin and eosin staining Identification of histopathology and enumeration 
of leukocyte infiltration in the brain parenchyma 
and meninges 
Anti-WNV immunohistochemistry Cells infected with WNV and the areas of 
infection 
Plaque assay Virus titre in the brain 
Griffonia simplicifolia isolectin B-4 Distribution and morphology of activated 
(GS-lectin) histochemistry microglia, vascular endothelial cells and 
macrophages 
Anti-ICAM-1 and VCAM-1 Cells expressing ICAM-1 and VCAM-1 
immunohistochemistry 
Anti -GFAP immunohistochemistry Distribution and morphology of normal and 
activated astrocytes 
Anti-MHC-II immunohistochemistry Distribution and morphology of cells expressing 
MHC-II molecules 
Anti-fibrinogen Leakage of vessel, area and extent of leakage 
immunohistochemistry 
Double labelling (labelling of 2 Ag) in Confirmation of cells infected with WNV and 
the same brain section using glial cells expressing ICAM-1 
immunohistochemistry 
Passive transfer of WNV -immune and Role of Ab in the i.n. and i.p. model 
normal sera 
Plaque reduction neutralization assay Titre of neutralizing Ab 
Adoptive transfer of WNV -immune Role of immune cells in the i.n. model 
and normal splenocytes 
Serum ELISA Titre of WNV- immune serum IgG 
TUNEL assay Apoptosis 
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Table: 2.2 Summary of antibodies and lectin used for immunohistochemistry. 
Primary antibody Dilution I so type Incubation Types of Method of Company 
used control temperature section antigen retrieved 
for primary 
antibody 
Rat anti-WNV 1:100 Normal rat lh at RT0 Paraffin 100~tl protease Prepared in our laboratory as 
Antibody serum section enzyme for4 described above. 
mins atRT" 
Biotiny lated 1:50 None 3h at 4°C Paraffin Microwaved for 8 Sigma Chemical Company 
Isolectin-B4 section mins in 500 ml Cat#L-2140 
citric buffer 
Rat anti-mouse 1:10 RatlgG2a 1.5h at 4°C Frozen Not used Hybridoma supernatant 
ICAM-1 section ATCC, YN 111.7.4 CRL 1878 
Rat anti-mouse 1:50 Rat lgG2a Overnight at Frozen Not used Pharmingen 
VCAM-1 4°C section Cat#01811D 
Rabbit anti-human 1:500 Polyclonal 1h atRT" Paraffin Microwaved for Dako 
Fibrinogen rabbit IgG section 29 mins in 500ml Cat# A0080 
citric buffer 
Rabbit anti-cow 1:750 Polyclonal 1h at RT0 Paraffin Not used Dako 
GFAP rabbit IgG section Cat#Z0334 
Rat anti-mouse undiluted Monoclonal overnight at Paraffin lOO~tl papain Hybridoma supernatant 
MHC-II ratlgG2b 4°C section enzyme for 5 (TIB 120 ATCC, M5/114.15.12) 
mins atRT0 
Chapter-3 
IFN -y exacerbates disease in WNV encephalitis 
3.1. Introduction 
Virus infection presents a profound challenge to host survival. There are numerous antiviral 
defence mechanisms that include both innate and adaptive defences. Cytokines are among 
these several sophisticated defence mechanisms and are produced by a variety of cell types 
in response to viral infection (Ramshaw et al. 1997). Of these. IFN-y, is one of the most 
important. A pleiotropic cytokine, it is produced by T H 1 cells, CD8+ T cells, NK cells (Harty 
et al. 2000; Salazar-Mather et al. 2000; Christensen et al. 1999) and macrophages (Gessani 
& Belardelli 1998). IFN-y regulates immune (Boehm et al. 1997) and inflammatory events 
(Benveniste 1998). Therefore, it is regarded as both immune (Young & Hardy 1995) and 
antiviral (Kohonen-Corish et al. 1990) in function. 
Several experimental animal models of viral encephalitis demonstrated the importance of 
endogeneous production of IFN-y for adequate host defence against virus infection (Nansen 
et al. 1998; Huang et al. 1993; Bouley et al. 1995; Karupiah et al. 1990). IFN-y may either 
directly inhibit viral replication (Kohonen-Corish et al. 1990) or activate and orchestrate the 
collaboration of several other effector molecules as part of antiviral defence (Billiau 1996). 
Thus, IFN-y activates CTL and NK cells (Utermohlen et al. 1996) which selectively 
eliminate virus-infected cells, as well as secreting IFN-y themselves (Harty et al. 2000; 
Biron et al. 1999). IFN-y activates macrophages to release several proinflammatory and 
antiviral cytokines, including TNF, IL-l, IL-6 (Janeway et al. 2001) and IFN-y (Gessani & 
Belardelli 1998), as well as increasing their microbicidal activities (Munoz-Fernandez & 
Fresno 1998). It is also required for the maturation and effector function of CD8+ T cells 
(Stohlman et al. 1998) and regulation of Ab production, especially in switching of lg into 
IgG2a and IgG3 subclasses (Young & Hardy 1995). IFN-y also induces MHC-1 and MHC-II 
molecules on a wide variety of cell types (Grau et al. 1997; Huynh & Dorovini-Zis 1993; 
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Momburg et al. 1986). Moreover, IFN-y induces increased production of NO and IDO 
enzymes (Guidotti et al. 2000; Karupiah et al. 1993; Takikawa et al. 1990), which are 
antiviral (Saxena et al. 2000; Yoshida et al. 1979). However, despite extensive studies, 
details of the mechanisms of the antiviral effects of IFN-y are not fully understood. 
Recruitment of inflammatory cells into the CNS is a critical step in antiviral host defence 
mechanisms. Until recently, the CNS has been seen characterized as an immune privileged 
site due to the presence of several unique features. First, the CNS parenchyma is separated 
from the blood circulation by the BBB. This prevents the entry of leukocytes, plasma 
proteins and cytokines. However, although access to the CNS is relatively restricted 
(Fontana 1987; Cserr et al. 1992), a small number of activated T lymphocytes, irrespective 
of their Ag receptor specificity, can pass through the BBB and subsequently migrate into the 
CNS (Hickey et al. 1991). Second, the normal CNS lacks professional APC such as B cells, 
dendritic cells and macrophages and this has been thought to prevent the initiation and 
propagation of Ag-specific immune responses (Becher et al. 2000). However, during CNS 
infection and inflammation microglia can act as APC (Bo et al. 1994; Weissenbock et al. 
2000). Finally, in the normal CNS, the expression of MHC molecules are very low or 
undetectable (Benveniste 1992; Neumann 2001). Therefore, the CNS cells are not 
recognized by activated T lymphocytes under normal conditions, even though these cells 
can enter the CNS parenchyma. While this is true, it is clear that interaction with CNS cells 
does occur, probably due to upregulated immune recognition molecules during infection, 
damage and inflammation. 
In viral encephalitis, massive amounts of inflammatory cells migrate into the CNS. When 
these cells find their respective target Ag in the CNS, an inflammatory reaction is started 
through the production of many proinflammatory cytokines, including IFN-y (Liu & 
Chambers 2001; Christensen et al. 1999), leading to upregulation of CAM (Nansen et al. 
1998; Irani & Griffin 1996) in the neurovascular endothelium (Fabry et al. 1992) and local 
production of chemokines (Asensio et al. 1999), which further help to recruit more 
inflammatory effector cells into the CNS. This initiates a cascade of inflammation in the 
CNS (Lassmann 1997). The mechanism of brain inflammation thus follows the same basic 
pattern that operates in inflammation at other sites of the body. 
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Although IFN -y plays a critical role in viral infection, the role of IFN -y has not been studied 
in WNV encephalitis to date. Moreover, due to the lack of defined in vivo animal models, 
understanding of the pathogenesis of WNV encephalitis is incomplete. Most previous 
studies on WNV encephalitis have been carried out in a neonatal or young (3-4 week-old) 
mice. These models do not reflect the disease profile of adult mice. Encephalitis develops 
more readily and severely in young mice, often with 100% mortality presumably due to the 
immature immune system. Therefore, an adult mouse model using 8-week-old, inbred 
C57BL/6 wild type (B6.WT) and gamma interferon deficient (B6.IFN-y-/-) mice 
backcrossed to C57BL/6 was developed in this project to define the pathogenesis of WNV 
encephalitis and to determine the role of IFN -y in this process. 
3.2. Materials and Methods 
3.2.1. Mice 
Female, specific-pathogen free, 8-week-old B6.WT and B6.1FN-y-/- mice, backcrossed to 
C57BL/6, and 3-week-old B6.WT were used. 
3.2.2. Virus infection of mice and tissue preparation 
To adopt an appropriate dose of WNV to develop this model, WNV was titrated in B6.WT 
mice as described in section 2.2.2.1. Five different doses were used: 3x106 pfu/mouse, 3x105 
pfu/mouse, l.2xl05pfu/mouse, 6x104 pfu/mouse and 1.2xl04 pfu/mouse. From this titration 
series, a dose of 6x 104 pfu/mouse was chosen for the study of pathogenesis. Groups of 36 
mice of B6.WT and B6.1FN-y-/- strains were inoculated with 6xl04 pfu/mouse and their 
survival rate was evaluated as described in section 2.2.2.1. To determine the kinetics of viral 
infection and leukocyte infiltration in the CNS parenchyma, a time course experiment was 
carried out. Groups of 120 mice/strain were inoculated with 6x104 pfu/mouse, tissues were 
collected and processed as described in section 2.2.2.2. To evaluate the route of access of 
WNV in a young mouse, 3-week-old B6.WT mice were used. Although these mice were not 
weighed, due to their smaller size compared to 8-week-old mice, 10 fold less virus i.e., 
6x103 pfu/mouse, was inoculated i.p. using groups of 16 mice, as described before. Mice 
were sacrificed on days 2, 3, 4 and 5 p.i. Brains and cervical spinal cords were collected and 
processed as described before. 
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3.2.3. Histopathology and immunohistochemistry 
Serial sections from paraffin-embedded tissues were stained with H and E, and were 
examined to evaluate the pathological changes occurring in the brain parenchyma of both 
groups of mice during encephalitis. 
• Detection of WNV antigen 
After dewaxing the paraffin sections, Ag was retrieved with digestion of sections in the 
protease enzyme derived from Streptomyces griseus (P-5005, Sigma Chemical Company), 
0.05% w/v made in PBS, pH 7.5 for 4 mins at RT0 and washed in Tris-buffer. After 
endogeneous peroxidase activity and non-specific blocking, sections were then incubated 
with lOOJLI of 1:100 diluted rat anti-WNV Ab for 1h at RT0 • After this, the remaining 
procedures were identical to those described in section 2.2.3. Mock-infected brain sections 
were used as controls for rat anti-WNV serum labelling and normal i.e., pre-immune rat 
serum was used as an isotype control for the primary Ab. 
• Detection of fibrinogen leakage 
Rabbit anti-human fibrinogen, 1:500 dilution (A0080, Dako, Denmark) was used to detect 
fibrinogen in the infected brain parenchyma, as a marker of blood-brain barrier damage in 
WNV encephalitis. After dewaxing and endogeneneous peroxidase blocking, sections were 
microwaved on high power in citrate buffer for 8 mins and boiled for 21 mins at medium 
high power. Sections were allowed to stand at RT0 for 30 mins in citrate buffer, and then 
washed in Tris-buffer. After blocking endogeneous peroxidase activity and non-specific 
blocking, sections were then incubated with 1 OOJLl of primary antibody for 1h at RT0 • After 
this, the remaining procedures were identical to those described in section 2.2.3. Mock-
infected brain sections were used as control for rabbit anti-human fibrinogen labelling. 
Polyclonal rabbit IgG was used as an isotype control for the primary antibody. 
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3.2.4. Determination of brain titre 
As described in section 2.1.2, virus titres in the brain were determined by plaque assay with 
slight modifications. The frozen brains collected from both groups of mice were thawed at 
RT0 • The brains were homogenized and 950~tl of CM was added to the tube. The brain 
homogenates were centrifuged at 2500 xg for 20 ruins at 4°C. The supernatant was 
collected, serially diluted in CM and lOO~tl plated onto vero cell monolayers grown in 
coverslips in 24 well plates. The plate was incubated for lh at 37°C, washed 2 times with 
CM and incubated for 24h at 3rC with 2 ml CM. After 24h incubation, the plaques were 
determined as described in section 2.1.2. Contiguous groups of labelled cells or individual 
labeled cell were counted over the whole cover slip as infected plaques and titres were 
calculated from the dilutions as pfu/gram. 
3.2.6. Quantification of cells and data analysis 
Quantification of cells and data were analysed as described in section 2.3 and 2.6 
respectively. Figures are mean values± SEM for the total number of fields examined from 
the indicated number of mice, n. 
3.3. RESULTS 
3.3.1. Survival in WNY encephalitis 
3.3.1.1. Titration of WNV in B6. WT mice 
Since one of the aims of this study was to establish and study a reliable adult model of 
WNV encephalitis, WNV was titrated in 8-week-old B6.WT mice. Five different doses 
were used. Mice were highly susceptible with 100% mortality to 3xl06, 3xl05 and 1.2xl05 
pfu/mouse. Mortality was 60% using 6xl04 pfu/mouse, whereas it was only 40% using 
1.2x 104 pfu/mouse. Clinical symptoms occurred from day 6 p.i. onwards, regardless of the 
dosage used. Mortality occurred between day 6-11 p.i. No further deaths occurred after day 
11 p.i. and mice appeared healthy. The cumulative comparative survival after infection in 
all groups is presented in figure 3 .1. 
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Figure: 3.1 Titration of stock vero-grown WNV in 8 week-old B6.WT mice. Groups of 10 
female mice/dose were inoculated i.p. with different doses of WNV and monitored for signs 
of illness 3 times a day over 14 days. The percent survival at each time point is shown. 
Mock-infected mice did not develop signs of illness. 
3.3.1.2. Role of IFN-yin survival in WNV encephalitis 
After a series of titrations, a dose of WNV was selected, which was normally lethal for 60% 
of B6.WT, so that a positive and negative role of IFN-y could be evaluated in WNV 
encephalitis. In all groups, therefore, 6xl04 pfu/mouse was used. This dose resulted in the 
first clinical signs of infection by day 6 p.i. These included general signs such as ruffled 
hair, reduced activity and hunching, as well as exudative conjunctivitis, weight loss and/or 
weakness, with or without CNS symptoms. Such symptoms included hind limb paralysis, 
tremors and occasionally convulsions. Since IFN-y is crucial to the effective immune 
response in many viral infections, the responses of B6.WT to WNV was compared with 
those of B6.IFN-y-/- mice. The cumulative comparative survival after infection in both 
groups is presented in figure 3.2. In both groups mortality occurred between day 7 and II 
p.i. and once clinical signs were observed, death invariably followed within 12-48h. 
Occasionally, however, the onset of disease was sudden and mice died without observable 
illness. Survival from infection in B6.IFN-y-/- was approximately 83%, significantly greater 
(p=0.002) than that of B6.WT, at approximately 40%. No further deaths occurred after day 
11 p.i. and mice appeared healthy in both groups. Surviving mice from both groups were 
rechallenged i.p. with 50-fold the original dose of WNV (3xl06pfu/mouse) and observed for 
3 weeks for signs of illness. No signs of illness were observed at this time from either group 
(data not shown). This demonstrates that IFN-y is not critical for survival either in primary 
or secondary WNV infection. Moreover, IFN-y may contribute to clinical illness and death 
in primary WNV infection. 
3.3.2. Histopathology 
Routine H& E staining of sagittal brain sections from B6.WT and B6.IFN-y-/- is shown in 
figure 3.3. Histopathological changes were clearly visible in the grey and white matter in 
both groups. These changes included diffuse infiltration of leukocytes consisting of both 
mononuclear and polymorphonuclear cells with occasional perivascular cuffing in both 
groups (Figure 3.3 c, d). Meningeal infiltration was also present at this time (Figure 3.3 e, 
f). Perineuronal microglial clusters and activated microglia were distributed throughout the 
brain in both symptomatic and asymptomatic mice from either group (Figure 3.3 c, f). 
Occasionally, at day 6 p.i., mice with high numbers of infected neurones throughout the 
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Figure: 3.2 Survival profiles of 8-week-old B6.WT and B6.1FN-y-/- mice infected with 
WNV. Groups of 36 female mice/strain were inoculated i.p. , 6x104 pfulmouse and moni-
tored for signs of illness 3 times a day over 30 days. The percent survival at each time point 
is shown. There is a signifificant difference (P= 0.002 by Fisher Exact test) between survival 
data of B6.WT and B6.1FN-y-/- mice. Mock-infected mice did not develop signs of illness. 
Figure: 3.3 Brain sections stained with Hand E from mock-infected and WNV-
infected B6.WT and B6.IFN-y-/- mice. Mock-infected brain parenchyma showing 
normal histology in B6.WT (a) and B6.IFN-y-/- (b) mice. Infected brain parenchyma 
showing infiltration of leukocytes (solid arrows) and activated microglia with 
nodule (open arrow) in B6.WT (c) Infected brain parenchyma showing infiltration 
of leukocytes (solid arrows) in B6.IFN-y-/- (d) mice. Marked meningitis was 
observed in both B6.WT (e) and B6.IFN-y-/- (f) mice. Adherent inflammatory 
leukocytes (solid arrow) on cerebrovascular endothelium during infection in B6.WT 
(g). Occasional frank haemorrhage (solid arrow) was observed in the brain 
parenchyma of infected B6. WT, associated with agonal convulsions (h). Scale bar = 
50j..tm. Abbreviation: BV- blood vessel. 

brain were observed to have frank haemorrhage into the brain parenchyma (Figure 3.3 h). In 
these mice, this finding was frequently associated clinically with agonal convulsions. 
3.3.3. Detection of WNY antigen in the CNS tissue 
Results from the preceding section clearly demonstrated that nearly twice the number of 
B6.IFN-y-/- mice survived WNV infection compared to B6.WT mice. To elucidate the 
involvement of IFN-y through the course of infection, the sites of WNV infection in the 
CNS, possible routes of access to the CNS, kinetics of progression and clearance of WNV 
from the CNS parenchyma was investigated in both groups of mice. 
3.3.3.1. Sites of infection in the brain 
Groups of 120 mice from B6.WT and B6.IFN-y-/- strains were infected with 
6xl04pfu/mouse, as described in Materials and Methods. Plaque assay was undertaken on 
brains from days 1-11 p.i. Immunoperoxidase labelling for WNV Ag was undertaken on 
brains from days 3, 5, 6, 7, 8, 9, 10, 11, 15 and 30 p.i. The pattern of infection observed was 
similar in both groups and is shown in figure 3.4. Positive staining was found only from 
day 6 p.i. in brain parenchyma, independent of clinical illness, and was first observed in the 
brainstem in both groups. Viral Ag was detected only in neurones and their processes 
(Figure 3.4 e, f) and infected neurones appeared morphologically normal. The number of 
infected neurones was increased after day 6 p.i. and was found predominantly in the base of 
the brain (Figure 3.4. g, h). 
The brainstem, base of the brain and cerebral cortex were the principal sites of detectable 
virus infection in the brain. Occasional pyramidal cells of the hippocampus were detectably 
infected in some animals of both groups on day 9 p.i. (data not shown). No infection of 
other parenchymal cells was seen and no viral antigen was detected in mock-infected mouse 
brains from B6.WT and B6.IFN-y-/- groups (Figure 3.4 a, b). Neurones in the OB were 
consistently negative for WNV antigen at all timepoints in both groups (Figure 3.4 c, d). 
The cerebellum was rarely observed to be infected in either group throughout the time 
course of infection. Extremely rarely (1 out of 194), microvascular endothelium in the 
brainstem stained positive for viral antigen in B6.WT on day 6 (data not shown). Infection 
of ependymal and choroid plexus cells and meninges was never observed. 
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Figure: 3.4 Brain sections from mock-infected and WNV-infected B6.WT and 
B6.IFN-y-/- mice labeled for WNV antigen. Immunoperoxidase labelling with rat 
anti-WNV and DAB substrate was used for the detection of viral antigen. Sections 
were briefly stained with haematoxylin as a counterstain. Mock-infected brainstem 
showing negative labelling for WNV antigen in both B6.WT (a) and B6.IFN-y-/- (b) 
mice. WNV antigen was first detected in the brainstem neurones in both B6.WT (e) 
and B6.IFN-y-/- (f) mice on day 6 p.i. and was found only in the cytoplasm and 
processes of neurones (solid arrows). Olfactory bulbs of infected mice from both 
groups were negative on day 5 p.i. (c) and day 6 p.i (d) in both strains. The number 
of infected neurones was increased on day 8 p.i. in B6.WT (e) and B6.IFN-y-/- (f), 
and was observed in the base of the brain at this timepoint. Scale bar = SOJ.!m. 
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3.3.3.2. Route ofCNS access by WNV 
Despite the absence of olfactory bulb staining for WNV in the adult model described here, 
the olfactory neuroepithelium is clearly a route of entry into the brain after peripheral 
inoculation in SLE and MVE virus infections (McMinn et al. 1996; Monath et at. 1983). 
Since these models make use of young 3-4-week-old mice, it was speculated that WNV 
might also use this route in a prepubertal animal. Therefore, 3-week-old B6.WT mice were 
inoculated i.p. with 10-fold less WNV, and the brains and spinal cord were examined as 
described above. The time course experiment showed that WNV was first detected in the 
brain at day 4 p.i. At this time, positive staining was observed throughout the brainstem 
(Figure 3.5 a), thalamus (Figure 3.5 b) and cortex, as well as the cervical spinal cord (Figure 
3.5 d), similar to the distribution seen in the adult mouse. However, no positive staining for 
WNV Ag was observed in the OB (Figure 3.5. b). 
In young mice, viral Ag was detected only in the cytoplasm and the processes of neurones 
both in the spinal cords and the brain. These data indicate that age does not influence the 
route of infection and types of target cells for WNV. However, age influenced the speed of 
WNV spread to the CNS. Since WNV was observed in the brain at least 48h before it was 
detectable in the adult model. 
Since there was no infection of the olfactory bulb and WNV was always observed first in 
the brainstem with extremely rare endothelial infection, spinal cords were examined to 
determine the infection of spinal cord and possible route of CNS access. No WNV staining 
at any level was observed in the spinal cord in both infected groups at day 4 (Figure 3.6 a). 
However, at day 5 p.i, a few motor neurones from the anterior horns of cervical spinal cord 
was postitively stained for WNV Ag (Figure 3.6 b) in both groups. Thus WNV was 
detectable in these neurones in both strains one day before WNV Ag was detectable in the 
brainstem. Numbers of infected motor neurones in the spinal cord further increased by day 6 
p.i. (Figure 3.6 c, d) in both groups, when WNV was first detected in the brainstem (Figure 
3.4 e, f). This strongly suggests that CNS infection with WNV first begins in the spinal 
cord. 
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Figure: 3.5 Brain and cervical spinal cord sections from WNV-infected 3-week-old B6.WT 
mice labelled for WNY antigen. Immunoperoxidase labelling with rat anti-WNV and DAB 
substrate was used for the detection of viral antigen. Sections were briefly stained with 
haematoxylin as a counterstain. WNV antigen was detected in the brainstem (a) (solid arrows) 
and thalamus neurones on day 5 p.i. (c) (solid arrows). At the sametime, WNV antigen was 
also detected in the spinal cord neurones (d) (solid arrows). WNV antigen was found in the 
cytoplasm and processes of the neurones in both brain and spinal cord. However, olfactory 
bulbs of infected mice were consistently negative (b) on day 5 p.i. Scale bar= 50Jtm. 
Abbreviation: BY- blood vessel. 
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Figure: 3.6 Cervical spinal cord sections from WNV-infected B6.WT and B6.IFN-y-/- mice 
labelled for WNV antigen. lmmunoperoxidase labelling with rat anti-WNV and DAB sub-
strate was used for the detection of viral antigen. Sections were briefly stained with 
haematoxylin as a counterstain. No WNV antigen was detected in the spinal cord on day 4 
p.i. in either mouse strain (a). WNV antigen was detected in a few neurones of the spinal 
cord on day 5 p.i. (b) (solid arrows), 24h before it was detectable in the brainstem in both 
strains. The number of infected neurones was increased on day 6 p.i. in the spinal cords in 
both B6.WT (c) and B6.IFN-y-/- (d) mice (solid arrows). Scale bar= 50Jim. 
3.3.3.3. Kinetics of progression and clearance of WNV 
A greater proportion of B6.IFN-y-/- than B6.WT mice had histologically detectable 
neuroneal infection between day 6 and 11 of infection. Outside of these days there was no 
detectable infection in either group. The percentage of mice positive for WNV Ag at each 
timepoint is presented in figure 3.7. The cumulative percentage of mice positive for viral Ag 
from day 6 to day 11 p.i. was 36.7% in B6.IFN-y-/- and 14.9% in B6.WT mice. 
Quantification of numbers of infected neurones showed no significant difference between 
the groups that displayed signs of clinical disease. However, in asymptomatic mice, 29.6% 
of the B6.IFN-y-/- group were positive for viral Ag compared to 7.4% of the B6.WT group 
(p=0.003). Thus the presence of virus did not correlate with the presence of clinical disease 
between the groups. 
To evaluate whether there were significant differences in the number of infected neurones 
between groups, WNV -positive neurones were quantified, as described in Materials and 
Methods. The kinetics of viral Ag detection in brain parenchyma was similar (Figure 3.9). 
In both groups, viral antigen was detected only from day 6 p.i. onwards, peaking on day 7 
and 8 p.i. and was always undetectable by day 15 p.i. There were no statistically significant 
difference in the mean number of infected cells between the groups at any timepoints. 
Since there was no difference in the number of infected neurones between the groups, virus 
titres in the brain were determined by plaque assay to see whether there was a difference in 
virus load in the brain between the groups. These results can be seen in figure 3.8. In both 
groups of mice, replicating WNV was detected from day 6 p.i. This increased, peaking on 
day 8 p.i. and decreasing subsequently to be undetectable by day 10 p.i. in both groups of 
mice. The maximum virus titre was 2.22 log10 pfu/gram in B6.IFN-y-/- and 2.23 log10 
pfu/gram in B6.WT mice brain on day 8 p.i. Although there was a difference in the virus 
titres between the groups at earlier timepoints, there was no significant difference in the 
virus titres at any timepoints. This confirms the kinetics of WNV Ag detection in the brain 
parenchyma detected by IHC. Moreover, the virus titres suggest that WNV Ag detected by 
IHC on day 10 and 11 p.i. was from non-replicating WNV. These results indicate that IFN-y 
does not play a critical role in the clearance of viral antigen from brain parenchyma. 
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Figure: 3.7 Percentage of mice positive for WNV-antigen: Groups, each of 120 
mice, from B6.WT and B6.1FN-y-/- strains were infected i.p. with 6xl04 pfu/mouse. 
Subgroups of mice in each strain were sacrificed from day 3 to 30 p.i. 
Immunoperoxidase labelling was used to detect viral antigen in the brain 
parenchyma of infected mice at each timepoint. Percentage of mice positive for 
WNV antigen throughout the time period is shown. 
Figure: 3.8 Kinetics of WNV replication in the brain. Groups, each of 64 mice, from 
B6.WT and B6.1FN-y-/- strains were infected i.p. with 6xl04 pfu/mouse. Subgroups 
of mice in each strain were sacrificed from day 1 to 11 p.i. Plaque assay was used to 
detect viral titre and replication in the brain of infected mice at each timepoint. 
Statistical analysis using ANOV A showed no significant difference in the titres 
between the groups. No viral antigen was detected in the brain of mock-infected 
mice from either group. 
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Figure: 3.9 Kinetics of WNV infection. Groups, each of 120 mice, from B6.1FN-y-/- and 
B6.WT strains were infected i.p. with 6x104 pfu/mouse. Subgroups of mice in each strain 
were sacrificed from day 3 to 30 p.i. lmmunoperoxidase labelling was used to detect viral 
antigen in the brain parenchyma of infected mice at each timepoint. The number of 
neurones positive for viral antigen was counted, as described in materials and methods. 
Sixty H.P.F. were counted per mouse brain and values for each timepoint amalgamated 
and expressed as mean ± SEM. Statistical analysis using ANOV A showed no signjficant 
difference in the numbers of infected neurones between the groups. No viral antigen was 
detected in the brain parenchyma of mock-infected mice from either group. 
However, absence of IFN-yresults in a greater number of mice acquiring detectable 
neuronal infection. 
3.3.4. Kinetics of leukocyte infiltration 
Since IFN-y plays a role in the activation and recruitment of cells to inflammatory sites, the 
kinetics of appearance and disappearance of infiltrating leukocytes in brain parenchyma was 
assessed on H& E-stained brain sections from the same mice as used to determine the 
kinetics of viral Ag expression. In both groups, leukocytes initially appeared in the 
meninges and brain parenchyma from day 5 p.i. onwards. Numbers of leukocytes were 
counted in the defined areas of the brain parenchyma, as described in Materials and 
Methods, and are shown in figure 3.10. 
In both strains, the kinetics of leukocyte infiltration was similar. However, the number of 
leukocytes infiltrating was significantly greater in the B6.WT than B6.IFN-y-/- brains on 
day 7 (p=<O.OOI). In B6.WT, infiltration was clearly evident from day 6 p.i., although some 
leukocyte infiltration on day 5 was observed in a few mice. Infiltration was significantly 
higher on day 7 (p=<0.001), compared to day 6, significantly decreasing by day 9 p.i 
(p=<0.001), compared to day 7, and completely returning to baseline values in survivors by 
day 30 p.i. In B6.IFN-y-/- mice, infiltration was observable from day 5, peaked on day 8, 
decreased by day 9 and returned to baseline values by day 30 p.i. However, there were no 
stastistically significant differences between the values obtained at any of these timepoints 
in this group. Despite the marked reduction of parenchymal leukocyte infiltration between 
days 11 and 15, conspicuous meningeal infiltration was still observed in both strains during 
this period, but this had returned to baseline levels by day 30 p.i. These data indicate that 
IFN-y is important for the recruitment of the full complement of leukocytes to the brain. 
3.3.5. Blood-brain barrier status 
Fibrinogen is part of the blood clotting cascade as factor I and does not normally pass into 
the brain parenchyma in the presence of an intact blood brain barrier (BBB) (Reese et al. 
1967). Thus extravascular detection in the brain parenchyma is considered a marker of 
increased BBB permeability. Fibrinogen lebelling has been used to demonstrate BBB 
breakdown in HIV encephalitis (Dallasta et at. 1999), Alzheimers disease (Mori et at. 
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Figure: 3.10 Kinetics of leukocyte infiltration. Groups, each of 120 mice, from B6.Wf and 
B6.IFN-y-/- strains were infected i.p. with 6x104 pfu/mouse. Subgroups of mice in each 
strain were sacrificed from day 3 to 30 p.i. H and E stained sections were used to quantify 
leukocyte infiltration in brain parenchyma. Sixty H.P.F. were counted per mouse brain, as 
described in materials and methods, and values for each timepoint amalgamated and 
expressed as mean± SEM. There was a significant difference at day 7 p.i. between B6.WT 
and B6.1FN-y-/- values (***p=<0.001 by ANOVA). No leukocyte infiltration was found 
in the brain parenchyma of mock-infected mice from either groups. 
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Figure: 3.11 Brain sections from mock-infected and WNV-infected B6.WT and B6.IFN-y-/-
mice labelled for extravascular fibrinogen. Immunoperoxidase labelling with rabbit anti-
fibrinogen and DAB substrate was used for the detection of fibrinogen leaking blood vessels. 
Sections were briefly stained with haematoxylin as a counterstain. No extravascular fibrino-
gen was found in mock-infected brain parenchyma in both B6.WT and B6.IFN-y-/- (a) mice. 
Extravascular fibrinogen was detected in very few mice in both B6.WT (b) (solid arrow) and 
B6.IFN-y-/- (c) (solid arrows) mice. Scale bar= 50tJ.m. 
1991), SFV encephalomyelitis (Eralinna et al. 1996; Soilu-Hanninen eta!. 1994) acute 
demyelination (Gay & Esiri, 1991). Therefore, immunohistochemical localization of 
fibrinogen was used to study the integrity of the BBB in WNV encephalitis using the same 
matched mice described above. Numbers of mice showing fibrinogen leakage are shown in 
Table 3.1. Leakage occurred in the highest proportion of animals between days 7 and 9 and 
was reduced or undetectable by day I 0. However, very little perivascular staining for 
fibrinogen (usually no more than one blood vessel per brain section) was detected in either 
group of mice throughout the time course of infection (Figure 3.11 b, c). Moreover, it did 
not correlate with the detection of viral antigen or with sites of leukocyte infiltration and 
WNV antigen was frequently detected in the presence of an intact BBB during the 
observation period. 
Table: 3.1 Proportion of mice showing fibrinogen staining at various timepoints p.i. 
Days post infection B6.WT% B6.IFN-y-/- % 
(no. of mice/total) (no. of mice/total) 
6 0.0 (0/8) 14.2 (117) 
7 12.5 (118) 28.5 (2/7) 
8 0.0 (0/5) 0.0 (0/6) 
9 33.3 (2/6) 25.0 (1/4) 
10 16.6 (1/6) 0.0 (017) 
-- - - ---
3.4. Discussion 
Since IFN-y is a critical cytokine in the eradication of many viruses, the pathogenesis of 
WNV encephalitis in normal and IFN-y-deficient mice was evaluated, using an adult model 
of WNV encephalitis developed in this project. Several studies on IFN-y and IFN-yR gene 
knockout mice have shown that IFN-y confers resistance to several microbial infections, 
including viruses (Nansen et al. 1998; Yu et al. 1996; Rodriguez et al. 1995; Utermohlen et 
al. 1996; Huang et al. 1993; Bouley et al. 1995; Karupiah et al. 1990), bacteria (Barbie et 
al. 1997; Rubbins et al. 1997), rickettsia (Li et al. 1987), fungi (Balish eta!. 1998) and 
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parasites (Wang et al. 1994; Suzuki et al. 2000), although the response to influenza A 
(Graham et al. 1993), murine gammaherpesvirus 68 (Sarawar et al. 1997) and SFV, VSV 
(Muller et al. 1994) appears unchanged in the genetic absence of IFN-y or IFN-y receptor. 
In contrast, my study shows that absence of IFN-y is associated with a marked reduction in 
mortality from approximately 60% in B6.WT to some 17% in B6.IFN-y-/- mice (Figure 3.2) 
in WNV infection. IFN-y gene knockout mice were more resistant to fatal disease compared 
to wild type and were completely resistant to secondary challenge WNV at a 50-fold higher 
dose than the first. Thus IFN-y is not critical for survival in either primary or secondary 
WNV infection. Moreover, it may exacerbate disease. 
Detection of WNV in the CNS was restricted to the cytoplasm and major dendrites of 
neurones in both groups of mice. There was no evidence of infection in glial cells, 
ependyma, choroid plexus or meninges. Thus absence of IFN-y does not alter the 
susceptibility to infection of different types of resident brain cells. Due to the lack of 
MHC-I on neurones in response to cytokine stimulation (Neumann 2001; Neumann & 
Wekerle 1998) and viral infection in vivo (Kimura & Griffin 2000), neurones are more 
vulnerable to infection compared to other CNS resident cells and enable certain viruses to 
escape immune regulation by virus-specific CDS+ T cells. Thus, neurones are a favoured 
site for the persistence of both productive and latent viral infection (Levine & Griffin 1992). 
Previous studies on neurotropic flaviviruses have also shown infection of neurones only, 
and not glia or endothelial cells (Shieh et al. 2000; McMinn et al. 1996; Iwasaki et al. 1986; 
Monath et al. 1983; Pogodina et al. 1983; Eldadah & Nathanson 1967). Since in vitro 
astrocytes and microglia readily become infected (Liu et al. 1989, Dr. Nicholas JC. King, 
USYD, personal communication), this apparent cellular specificity within the CNS seems 
unlikely to indicate the exclusive expression of specific receptors for WNV at the neuronal 
surface and seems more in keeping with a possible mode of neurone-to-neurone spread. 
Neurotropic viruses can invade the CNS across the BBB via infected endothelial cells 
(Wisniewski et al. 1983), access presumably being further facilitated by destruction of the 
BBB (Soilu-Hanninen et al. 1994; Johnson 1964) or may be transported through the 
endothelial cells without replication (Coffin & Lu 1957; Liou & Hsu 1998) or via 
diapedesis of infected leukocytes (Dallasta et al. 1999). Despite their in vitro susceptibility 
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to infection (Shen et al. 1997), endothelial infection was rarely observed in the brain in my 
model. Moreover, while destruction of BBB in WNV encephalitis occurred in a few mice in 
both groups (Table 3.1 and Figure 3.11 ), WNV was usually detectable in neurones without 
evidence of BBB disruption. Vice versa, evidence of BBB destruction was not necessarily 
accompanied by detectable WNV in neurones. A similar result was found in Borna disease, 
in which viral Ag was detected in the brain parenchyma in the presence of intact BBB 
(Hatalski et al. 1998). Since no infection of infiltrating leukocytes in the brain parenchyma 
was observed at any timepoints in my study, this route of infection also seems unlikely. 
Thus in the absence of a meticulous transmission electron microscopic study to exclude it, a 
cerebrovascular transendothelial transport route of WNV entry into the brain remains a 
possibility in this model. 
The olfactory neuroepithelium is thought to be a portal of entry into the CNS from the 
circulation after peripheral inoculation for several neurotropic viruses. For example, SLE 
(Monath et al. 1983), TBE (Albrecht 1962), MVE (McMinn et al. 1996), Venezuelan 
equine encephalitis (VEE) (Vogel et al. 1996; Charles et al. 1995) and neurovirulent 
influenza virus A (Reinacher et al. 1983). In my model there was no detectable WNV Ag in 
the OB at any point during the period of infection. In both groups, viral Ag was first 
detectable in the spinal cord at day 5 p.i., in the brainstem on day 6 and in other adjacent 
areas after this in a similar pattern in both groups (Figure 3.4 and 3.6). Since this WNV 
model is in adult mice, young 3-week-old mice were infected with WNV i.p. to evaluate 
whether age influences the route of access of WNV to the brain. Interestingly, patterns of 
WNV Ag detection in the young mouse model (Figure 3.5) were also similar to the adult 
model. It seems unlikely, therefore, that CNS invasion occurred via the OB in this model, or 
that the absence of IFN -y influences this route of infection. This leaves open the possibility 
that peripheral nerves may be the route of CNS invasion in WNV in this model. Kundin et 
al. (1962) demonstrated that WNV can infect peripheral nerves and Shieh et al. (2000) have 
shown that WNV Ag was detectable in the neurones of brainstem and spinal cords of fatally 
infected human cases. The time course experiment in our model showed the infection of 
motor neurones in the cervical spinal cord one day before WNV Ag was detected in the 
brainstem. This suggests that infection of the spinal cord may occur via retrograde axonal 
transport in motor nerves supplying infected striated muscle. Several animal models of viral 
encephalitis have demonstrated that neurotropic viruses can use pheripheral nerves as a 
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route of CNS invasion from the periphery, such as rabies (Tang et al. 1999; Murphy et al. 
1973), human poliovirus (Nathanson & Bodian 1961), Borna disease virus (Carbone et al. 
1987) models, for example. These viruses replicate within nerves and are moved through 
the host by the axonal transport system of neurones. 
Several studies in animal models of viral encephalitis have demonstrated the requirement of 
IFN-y for the control of viral infection in the CNS (Bartholdy et al. 2000; Geiger et al. 
1997; Parra et al. 1999; Christensen et al. 1999; Nansen et al. 1999; Rodriguez et al. 1995; 
Finke et al. 1995) Lewandowski et al. (1998) demonstrated that mice deficient in IFN-y 
production in the CNS had increased neuronal infection and death from HSV infection. 
Tishon et al. (1995) showed that IFN-y is required for the termination of persistent viral 
infection. Moreover, the athymic nude mouse model (immunodeficient mice) illustrate the 
role of IFN-y in viral infection (Kohonen-Corish et al. 1990). In contrast, in the WNV 
model, both the kinetics of infection, virus titres and the numbers of neurones infected were 
similar in B6.WT and B6.1FN-y -/-mice (Figure 3.8 and 3.9), although significantly greater 
numbers of B6.1FN-y-/- mice manifested detectable neuronal infection, compared to 
B6.WT (Figure 3.7). However, virus was still cleared from the CNS in the absence of 
IFN-y. This indicates that IFN-y is not required for the clearance of WNV. 
Inflammation is typical of a variety of CNS diseases and leukocyte recruitment to the CNS 
is a hallmark feature of viral encephalitis (Lassmann 1997). It is an important component of 
host defence and is often required for elimination of virus from the CNS. IFN-y is thought 
to play a role in the recruitment of inflammatory leukocytes in numbers of viral infections 
(Liu & Chambers 2001; Baumgarth & Kelso 1996). Consistent with this, the numbers of 
infiltrating leukocytes in the CNS parenchyma were significantly reduced in the absence of 
IFN-y in my model.In the B6.WT brain, maximal infiltration on day 7 p.i. was 
approximately 4-fold that in the B6.IFN-y-/- (Figure 3.10), suggesting that IFN-y plays an 
important role in the cerebral recruitment and extravasation of leukocytes in WNV 
encephalitis. There was no observable difference in morphology between the infiltrating cell 
populations seen in brains from either group. Whether there are functional differences in 
various leukocyte subsets infiltrating into the brain or whether the pathogenesis of 
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encephalitis is linked merely to quantitative differences in leukocyte infiltration is not clear 
yet. 
In the CNS parenchyma, IFN-y like immunoreactivity has been observed in the neurones 
previously (Kiefer & Kreutz berg 1990) and recently, it has been confirmed that neurones 
can produce IFN-y (Mori et al. 2001). IFN-y mRNA, although not IFN-yprotein, has been 
detected in purified cultures of astrocytes and microglia (Benveniste 1998). Recently, 
Morris & Esiri (1998) observed the constitutive expression of IFN-y at low levels in 
scattered microglia and some microvascular endothelium both in the normal and inflamed 
brain. However, although CNS resident cells are capable of producing IFN-y, the major 
source of IFN-y in the CNS in many viral encephalitides and CNS disorders has been 
ascribed to infiltrating T cells (Binder & Griffin 2001; Harnmarberg et al. 2000; Finke et al. 
1995; Cantin et at. 1995; Krakowski & Owens 1996). Therefore, T cells play a decisive role 
in the course and clinical outcome of viral CNS infection via secretion of IFN-y. The T cells 
that infiltrate into the CNS in viral encephalitis are activated and produce numbers of 
proinflammatory cytokines, including IFN-y, which is essential for the elimination of virus 
from the CNS in numbers of viral infections as discussed before, however, my study 
suggests a role for IFN -y in exacerbating disease in WNV encephalitis. 
There is strong evidence that IFN-y is a major disease-promoting cytokine. A small clinical 
trial during early 1980s using systemic administration of IFN-y was found to exacerbate 
disease in MS patients (Popko et al. 1997). Detection of IFN-y in post mortem samples of 
MS patients as well as detection of increased numbers of IFN-y-secreting T cells in the CSF 
of patients further support a role for IFN-y in disease exacerbation (Billiau 1996). MS is a 
chronic inflammatory neurological disease characterized by infiltration of leukocytes into 
the CNS, localized myelin destruction, and loss of oligodendrocytes and axons (Al-Omaishi 
et al. 1999). The role of IFN-y in disease exacerbation has been studied well in EAE, an 
animal model for MS. In this model, IFN-y produced by infiltrating activated T cells in the 
CNS is thought to be a key mediator of inflammation that induces pathogenesis of 
immune-mediated demyelinating disorders since these processes can be inhibited by anti-
IFN-y Abs (Olsson 1995). Moreover, adoptive transfer of IFN-y-secreting T cells isolated 
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from animals affected by EAE can cause EAE themselves in naive animals (Popko et al. 
1997). 
The immunopathological role of IFN-y in viral infections is poorly understood. LCMV has 
been extensively studied as a model of viral induced immunopathology' mediated by cos+ 
T cells (Doherty & Zinkemagel 1974; Zinkemagel 1992). However, how T cells mediate 
immunopathology in LCMV infection is still unknown. Although, Leist et al. ( 1989) 
demonstrated that treatment of mice with sheep anti-IFN-y Ab protect them from lethal 
LCMV infection despite enhanced LCMV replication in the CNS compared to control mice, 
it was not well clear that IFN-y was the cause of immunopathology in this model. 
In conclusion my model of WNV encephalitis clinically and histopathologically very 
similar to that seen in humans. This makes it relevant to the study of human disease. IFN-y 
is not important for survival in WNV encephalitis or generation of secondary anti-WNV 
immunity and clearance of WNV from the CNS, but is on the contrary critically involved in 
exacerbating disease. Only neurones are infected in WNV encephalitis and lack of IFN-y 
did not alter the susceptibility of CNS resident cells. WNV may enter into the brain via 
axonal pathways through the spinal cord both in the presence and absence of IFN-y. 
Leukocyte recruitment is significantly reduced in the absence of IFN-y and may be the 
major source of IFN-y in wild type mice. IFN-y on its own or in combination with other 
proinflammatory cytokines, could influence the CNS immune response as well as CNS 
functions via inducing to release several other cytokines, reactive oxygen species, NO and 
IDO. The precise mechanisms by which IFN-y exerts its function in exacerbating disease in 
WNV encephalitis are unknown. Taken together, these results suggest that WNV 
encephalitis is an immunopathological disease. 
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Chapter-4 
Microglia, not astrocytes are activated in 
WNV encephalitis 
4.1. Introduction 
Glial cells are supporting cells of the nervous system that help to maintain neuronal function 
and viability by providing both mechanical and metabolic support for neurones. Glial cells 
include microglia, astrocytes, oligodendrocytes and ependymal cells (Afifi & Bergman 
1998). Oligodendrocytes provide support for neurones by producing the myelin sheath that 
insulates axons. Ependymal cells are modified to produce CSF by transport and secretion of 
materials derived from adjacent capillary vessels in the CNS and this provides a hydrostatic 
buffer in which CNS is suspended (Burkitt 1993; Afifi & Bergman 1998). Astrocytes 
provide trophic support for neurones, maintain the BBB, regulate extracellular pH and 
potassium ion levels, guide neuronal development, remove spent neurotransmitters and 
synthesize essential neurotrophic factors (reviewed in Schoneboom et al. 1999; Dong & 
Benveniste 2001; Patel et al. 1996). Microglia represent the defence cells ofthe CNS (Chao 
et al. 1994; Matyszak 1998; Kreutzberg 1996). Among glial cells, microglia and astrocytes 
represent two highly reactive glial cells which respond to infectious and inflammatory 
stimuli (Aloisi et al. 2000) by producing various kinds of cytokines, chemokines, cytotoxic 
metabolites and growth factors, as well as upregulating or inducing de novo expression of 
various receptor molecules that are implicated in immune reactivity in conjunction with the 
peripheral immune system (Chao et al. 1994; Merrill & Benveniste 1996; Brodie et al. 
1997; Dallasta et al. 2000; Glabinski et al. 1999; Grzybicki et al. 1997; Benveniste 1992; 
Schijns et al. 1991; Persidsky et al. 1999; Sauder et al. 2000; Asensio et al. 1999) 
Astrocytes are the largest of the glial cells and outnumber neurones 10-1 in the mammalian 
brain (Benveniste 1992). They are distributed throughout the CNS in close association with 
neurones and blood vessels. They can be distinguished by their large stellate shape 
comprising cell bodies with many radiating processes. Some of these processes form 
terminal expansions that are applied to the terminal blood vessels (Figure 4.2 a) (Carpenter 
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1991). Astrocytes contain bundles of intermediate filament of cytoskeletal protein, known 
as GFAP (Eddleston & Mucke 1993), having a molecular weight of 41-51 kDa depending 
upon the species (reviewed in Martin & O'Callaghan 1995). Several markers have been 
used for the identification of astrocytes, including SlOO~, GFAP and glutamate synthetase 
(reviewed in Mucke & Eddleston 1993). Morphological changes in astrocytes visualized 
with any of these markers are considered an indicator of a change in the function of these 
cells. Astrocytes are immunocompetent cells of the CNS. They can divide and multiply, and 
respond to various CNS infections and demyelinating diseases (Dong & Benveniste 2001; 
Benveniste 1992). This response is known as astrogliosis or reactive astrocytosis, 
characterized by an increase in the numbers and size of cells with enhanced expression of 
GFAP (Mucke & Eddleston 1993). Astrogliosis may also result from interference with 
blood supply (Buchanan 1951 ), since astrocytes extend their processes to the blood vessels 
for the exchange of metabolites and wastes to and from neurones (Dong & Benveniste 
2001; Burkitt 1993). It has been observed that lack of astrogliosis in response to neuronal 
injury increases disease. Such dysfunction can lead to reduce neurotrophic support and 
increased neurotoxin levels with resultant neurological disease (Benveniste 1992). 
In contrast to astrocytes, microglia are the smallest glial cells. They are ubiquitously 
distributed in the CNS, comprising up to 20% of the total glial cell population in the rodent 
brain and are located in close proximity to neurones in the grey matter and between fibre 
tracts in the white matter (Lawson 1990). It used to be thought that the CNS was an 
immune-privileged site due to the presence of the BBB, which isolates the CNS from 
peripheral immune system, lack of lymphatic drainage and low or absent expression of 
MHC molecules. But from several studies it is clear that microglia are part of a substantial 
immune response capability within the CNS (Cross & Woodroofe 2001; Mori et al. 2001; 
Chao et al. 1994) and are seen as the first line of defence in the CNS against infectious 
diseases, inflammation, brain tumors, neurodegeneration, etc., (Kreutzberg 1996). Microglia 
are considered to arise from the monocyte lineage that enter the brain during embryonic 
development in response to naturally occurring cell death (Moore & Thanos 1996) prior to 
the formation of the BBB (Davis et al. 1994 ). Within the developing CNS, monocytes 
transform into ramified cells through the intermediate form known as amoeboid microglia 
(Perry & Gordon 1988). Therefore, microglia are functionally related to peripheral tissue 
macrophages (Ling & Wong 1993). Like tissue macrophages, microglia are involved in the 
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local CNS immune responses. Once activated, they can destroy invading microorganisms 
(Kreutzberg 1996), remove cell debris and enhance neuronal survival by secreting many 
different neurotrophic factors, thus facilitating a return to normal tissue homeostasis 
(Nakajima & Kohsaka 1998). 
In the normal adult brain, microglia display a ramified morphology with small somata and 
numerous processes radiating therefrom (Ling & Wong 1993). They exhibit a 
downregulated immunophenotype (Streit et al. 1999; Banati et al. 1993). These ramified 
microglia are thus known as resting microglia (Dickson et al. 1993) and are generally 
considered as inactive macrophages, capable of converting rapidly into the active 
phenotypes (Davis et al. 1994). These cells can divide and multiply during activation 
(Dickson et al. 1991) but do not divide while resting (Ling & Wong 1993). The function of 
resting microglia in the CNS is poorly understood, however, it has been suggested that they 
may contribute to the normal function of brain tissue by inactivating neurotransmitters, 
cleansing extracellular fluid and otherwise providing neurotrophic support (Davis et al. 
1994). Unlike astrocytes, microglia and their processes are not specifically associated with 
blood vessels (Dickson et al. 1991). 
Microglia function as intrinsic sensors to threats to the CNS, as indicated by rapid changes 
in their morphology (Greenfield 1997). The degree of activation or alteration in morphology 
reflects the severity of the injury (Streit et al. 1999). Activated microglia are characterized 
by larger cell bodies with shorter, stouter processes. This is the first stage of activation and 
these cells are still non-phagocytic in nature (Kreutzberg 1996). In the second stage of 
activation, microglia withdraw all processes and transform into phagocytic cells, and are 
termed microglia-derived brain macrophages (Streit et al. 1999). Phagocytic microglia are 
typically small and spherical, but also exhibit rod-shaped and other morphologies. These 
microglia are known as amoeboid or reactive microglia (Davis et al. 1994) and are a 
prominent feature of inflammatory conditions (Dickson et al. 1991). Thus, activation of 
microglia occurs in a graded fashion, however, this graded response can not be 
differentiated from the influx of monocytes with full macrophage capabilities, as can occur 
with destruction of the BBB from the circulation (Kato & Walz 2000). Both activated and 
phagocytic forms of microglia can return to the resting, ramified state (reviewed in Stence et 
al. 2001). Besides changes in morphology, activated microglia can also proliferate, migrate 
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to the site of injury (Cuadros & Navascues 1998), increase their synthesis of secretory 
products, as well as present Ag to infiltrating T cells by expressing MHC molecules (Moore 
& Thanos 1996; Stoll & Jander 1999; Havenitb et al. 1998). Moreover, depending upon 
neuronal stress, microglia may displace synapses, known as synaptic stripping, to 
deafferentiate and isolate stressed neurones (Banati 1993). It has been suggested that 
microglial activation is induced by neurones (Sudo et al. 1998; Kreutzberg 1996). 
Moreover, increasing evidence suggests that glial cell activation is mediated by IFN-y both 
in vivo and in vitro (Meda et al. 1995; Sethna et al. 1991; Yong et al. 1991). However, the 
actual mechanism by which microglia are activated and how this corresponds to the severity 
of neuronal injury is not fully understood. 
Although astrocytes and microglia are activated in many viral infections of the CNS (Kure 
et al. 1990; Christian et al. 1996; Iwasaki et al. 1986; Sauder et al. 1999; Brodie et al. 1997) 
this process has not been studied in detail in any viral encephalitis model, including WNV 
encephalitis. For these reasons, the types of glial cells, the kinetics of their activation and 
the role of IFN-y in this activation were investigated in WNV encephalitis by comparing 
CNS responses of IFN-y-deficient mice with that of tbe congenic B6.WT mice. 
4.2. Materials and Methods 
4.2.1. Mice 
Female, specific-pathogen free, 8-week-old B6.WT and B6.IFN-y-/- mice, backcrossed to 
C57BL/6, were used. 
4.2.2. Yirus infection of mice and tissue preparation 
A time course experiment was performed to determine the types of glial cell activated and 
the kinetics of activation, as well as their normalization in the CNS. Groups of 120 mice, 
each of B6.WT and B6.IFN-y-/-, were inoculated with WNV i.p. at 6x104 pfu/mouse. 
Tissues were collected and processed as described in section 2.2.2.2. Groups of 21 B6.WT 
mice were inoculated i.n. with 6xl04 pfu/mouse and tissues were collected and processed as 
described in section 2.2.2.2. Mice were mock-infected with DMEM as controls. 
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4.2.3. Histopathology 
Serial sections from paraffin-embedded tissues used for immunohistochemistry and lectin 
histochemistry were routinely stained with H and E, and examined to evaluate the 
pathological changes, including glial cell activation, in both groups of mice. 
4.2.4. Lectin histochemistry and Immunohistochemistry 
Paraffin-embedded sections were used for both immunohistochemistry and lectin 
histochemistry. 
• Detection of activated microglia by lectin histochemistry 
Isolectin-B4 derived from Grif.fonia simplifolia (L-2140, Sigma Chemical Company) (GS-
lectin) was used as a marker for the visualization of activated microglia in the brain. GS-
lectin binds to glycoprotein a-D-galactose, which is important for cell recognition and 
adherence (Dickson et al. 1991). Cells of the monocyte/macrophage lineage, vascular 
precursor cells and vascular endothelium can be labelled with GS-lectin (Streit et al. 1987; 
Medana et al. 1997). Several reports suggest that increased staining intensity with GS-lectin 
correlate with activation of macrophages/microglia (Maddox et al. 1982; Streit et al. 1987; 
Medana et al. 1997). 
After dewaxing, the sections were microwaved on high power in citrate buffer for 8 mins. 
After this treatment, sections were allowed to stand at RT0 for 30 mins in citrate buffer, 
washed in Tris-buffer for 5 mins and endogeneous peroxidase activity was blocked, as 
described in section 2.2.3. Sections were washed 3 times with Tris-buffer for 10 mins and 
then incubated with 100~-tl of 1:50 diluted biotinylated GS-lectin for 3h at 4°C. After rinsing 
in Tris-buffer for 10 mins, sections were incubated with 100 ~-tl of horseradish peroxidase 
complex, 1:100 dilution, according to the manufacturer's instructions. After this step, the 
rest of the procedure was identical to that described in section 2.2.3. Mock-infected brain 
sections were used as controls for GS-lectin labelling. 
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• Detection ofMHC-11 expression 
After dewaxing the sections, Ag was retrieved with digestion of sections in papain 
(02310807, CSL, Australia) for 5 mins at RT0 , according to the manufactures's instructions 
and washed in Tris-buffer. After blocking the endogeneous peroxidase activity and 
non-specific staining as described before, sections were then incubated with undiluted rat 
anti-mouse MHC-II Ab, a hybridoma (TIB 120: ATCC, M5/114.15.12) supernatant, 
overnight at 4 °C. The rest of the staining procedure was identical to that described in 
section 2.2.3. Mock-infected brain sections from both groups of mice were used as controls 
for MHC-II expression and monoclonal rat IgG2b was used as an isotype control for the 
primary antibody. 
• Detection of astrocyte activation by GFAP immunohistochemistry 
After dewaxing the sections, endogeneous peroxidase activity and non specific staining 
were blocked, as described in section 2.2.3. Sections were then incubated with lOOJLl of 
1:750 diluted polyclonal rabbit anti-cow GFAP Ab (Z0334, Dako) for lh at RT0 • The rest of 
the staining procedure was as described in section 2.2.3. Mock-infected brain sections from 
both groups of mice were used as controls for GFAP upregulation and polyclonal rabbit IgG 
was used as an isotype control for the primary Ab. 
• Double labelling for WNV antigen and activated microglia 
Alkaline phosphatase substrate, 5-Bromo-4-Chloro-3-Indolyl Phosphate/Nitroblue 
Tetrazolium (BCIP/NBT, Vector Laboratories, Burlingame, CA), was used to give a blue 
cytoplasmic signal for WNV Ag whereas horseradish peroxidase substrate, DAB, was used 
to detect activated microglia. Activated microglia were detected as described above and 
WNV Ag was detected as described in section 3.2.3. 
4.2.5. TUNEL labelling 
After dewaxing, sections were stained for apoptosis using In situ Apoptosis detection kit, 
A pop tag® peroxidase (Intergen Company) according to the manufacturer's instructions. 
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4.2.6. Quantification of cells and data analysis 
Quantification of cells and data were analysed as described in section 2.3 and 2.6 
respectively. Figures are mean values± SEM for the total number of fields examined from 
the indicated number of mice, n. 
4.3. Results 
4.3.1. HistQpathological changes jn the brain parenchyma during infection 
The main aims of this study were to determine the extent and distribution of activated glial 
cells within the CNS in response to WNV infection and to characterize the types of 
activated glial cells. Brain sections from both groups of mice were stained routinely with H 
and E. Histology of mock-infected mouse brain was normal (Figure 4.1 a). 
Histopathological lesions were observed after infection in both groups. H and E stain 
showed activation of glial cells, including rod shaped morphology (Figure 4.1 b) with the 
formation of nodules (Figure 4.1 c) throughout the brain in B6.WT and B6.1FN-y-/- mice as 
well as the presence of inflammatory cells. These were obsereved from day 7-11 p.i. in both 
groups of mice (Figure 4.1 b). 
4.3.2. No Astrqcytes activatiQn in WNY encephalitis 
Upregulation of GFAP was used as a marker for the activation of astrocytes in WNV 
encephalitis. Interestingly, no activation of astrocytes was observed at any of the timepoints 
in B6.WT and B6.IFN-y-/- mice. Mock-infected brain parenchyma from both groups of 
mice showed low intensity GFAP staining of astrocytes (Figure 4.2 a). However, on day 10 
p.i., in one B6.WT mouse a few astrocytes were activated in the brainstem, as demonstrated 
by increased GFAP staining (Figure 4.2 b), compared to astrocytes from mock-infected 
mice (Figure 4.2 a). This result suggests that astrocytes do not generally play a significant 
role in WNV encephalitis. 
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Figure: 4.1 Hand E stained brain sections of mock-infected and WNV -infected mouse brain. 
Mock-infected brain parenchyma showing normal histology (a). Infected brain parenchyma 
showing microglial activation (solid arrows) on day 8 p.i. (b) and nodules (solid arrow) (c) 
on day 10 p.i. These micrographs are representative of histopathology observed in both 
B6.WT and B6.IFN-y-/- mice. Scale bar= 50Jim. 
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Figure: 4.2 Mock-infected and WNY-infected B6.WT mouse brain sections labelJed for 
GFAP. Astrocytes were less intensely stained with anti-GFAP antibody in mock-infected 
brain (a) (solid arrows). Some of the end feet of astrocytes cover a blood vessel (a) (open 
arrows). Activated astrocytes showed intense staining with increased production of GFAP 
in the brainstem of only one WNY-infected B6.WT mouse brain on day 10 p.i. (b) (solid 
arrows). Scale bar= 50Jtm. 
4.3.3. Activation of microglia in WNV encephalitis 
4.3.3.1. Activation of microglia in the absence of IFN-y 
As described earlier, H and E staining showed activation of glial cells in B6.WT and 
B6.IFN-y-/- mice. Since, astrocytes were poorly or not activated, this study was completely 
focused on microglial activation. Several markers are available to dectect activated 
microglia, however most of them are immunological markers, such as MHC-11 expression, 
I CAM-I expression, increased CR3 complement receptor, etc.,. Since this study focused on 
the role of IFN-y in microglial activation, including MHC-11 and ICAM-1 expression, the 
non-immunological marker, GS-lectin was chosed to define microglial activation 
throughout the study. GS-lectin is a ligand for a-D-galactose, embedded in the plasma 
membrane of microglia!macrophages and endothelial cells only. GS-lectin does not stain 
neurones, astrocytes or oligodendrocytes and this combined with cell morphology makes it 
a selective marker for activated microglia in the CNS (Cross & Woodroofe 2001). 
Resting microglia under normal condition do not posses enough a-D-galactose residues to 
be prominently labelled with GS-lectin (Medana et al. 1996), however during activation 
they increase sugar residues, which labelled strongly with GS-lectin. Therefore, resting 
microglia from mock-infected brain showed either negative labelling or very faint labelling 
with GS-lectin throughout the brain (Figure 4.3 a, c and e). After infection, microglial 
activation was observed throughout the brain, indicated by intensely positive labelling in 
both groups of mice (Figure 4.3 b, d and f). 
Activated microglia were first detectable in the brain at day 7 p.i., within 24h of WNV Ag 
detection in the brain in both groups of mice (Figure 4.4 A and B). Since infiltration of 
leukocytes in the brain parenchyma was observed 48h before microglial activation in both 
groups of mice (Figure 4.5 A and B), it was important to investigate whether microglial 
activation was mediated by infiltrating leukocytes or in response to the neuronal infection in 
the i.p. model. To confirm this, groups of mice were infected i.n. and, brain sections were 
stained with GS-lectin and anti-WNV Ab. The kinetics of WNV Ag detection and 
microglial activation in the i.n. model is presented in figure 4.4 C. The kinetics of leukocyte 
infiltration and microglial activation in the i.n. model is presented in figure 4.4 C. In the i.n. 
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Figure: 4.3 Microglial activation in different parts of the brain section stained with GS-lectin. 
No microglial activation was observed anywhere in the brain parenchyma of mock-infected 
brain (a, c and e). Microglia were highly activated throughout the brain in infected mice (b, d 
and f). These micrographs are representative of both B6.1FN-y-/- and B6.WT mice. 
Scale bar = 1 OOJ.tm. 
Figure: 4.4 Kinetics of microglial activation and WNV antigen detection in the i.p. 
and i.n. model. Groups, each of 64 mice, from B6.WT and B6.1FN-y-/- strains were 
infected i.p. with 6xl04 pfu/mouse and groups of 15 mice from B6.WT were 
infected i.n. with 6x 104 pfu/mouse. Subgroups of mice in each strain in each model 
were sacrificed from day 3 to 7 p.i. in both models. Lectin histochemistry was used 
to detect activated microglia and immunoperoxidase labeling was used to detect 
WNV antigen in the brain of infected mice. The number of +ve cells labelled with 
OS-lectin and anti-WNV antibody were counted, as described in Materials and 
Methods. Sixty H.P.F. were counted per mouse brain and values for each timepoint 
amalgamated and expressed as mean ± SEM. Kinetics of microglial activation and 
WNV antigen detection in B6.WT (A) and B6.1FN-y-/- mice in the i.p. model ( B) 
and B6.WT in the i.n. model (C) are shown. Arrows indicate first appearance of 
infiltrating leukocytes. Note the change of scale at 4 positive cells/H.P.F. (broken 
line) in figure C. 
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Figure: 4.5 Kinetics of microglial activation and detection of leukocytes in the brain 
parenchyma in the i.p. and i.n. model. Groups, each of 64 mice, from B6.WT and 
B6.IFN-y-/- strains were infected i.p. with 6xl04 pfu/mouse and groups of 15 mice 
from B6.WT were infected i.n. with 6xl04 pfu/mouse. Subgroups of mice in each 
strain in each model were sacrificed from day 3 to 7 p.i. in both models. Lectin 
histochemistry was used to detect activated microglia and, H and E stain was used to 
detect leukocyte infiltration in the brain parenchyma of infected mice. The number 
of +ve cells labelled with GS-lectin and leukocytes were counted, as described in 
Materials and Methods. Sixty H.P.F. were counted per mouse brain and values for 
each timepoint amalgamated and expressed as mean ± SEM. Kinetics of microglial 
activation and leukocytes detection in B6.WT (A) and B6.IFN-y-/- in the i.p. model 
(B) and B6.WT in the i.n. model (C) are shown. Arrows indicate first detection of 
WNV antigen in the brain. Note the change of scale at 4 positive cells/H.P.F. 
(broken line) in figure C. 
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model, activated microglia were detected at the same time as WNV Ag was detected in the 
OB, co-localising with WNV -positive neurones in the OB at day 3 p.i., while leukocyte 
infiltration was observed 48h after microglial activation. These results indicate that 
microglial activation is independent of both leukocyte infiltration and the presence of IFN-y 
and suggest that they were activated in response to neuronal infection. 
4.3.3.2. Morphology of microglial changes during activation 
Microglia were activated throughout the brain with markedly altered morphology between 
day 7-11 p.i. in B6.WT and B6.IFN-y-/- mice. The progression of activation can be seen in 
figure 4.6. During early activation, microglia showed highly branched processes, exhibiting 
ramified morphology, with little GS-Iectin labelling (Figure 4.6 a). During activation, the 
processes became thicker with increased staining intensity (Figure 4.6 b), ultimately 
withdrawing (Figure 4.6 c, d and e). In the last step of activation, microglia became round 
or elongated (rod shaped). These are known as amoeboid or reactive microglia (figure 4.6 
f). Amoeboid microglia were clustered around neurones (Figure 4.6 h). The morphology 
and staining characteristics of microglial cells returned to normal by day 30 p.i. in both 
groups of mice. These results indicate that microglial activation is independent of IFN-y. 
4.3.3.3. Kinetics of microglial activation 
As discussed earlier, although microglia were activated in both groups of mice from day 7 
p.i., not all mice were positive for microglial activation in both groups. The percentage of 
mice positive for microglial activation is shown in figure 4.7. There was no difference in the 
percentage of mice positive for microglial activation between the groups. Interestingly, in 
both groups of mice more than 85% surviving mice had microglial activation on day 11 p.i., 
and at this timepoint WNV Ag was nearly undetectable (discussed in section 3.3.3.3). None 
of the mice positive for WNV was negative for microglial activation. Mice surviving after 
day 11 p.i. continued to survive until 90 days p.i. without clinical symptoms. After day 90 
p.i., mice were sacrified. 
Since there was no difference in the percentage of mice positive for microglial activation, 
GS-lectin-positive microglia were quantitated, as described in Materials and Methods to 
evaluate whether there was a significant difference in the number of activated microglia 
84 
Figure: 4.6 WNV-infected B6.WT mouse brain sections stained with GS-lectin 
showing different morphologies of activated microglia. Microglia during early 
activation showed highly branched processes exhibiting a ramified morphology, 
lightly stained with GS-lectin (a) (solid arrows). During activation, the processes 
became more thicker with increased staining intensity (b, c and d) (solid arrows), 
and begin to withdraw (d and e) (solid arrows). They finally achieve an amoeboid 
morphology, including rod (f) (solid arrows) or spherical forms (g) (solid arrows). 
These amoeboid microglia were the predominant type clustered around neurones (h) 
(solid arrow). These micrographs are representative of both B6.WT and B6.IFN-y-/-
mice. Scale bar = 50J.tm. 
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Figure: 4.7 Percentage of mice positive for microglial activation. Groups, each of 110 mice, 
from B6.WT and B6.1FN-y-/- strains were infected i.p. with 6x104 pfu/mouse. Subgroups of 
mice in each strain were sacrificed from day 3 to 15 p.i. Lectin histochemistry was used to 
detect activated microglia in the brain. Percentage of mice positive for microglial activation 
throughout the time period is shown. No microglia were activated in the brains of mock-
infected mice in either group. 
between the groups. The kinetics of microglial activation were similar and are shown in 
figure 4.8. In B6.WT mice, microglial activation was significantly increased on days 7-11 
(p=<0.001), peaking on day 10 p.i. and reduced nearly to baseline values in survivors by 
day 15 p.i. In B6.IFN-y-/- mice, microglial activation was significantly increased on days 8-
11 (p=<0.001), peaking on day 9 p.i. and reduced nearly to baseline values in survivors by 
day 15 p.i. These numbers returned completely to baseline values in survivors by day 30 p.i. 
in both groups of mice (Figure 4.8) after WNV Ag was completely undetectable from day 
15 p.i. These results provide further support for the hypothesis that microglial activation 
was in response to neuronal infection. Although the kinetics of microglial activation was 
similar between the groups, the number of activated microglia was significantly higher 
(p=<0.001) in B6.IFN-y-/- mice compared to B6.WT on day 9 p.i. This result suggests that 
lack of IFN-y enhanced microglial activation in WNV encephalitis. 
4.3.3.4. Kinetics of microglial nodules formation 
Microglial nodules are a hallmark of viral encephalitis (Dickson et al. 1991; Dickson et al. 
1993). In aggrement with this, microglial nodules were also observed in WNV encephalitis 
from day 7 onwards (Figure 4.1 c and Figure 4.6 h) in both groups of mice. The size and 
number of nodules were also increased between days 7-11, consisting of approximately 3-
30 microglia displaying amoeboid morphology/nodule. In the beginning, at day 7-8 p.i., the 
nodules were small and consisted of loose aggregates of activated microglia in both groups 
of mice. After day 8 p.i. in B6.IFN-y-/- and after day 9 p.i in B6.WT mice, the nodules were 
larger with densely aggregated activated microglia. To evaluate whether there was a 
significant difference in the numbers of nodules formed between the groups, they were 
counted in whole brain sections stained with OS-lectin. The number of nodules peaked on 
day 10 and 11 p.i. in B6.WT, whereas in B6.IFN-y-/- mice, nodules were maximal on day 9 
p.i. (Figure 4.9). The number and size of nodules were decreased from day 15 p.i. in both 
groups of mice. The kinetics of nodule formation was similar and there were no statistically 
significant differences in the total numbers of nodules formed between the groups at any 
timepoints. 
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Figure: 4.8 Kinetics of microglial activation. Groups, each of 120 mice, from B6.Wf and 
B6.1FN-y-/- strains were infected i.p. with 6xl04 pfu/mouse. Subgroups of mice in each 
strain were sacrificed from day 3 to 30 p.i. Lectin histochemistry was used to detect activated 
microglia in the brain parenchyma of infected mice. The number of activated microglia was 
counted, as described in materials and methods. Sixty H.P.F. were counted per mouse brain 
and values for each timepoint amalgamated and expressed as mean ± SEM. No microglia 
were activated in the brains of mock-infected mice in either group. (***p = <0.001 by 
ANOVA). 
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Figure: 4.9 Kinetics of microglial nodule formation. Groups, each of 110 mice, from 
B6.WT and B6.IFN-y-/- strains were infected i.p. with 6x104 pfu/mouse. Subgroups of 
mice in each strain were sacrificed from day 3 to 15 p.i. Lectin histochemistry was used to 
detect activated microglia in the brain parenchyma of infected mice. The number of nod-
ules was counted in a whole brain section, values for each timepoint amalgamated and 
expressed as mean ± SEM. Statistical analysis using ANOV A showed no significant dif-
ference in the numbers of nodules formed between the groups. 
4.3.3.5. Formation of microglial nodules did not correlate with neuronal death 
It has been suggested that clustering of amoeboid microglia around the neurones reflect 
neuronal cell death (Adams et al. 1994; Raivich et al. 1999). Therefore, in order to 
determine whether neurones at the centre of these clusters were dead or dying, we used a 
TUNEL assay on these brain sections. Mock-infected brain from both groups showed no 
cell death (Figure 4.10 a). Brain sections showing maximum neuronal infection were chosen 
for TUNEL assay. Very few cells were labelled with TUNEL in both groups of mice 
(Figure 4.10 band c). All TUNEL-positive cells were counted in whole brain sections and 
compared with the total number of infected neurones. Interestingly, it was found that less 
than 0.1% of neurones were apoptotic, compared to the total number of neurones infected 
while only I% of neurones at the centre of a nodule were apoptotic compared to the total 
number of nodules from either group. Moreover, the number and sites of TUNEL-positive 
neurones did not correlate with the number and sites of microglial clustering in the brain 
parenchyma (data not shown). It follows that most neurones surrounded by activated 
microglia had not undergone cell death. Since microglia were highly activated in both 
groups of mice, a double-labelling for viral Ag and activated microglia was carried out to 
confirm that only neurones were infected and also to determine the numbers of microglia 
clustering around delectably infected neurones. In no case were microglia found to be 
infected with WNV. However, microglia surrounded infected neurones, showing typical 
phagocytic morphology in both groups (Figure 4.11). Indeed, many apparently uninfected 
neurones detected by immunoperoxidase were also associated with microglial nodules from 
day 7 onwards of the time course. 
4.3.3.6. Unimpared MHC-II expression in microglia in the absence of IFN-y 
Microglia act as an APC in the CNS. Expression of MHC-II in microglia is inducible and 
IFN-y is a potent inducer of microglial MHC-II expression both in vivo and in vitro (Raivich 
et al. 1999; Deckert-Schluter et al. 1999). Therefore, the status and role of IFN-y in 
MHC-II upregulation in microglia was determined. Mock-infected mice from either group 
were negative for MHC-II expression (Figure 4.12 a). After infection, MHC-II expression 
was observed in both groups of mice (Figure 4.12 band c). In B6.IFN-y-/- mice MHC-II 
expression was observed only on a very few neurovascular endothelial cells on day 6 p.i. 
From day 7 p.i., a few infiltrating leukocytes, the neurovascular endothelial cells, 
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Figure: 4.10 Brain sections from mock-infected and WNV -infected B6.WT and B6.1FN-y-/-
mice on day 9 p.i. labelled for apoptosis by TUNEL assay. No cell death was found in the 
mock-infected brain parenchyma in both B6.WT and B6.1FN-y-/- mice (a). Brain sections 
showing maximum WNV antigen were selected for TUNEL assay. Few cells were labelled 
with TUNEL (solid arrows) in both B6.WT (b) and B6.1FN-y-/- (c) mice. Scale bar= 50~m. 
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Figure: 4.11 Mock-infected (a) and WNV-infected B6.IFN-y-/- (b) mouse brain parenchyma 
double-labelled for WNV antigen and activated microglia on day 9 p.i. Alkaline phosphatase 
labelling using rat anti-WNV and BCIP/NBT substrate for WNV antigen detection is shown 
in blue. GS-lectin and DAB substrate were used for the detection of activated microglia and 
these displayed a phagocytic morphology (brown). Infected neurones (open arrows) were 
surrounded by clusters (nodules) of activated microglia (solid arrows). Uninfected neurones 
are indicated by arrow heads. These micrographs are representative of histopathology 
observed in both B6.WT and B6.1FN-y-/- mice. Scale bar= 50f..UD. 
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Figure: 4.12 MHC-II expression in the brain parenchyma. lmmunoperoxidase labelling was 
used to detect MHC-Il in mock-infected and WNV-infected mouse brains on day 11 p.i. 
from B6.WT and B6.IFN-y-/- mice. There was no constitutive expression of MHC-11 in the 
brain parenchyma in either group (a). After WNV infection, MHC-11 was expressed in 
microglia (solid arrows) and perivascular ceJls (open arrows) in both B6.WT (b) and 
B6.IFN-y-/- mice (c). Only activated microglia displaying ameboid morphology were 
labelled with anti-MHC-Il antibody in both groups of mice (solid arrows). 
Scale bar=50Jlm. 
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Figure: 4.13 Comparision of microglial activation and microglial MHC-11 expression. 
Groups, each of 70 mice, from B6.Wf (A) and B6.1FN-y-/- (B) strains were infected i.p. with 
6x104 pfulmouse. Subgroups of mice in each strain were sacrificed from day 3 to 15 p.i. 
Lectin histochemistry and immunoperoxidase labelling was used to detect activated microglia 
and expression of MHC-11 antigen in the brain parenchyma of infected mice, respectively. 
The brain sections showing maximum microglial activation as detected by GS-lectin, was 
selected for MHC-11 labelling at each timepoint. Numbers of GS-lectin-positive microglia 
and MHC-11-positive microglia were counted, as described in materials and methods. Sixty 
H.P.F. were counted per mouse brain and values for each timepoint amalgamated and 
expressed as mean ± SEM. No microglia were activated or expressed MHC-11 antigen in the 
brains of either strain of mock-infected mice. (***p = <0.001 by ANOVA). n=3 from d6-d10 
p.i. and n=1 on day 15 p.i. in both groups. 
perivascular macrophages and microglia only those displaying amoeboid morphology 
expressed MHC-II in both strains of mice. These MHC-II-positive cells were scattered 
throughout the brain. The brain sections showing high microglial activation were chosen for 
the study of MHC-II expression to determine the relationship between microglial activation 
detected by GS-lectin and MHC-II expression on microglia. The number of 
MHC-11-positive microglia were counted, as described in Materials and Methods and 
compared with GS-lectin-positive microglia. It was found that the number of MHC-II 
expressing microglia was significantly less (p=<0.001) compared to the GS-lectin positive 
microglia from either group at any timepoints from day 7-10 p.i. (Figure 4.13). These data 
indicate that induction of MHC-II expression is independent of IFN-y and relatively few 
activated microglia are induced to express MHC-II in WNV encephalitis. 
4.4. Discussion 
The glial cells, predominantly microglia and astrocytes, represent highly reactive CNS cells 
that respond to infectious and inflammatory stimuli by upregulation or de novo expression 
of various cell surface molecules, which are implicated in the control of CNS infections. 
Several experiments have shown the importance of IFN-y in glial cell activation. Therefore, 
to investigate types and kinetics of glial cell activation, and the role of IFN-y in glial cell 
activation in WNV encephalitis, the brain parenchyma of infected B6.WT and B6.IFN-y-/-
mice was stained with GS-lectin and anti-GFAP Ab to label microglia and astrocytes, 
respectively. 
Astrocytes play a key role in the normal CNS and have a number of important physiological 
properties related to the CNS homeostasis (Benveniste 1998). They can be identified by de 
novo expression of GFAP (Martin and O'Callaghan 1995), which is enhanced during 
activation (Eddleston & Mucke 1993). Therefore, upregulation of GFAP was used in this 
study as a marker of astrocyte activation. Astrocytes can respond during infection of the 
CNS as well as in inflammatory demyelinating disease (Mucke & Eddleston 1993; Brodie et 
at. 1997; Schonrock et at. 1998) with an increase in number and size of enhanced 
GFAP-expressing cells, i.e., astrogliosis (Eddleston & Mucke 1993). Several experiments 
have demonstrated the activation of astrocytes in CNS infections both in vivo and in vitro 
(Weissenbock et at. 2000; Schoneboom et at. 1999; Bi et at. 1995; Chen et at. 2000; Liu et 
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at. 1989; Medana et at. 1996). In vitro experiments suggest that astrogliosis is mediated by 
IFN-y (Balasingam et at. 1994; Yong et at. 1991). However, in WNV encephalitis, only 
extremely rarely were astrocytes activated in both B6.WT and B6.1FN-y-/- mice, suggesting 
that astrocytes do not play a significant role in WNV encephalitis. Moreover, the presence 
of IFN-y neither induced astroglial activation nor reduced its activation, suggesting that 
activation of astrocytes is not mediated by IFN-y. 
Since, astrocytes were not activated in WNV encephalitis, this study thus mainly focused on 
microglial activation. Microglia are found to be activated in several CNS diseases. These 
include human neurological disorders (Banati et at. 1993; Paresce et at. 1996; Schluesener 
et at. 1996), EAE (Bauer et al. 1995), ischemia (Morioka et al. 1992), viral encephalitis 
(Sampson et at. 2000; Shieh et al. 2000, Kure et al. 1990; Christian et at. 1996; Iwasaki et 
at. 1986; Sauder et at. 1999; Mokhtarian et at. 1996; Bi et at. 1995), parasite infection 
(Deckert-Schluter et at. 1999; Medana et at. 1997) and radiation injury of the CNS 
(Kyrkanides et at. 1999). Being extremely sensitive in nature, hardly any disease of the 
nervous system occurs without microglial activation. Microglial activation in all CNS 
diseases is characterized by proliferation, increased or de novo expression of marker 
molecules, such as MHC Ag, and migration, with the eventual change into a 
macrophage-like phenotype and the production of a variety of secretory molecules, 
including cytokines, chemokines, reactive oxygen and nitrogen species (Banati et at. 1993; 
Benveniste 1992). In WNV encephalitis, microglia were highly activated throughout the 
brain (Figure 4.3), as identified by their enlarged size and dramatic alteration in their 
morphology with intense OS-lectin staining. Resting microglia labelled very weakly or not 
at all with OS-lectin. 
Meddana et at. ( 1997) showed that breakdown of BBB would facilitate microglial 
activation. However, in WNV encephalitis microglia were activated in the presence of an 
intact BBB (see section 3.3.5), suggesting that microglial activation is independent of BBB 
permeability. In this model, microglial activation was observed within 24h of WNV Ag 
detection in the the brain at or near the sites of neuronal infection in both groups of mice 
(Figure 4.4 ). Sudo et at. (1998) suggested that microglial activation is induced by stressed 
neurones. Therefore, I speculate that microglia in this study may be activated in response to 
the infected neurones. However, it has been also suggested that activated T cells and 
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monocytes/macrophages induce microglial activation (Langford & Masiah 2001; Gehrmann 
et al. 1993, Aloisi et al. 2000; Sedgwick et al. 1998; Bauer et al. 1995). Since, infiltration 
of leukocytes were observed 48h before microglia were activated in my model (Figure 4.4 ), 
it was hypothesized that microglial activation may be mediated by these infiltrating 
leukocytes. To confirm this hypothesis, groups of mice were infected i.n. with the same 
dose of WNV and brain parenchyma were examined for microglial activation, leukocyte 
infiltration and WNV A g. Interestingly, it was found that microglia were activated near the 
sites of neuronal infection at the same time, day 3 p.i. in the OB, in the absence of any 
infiltrating leukocytes (Figure 4.5). Moreover, the progress of microglial activation through 
the brain closely matched that of the advancement of WNV infection of neurones from 
rostral to caudal in the i.n. model. Leukocyte infiltration was observed only after 48h of 
microglial activation, suggesting that microglial activation was independent of leukocyte 
infiltration and was mediated by infected neurones. This finding is supported by facial-
nerve transection model. In this model, after facial nerve axotomy microglia were activated 
in the absence of any infiltrating haematogenous cells (Kreutzberg 1996). 
Upon induced, stressed neurones rapidly change their gene expression to stimulate nearby 
microglia via neurotransmitters or neuropeptides. Microglia respond immediately (Banati et 
al. 1993) and undergo graded changes in their morphology (Raivich et al. 1999, Davis et al. 
1994). In WNV encephalitis, activated microglia displayed all the different stages of 
activation (Figure 4.6) between day 7-11 p.i. These different stages of activated microglia 
may have different roles in WNV encephalitis. Double-labelling experiments confirmed that 
microglia were not infected with WNV (Figure 4.11 ). Mori et al. (2001) suggested that the 
transformation of resting microglia into amoeboid form is dependent on IFN-y. However, in 
WNV encephalitis the amoeboid form of microglia occurred in the complete absence of 
IFN-y. 
Increasing evidence from both in vivo and in vitro studies suggests that IFN-y plays an 
important role in microglial activation (Grau et al. 1997; Meda et al. 1995; Sethna et al. 
1991). In contrast, in WNV encephalitis lack of IFN-y did not reduce microglial activation. 
The kinetics of activation and the percentage of mice showing microglial activation in 
B6.WT and B6.IFN-y-/- (Figure 4.7) was similar between the groups. Furthermore, 
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significantly higher microglial activation occurred in the absence of IFN-y on day 9 p.i in 
B6.IFN-y-/- mice (Figure 4.8), indicating that microglial activation is independent to IFN-y; 
moreover, its absence enhanced microglial activation in WNV encephalitis. 
Formation of microglial nodules, consisting of amoeboid microglia are the prominent 
features of viral encephalitis (Dickson et al. 1991). In the WNV model, microglial 
activation was associated with significant numbers of microglial nodules (Figure 4.9). These 
were observed from day 7 p.i. in both groups of mice. The number of nodules increased 
subsequently and peaked on day 11 p.i. At this timepoint WNV was nearly undetectable. 
The formation of microglial nodules is thought to indicate neuronal death (Neumann 2001; 
Adam 1994). However, the incidence of neuronal death in WNV encephalitis, compared to 
the numbers of microglial nodules is not consistent with the current notion that nodules are 
indicative of neuronophagia. Thus, the presence of microglial nodules does not equate with 
neuronal death in WNV encephalitis. 
As discussed earlier, microglial activation was observed within 24h of WNV Ag detection 
at or near the sites of neuronal infection and was maximal between day 9-11 p.i. in both 
groups of mice. The number and morphology of activated microglia, as well as the number 
of nodules, had reduced to nearly baseline levels only when WNV Ag was undetectable, at 
day 15 p.i. These results suggest that these activated microglia may play a role in the control 
of WNV in the neurones. Recently, Cheeran et al. (2001) demonstrated the antiviral role of 
microglia in vitro. He infected the coculture of astrocytes and microglia with 
cytomegalovirus (CMV) and found 60% reduction in viral gene expression compared to the 
CMV infected purified astrocytes culture lacking microglia. These microglia were found to 
produce antiviral cytokines, like TNF, soon after CMV infection and this may have helped 
control infection of astrocytes. It has been also shown that microglia can produce potent 
antiviral cytokines like IFN-a and their receptors (Yamada et al. 1994; Akiyama et al. 
1994; Yamada & Yamanaka 1995). Several experiments on animal models of neurotropic 
viral infections showed that these antiviral cytokines dramatically reduce the viral gene 
expression in the CNS (Akwa eta! 1998; Carr et al. 1998; Schijns et al. 1991). Moreover, 
microglia express FeR and CR3 receptors on their surface (Dickson et al. 1991 ), which 
increase during activation (Nakajima & Kohsaka 1998). Thus, in my model, activated 
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microglia may be involved in the control of WNV in conjunction with Ab produced locally 
by infiltrating leukocytes in the brain via non-cytotoxic mechanisms. 
Work on neurological disorders and viral encephalitis suggest that activated microglia may 
play a cytotoxic role through the production of various cytotoxic metabolites, as well having 
phagocytic properties (Banati et al. 1993; Bauer et al. 1994; Benveniste et al. 2001; 
Gonzalez-Scarano & Baltuch 1999; McGeer et al. 1993). As discussed earlier, in WNV 
encephalitis presence of nodules did not correlate with neuronal death in either B6.WT or 
B6.IFN-y-/- mice. Moreover, more than 85% of surviving mice showed high microglial 
activation with only rare neurone degeneration. Despite extensive microglial activation, 
surviving mice after day 11 p.i. did not show any signs of clinical illness for 90 days p.i. 
These data, therefore, suggest that activated microglia in this model may play a protective 
role rather than a cytotoxic role. Increasing evidence supports the potential role of activated 
microglia in neuronal survival (Nakajima & Kohsaka 1998). For example, production of 
neurotrophic factors such as nerve growth factor (NGF) and brain derived neurotrophic 
factor (BDNF) promote the development and normal function of neurones and glia (Elkabes 
et al. 1996; Mallat et al. 1989). Basic fibroblast growth factor regulates the development 
and regeneration of neurones (Shimojo et al. 1991). Plasminogen enhances neuronal 
outgrowth (Nakajima et al. 1992) and similarly, thrombospondin, secreted by amoeboid 
microglia, stimulate neurite growth and regeneration (Chamak et al. 1994). 
In addition, different cytokines produced by activated microglia eg., IL-6, IL-l, IL-1~, 
TGF-~ and IL-3 support neuronal survival and remyelination (Mason et al. 2001; Hama et 
al. 1989; Kamegai et al. 1990; Frei et al. 1989; Giulian et al. 1994; Pratt & McPherson 
1997). Soontornniyomkikj et al. ( 1998) demonstrated that in HIV -1 encephalitis, BDNF 
protein is produced only by activated microglia and suggest that these cells may therefore 
provide a local supplementary source of BDNF to the neurones to survive. The production 
of these neurotropic factors from activated microglia may therefore, play a role in trophic 
support for injured neurones. Importance of microglial activation in neuronal survival has 
been investigated by Berezovskaya et al. (1995) in the ischemic lesion model in 
CSF-1-deficient mice. Since, CSF-1 acts as a potent mitogen for microglia (Giulian & 
Ingeman 1988), lack of CSF-1 resulted abnormal microglial activation, which increased 
neuronal vulnerability to ischemia, compared to control mice. 
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Microglia are major APC within the CNS (Shrikant 1996). MHC-II can be expressed 
constitutively in the human microglia (Gehrmann et al. 1993) and rat microglia (Sedgwick 
et al. 1993), although it was once thought not to be (Griffin et al. 1992). In contrast, in the 
WNV encephalitis model, microglia from mock-infected mice were consistently negative 
for MHC-II (Figure 4.12 a) significant expression was induced after infection. The 
induction of MHC-II is required to present Ag to CD4+ T cells. Induction of MHC-11 in 
microglia has been shown in many human neurological disorders and encephalitic models 
(Deckert-Schluter et al. 1999; Bo et al. 1994; Song & Jia 1999; Schmitt et al. 1998; 
Morioka et al. 1992; Caplazi & Ehrensperger 1998; Gehrmann et al. 1993). Increasing 
evidence suggests that similar to the MHC-II induction in peripheral cells, IFN-y is a potent 
inducer of MHC-11 in microglia (Deckert-Schluter et al. 1999; Pazmany et al. 2000; Aloisi 
et al. 1998). In contrast, in WNV encephalitis, MHC-II was induced in microglia in both 
infected B6.WT and B6.1FN-y-/- mice. Thus, the presence of IFN-y did not massively 
upregulate MHC-II in B6.WT; nor did the absence of IFN-y reduce the expression of 
MHC-II in microglia in the B6.1FN-y-/- mouse (Figure 4.12 a, band 4.13). Moreover, the 
kinetics of MHC-II expression was similar between the groups. These results suggest that 
MHC-II induction in microglia is independent of IFN -y. 
Since the numbers of activated microglia detected by GS-lectin were significant in both 
groups of mice, numbers of GS-lectin positive microglia and MHC-II-expressing microglia 
were compared. Interestingly, it was found that the MHC-II-expressing microglia were 
significantly less (p=<0.001) compared to the number of GS-lectin-positive microglia 
except on day 15 p.i.(Figure 4.13). Moreover, almost all MHC-II-expressing microglia 
displayed amoeboid morphology in both groups of mice (Figure 4.13 and b). These results 
suggest that microglia are relatively resistant to MHC-11 induction during WNV encephalitis 
and may perhaps not actively participate in Ag presentation to T cells. It has been suggested 
that MHC-II expression is regulated by neurones and blockade of neuronal activity 
significantly increased microglial MHC-II expression (Neumann & Wekerle 1998). The low 
levels of MHC-II induction, despite high activation of microglia coupled with the 
observation that only amoeboid microglia expressed MHC-II, therefore may mean that 
neurones induce MHC-II expression on microglia as a last resort in WNV encephalitis. 
92 
In conclusion, only microglia, not astrocytes are activated in WNV encephalitis. Microglial 
activation is independent of IFN-y. In both groups of mice, microglia were activated within 
24h of WNV Ag detection in neurones and returned to normal only after WNV Ag was 
undetectable, suggesting that microglial activation are induced by infected neurones. 
Moreover, the low incidence of neuronal death, despite formation of large numbers of 
microglial nodules with highly activated microglia, further suggest that microglia may play 
an active role in controlling and/or eradicating WNV directly or indirectly in the neurones 
via non-cytotoxic mechanisms and may furthermore provide trophic support to these 
neurones. MHC-II expression on microglia is independent of IFN-y, but relatively little 
MHC-ll expression was induced, compared to levels of activation detected by GS-lectin. 
The functional significance of activated microglia seen in areas/nodules surrounding 
WNV -infected neurones need to be further investigated. 
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Chapter-S 
Enhanced expression of cell adhesion molecules in 
the CNS in the absence of IFN-y in 
WNV encephalitis 
5.1. Introduction 
Leukocyte recruitment to the CNS parenchyma is a feature of viral encephalitis. Under 
normal conditions, the CNS parenchyma is separated from the peripheral immune system 
through the BBB formed by interendothelial tight junctions, which form an impermeable 
seal between the cells. Thus, the BBB plays a critical role in regulating cell trafficking 
through the CNS (Andjelkovic & Pachter 1998) (See section 1.2.3.). A number of studies 
have explored inflammatory responses in the CNS in infectious, inflammatory and 
autoimmune demyelinating diseases. All are characterized by the migration of acute and 
chronic inflammatory cells from blood into the CNS across the extravascular tissue (Caplazi 
& Ehrensperger 1998; Eralinna et al. 1996; Krakowski & Owens 1996; Johnson et al. 
1985). Similar to peripheral inflammation, the upregulation of CAM on the surface of 
neurovascular endothelial cells and the production of cytokines and chemokines at the site 
of the BBB play an important role in mobilizing peripheral inflammatory cells into the CNS 
(Clark et al. 1995; Sobel et al. 1990; Matyszak 1998; Stanimirovic & Satoh 2000). 
The process of leukocyte migration to sites of inflammation is believed to begin with the 
activation of endothelial cells by inflammatory mediators, leading to increased expression 
of CAM, including selectins and the immunoglobulin superfamily of CAM (Meager 1999; 
Imhof & Dunon 1995). During extravasation, leukocytes make initial transient contact with 
neurovascular endothelial cells lining the vessel wall, roll along the endothelial cells, firmly 
adhere and extravasate out of the vasculature. As described earlier in section 1.4.1.4., 
selectins play an important role in initial attachment and rolling of leukocytes along the 
vessel wall, where firm adhesion is produced by the interaction of leukocyte integrins with 
immunoglobulin superfamily of CAM, including ICAM-1 and VCAM-1, expressed on 
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endothelial cells during inflammation. Therefore, the expression of ICAM-1 and VCAM-1 
on the cerebral endothelium, which do not express these molecules under normal condition 
(Matyszak 1998), is critical for transmigration of leukocytes into the CNS parenchyma. 
ICAM-1 is a ligand for LFA-1 and VCAM-1 is a ligand for VLA-4. Both of these integrins 
are constitutively expressed on the surface of leukocytes. ICAM-1 and VCAM-1 have been 
extensively studied in in vitro culture systems (Linke et al. 2000; Shen et al. 1997; Wong & 
Dorovini-Zis 1995; Brankin et al. 1995; Wong & Dorovini-Zis 1992) and have been found 
to be induced by proinflammatory cytokines such as IFN-y, TNF and IL-l (Barten & 
Ruddle 1994; Dobbie et at. 1999; Lee et al. 1999; de Jong et al. 1996). These cytokines not 
only induce the cerebral endothelium to express ICAM-1 and VCAM-1, but also induce 
expression of these molecules in astrocytes and microglia (K yrkanides et al. 1999; Shrikant 
et al. 1994; Zielasek et al. 1993). 
The expression and upregulation of ICAM-1 and VCAM-1 in the cerebral endothelium 
allows recruitment of cells from blood to the CNS parenchyma and thus, initiates 
inflammation within the CNS. This process is the first step in the immune response and is 
required for host defence, as well as tissue repair. Infiltrating NK and T lymphocytes help to 
eliminate virus-infected cells from the CNS, plasma cells produce neutralizing Ab, which 
inactivates extracellular virus and hence, prevents virus spread in the CNS, and infiltrating 
macrophages help to clear cellular debris (Hatalski et al. 1998; Williamson & Stahlman 
1990; Fehniger et at. 1998; Chan et al. 1989). Moreover, these infiltrating cells produce 
different kinds of cytokines that enhance the activation of resident CNS cells and induce 
them to produce many different kinds of cytokines and neurotrophic growth factors which 
help to return the CNS to normal homeostasis (Aloisi et al. 2000). Therefore, ICAM-1 and 
VCAM-1 play a crucial role in neuroinflammation during viral encephalitis. 
The physiological role of adhesion molecule expression on glial cells has not been 
characterized. However, from the general role of CAM in other cell types, it is inferred that 
expression of CAM in glial cells may guide infiltrating leukocytes into and through the 
CNS parenchyma (Merrill & Benveniste 1996). A diagrammatic representation of 
interactions among inflammatory leukocytes, endothelial cells and glial cells expressing 
ICAM-1 is presented in figure 5.1. It has also been reported that neurones can express both 
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Figure: 5.1 Interactions among lymphocytes, endothelial cells, astrocytes and microglia. T 
lymphocytes interacting with E-selectin and ICAM-1 + endothelial cells and astrocytes of the 
BBB, followed by extravasation through the BBB, and then migration through brain paren-
chyma via further interactions with ICAM-1+ astrocytes and microglia. In addition VLA-4 
expression by T cells and VCAM-1 expression by endothelial cells and glial cells leads to the 
same interactions as dipicted for ICAM-1 and LFA-1. Abbreviations: BBB, blood-brain barri-
er, ICAM-1, intercellular adhesion molecule-1, LFA-1, lymphocyte function-associated anti-
gen, VLA-4, very late antigen-4, VCAM-1, vascular cell adhesion molecule-1, A, astrocyte, 
M, microglia. Symbols: lymphocyte 'f, endothelial cell<31E>, astrocyte* , microglia* . 
Modified from Merrill & Benveniste 1996. 
ICAM-1 and VCAM-1 in in vitro culture upon stimulation with cytokines (Hery et al. 
1995), however, this has not been reported in vivo. 
Despite their importance in inflammation, the upregulation of ICAM-1 and VCAM-1 in any 
viral encephalitis has not been studied in detail. Results in chapter 3 clearly demonstrated 
that total numbers of leukocytes recruited to the brain were reduced in B6.IFN-y-/-
compared to B6.WT mice. Therefore, immunoperoxidase labelling for ICAM-1 and 
VCAM-1 was undertaken in mock-infected and WNV-infected brains from both groups to 
determine whether the reduced leukocyte numbers correlated with a failure to upregulate 
these adhesion molecules on neurovascular endothelium in the absence of IFN-y. The 
intensity of ICAM-1 and VCAM-1 was evaluated and the number of ICAM-1 and VCAM-1 
expressing blood vessels were quantitated. 
5.2. Materials and Methods 
5.2.1. Mice 
Female, specific-pathogen free, 8-week-old B6.WT and B6.IFN-y-/- mice, backcrossed to 
C57BL/6, were used. 
5.2.2. Virus infection of mice and tissue preparation 
To determine the kinetics of ICAM-1 and VCAM-1 expression in the CNS, a time course 
experiment was carried out. Groups of 120 mice/strain were inoculated with 6xl04 
pfu/mouse. Tissues were collected and processed as described in section 2.2.2.2. 
5.2.3. Immunohistochemistry 
Serial sections from paraformaldehyde-fixed, frozen tissues were stained with anti-ICAM-1 
and anti-VCAM-1 antibodies, and examined to determine the kinetics of expression and 
upregulation of these CAM during encephalitis in both groups. 
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• Detection of ICAM-1 expression 
Hybridoma supernatant from rat anti-mouse ICAM-1 (CD54) at 1:10 dilution (YNl/1.7.4; 
ATCC CRL 1878) was used as the primary antibody for labelling ICAM-1 expression. 
Frozen sections were rehydrated with Tris-buffer for 5 mins. After endogeneous peroxidase 
and non-specific blocking procedures, as described before in section 2.2.3, sections were 
incubated with primary Ab at 4°C for 1.5h. The rest of the staining procedure was identical 
to that described in section 2.2.3. Mock-infected brain sections from both groups were used 
as controls for ICAM-1 labelling. Monoclonal rat IgG2a was used as an isotype control for 
the primary antibody. 
• Detection ofVCAM-1 expression 
Rat anti-mouse VCAM-1 (CD106) Ab at 1:50 dilution (018!1D, Pharmingen, San Diego, 
CA) was used as the primary antibody for labelling VCAM-1 expression. Frozen sections 
were rehydrated with Tris-buffer for 5 mins and endogeneous peroxidase activity was 
blocked with 2.0% H20 2 in Tris-buffer for 30 mins. After endogeneous peroxidase and non-
specific blocking procedures, sections were incubated with primary Ab for overnight at 4°C. 
The rest of the staining procedure was identical to that described in section 2.2.3. Mock-
infected brain sections from both groups were used as controls for VCAM-1 labelling. 
Monoclonal rat lgG2a was used as an isotype control for the primary Ab. 
• Double labelling for ICAM-1 expression and activated microglia 
Alkaline phosphatase substrate, 5-Bromo-4-Chloro-3-lndolyl Phosphate/Nitroblue 
Tetrazolium (BCIP/NBT, Vector Laboratories, Burlingame, CA), was used to give a blue 
signal for activated microglia, whereas horseradish peroxidase substrate, DAB, was used to 
detect ICAM-1 expression in microglia. ICAM-1 expression was detected by the procedure 
described above and activated microglia was detected by the procedure described in section 
4.2.4. 
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5.2.4. Quantification of cells and data analysis 
Quantification of cells and analysis of data was carried out as described in section 2.3 and 
2.6, respectively. Figures are mean values ± SEM for the total number of fields examined 
from the indicated number of mice, n. 
5.3. Results 
5.3.1. Expression of ICAM-1 on neurovascular endothelium 
Since IFN-y plays an important role in the activation of neurovascular endothelium and the 
induced expression of immunoglobulin superfamily of CAM, the kinetics of ICAM-1 
expression in the brain parenchyma was assessed using anti-ICAM-1 
immunohistochemistry. Brains of mock-infected B6.WT mice showed no labelling for 
ICAM-1 on neurovascular endothelium (Figure 5.2 a), indicating that ICAM-1 is not 
constitutively expressed in wild type mice. In contrast, ICAM-1 was constitutively 
expressed at low levels in mock-infected B6.IFN-y-/- mice (Figure 5.2 b). During infection, 
activated leukocytes migrate into the brain. They bind to cell surface molecules such as 
ICAM-1, expressed on endothelium (Figure 5.2 c, open arrow) and transmigrate into the 
brain parenchyma (Figure 5.2 d, open arrows). After infection, much greater expression of 
ICAM-1 was observed in the blood vessels of B6.1FN-y-/- mice (Figure 5.2 f) compared to 
B6.WT (Figure 5.2 e). 
To evaluate whether there was a significant difference in the number of blood vessels 
expressing ICAM-1 between the groups, ICAM-1-positive blood vessels were quantitated as 
described in Materials and Methods. The kinetics, intensity of staining and number of blood 
vessels expressing ICAM-1 in B6.IFN-y-/- mice were very different from that of B6.WT 
(Figure 5.3). In B6.WT mice, vessels expressing ICAM-1 at low levels were initially 
observed at day 3 p.i. The number of ICAM-1-expressing vessels increased at day 6 p.i., 
and was maximal on day 9 p.i. In B6.1FN-y-/- mice, vessels expressing ICAM-1 were 
upregulated from day 3 p.i., numbers peaking on days 8 and 10 p.i. The number of ICAM-1-
positive vessels was significantly higher (p=<0.001 on each day) in B6.1FN-y-/- mice from 
day 6 onwards compared to B6.WT. However, in both groups expression of ICAM-1 and 
number of vessels expressing increased levels returned to the nearly baseline values of the 
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Figure: 5.2 ICAM-1 expression in WNV encephalitis. Immunoperoxidase labelling was used 
for the detection of ICAM-1 in mock-infected and WNV-infected mouse brains from both 
groups There was no constitutive expression of ICAM-1 in the mock-infected brain of B6.WT 
mice (a). In contrast, ICAM-1 was constitutively expressed in the mock-infected brain of 
B6.1FN-y-/- mice (b) . During leukocyte migration to the brain parenchyma, leukocytes bind 
to ICAM-1 (c) (open arrow), expressed on endothelium of infected B6.WT mouse brain (c) 
(solid arrow) and transmigrate to the parenchyma (d) (open arrows). ICAM-1 expressed in the 
blood vessels (d) (solid arrows) facilitates the entry of leukocytes to the brain parenchyma. 
Both the number of ICAM- 1 + blood vessels and their staining intensity was higher in the 
infected brain parenchyma from B6.IFN-y-/- (f) compared to B6.WT mice. Scale bar-50Jim. 
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Figure: 5.3. Kinetics of ICAM-1 upregulation. Groups, each of 70 mice, from B6.Wf and 
B6.IFN-y-/- strains were infected i.p. with 6x104 pfu/mouse. Subgroups of mice in each 
strain were sacrificed from day 3 to 15 p.i . Immunoperoxidase labelling was used to detect 
the expression of ICAM-1 in the blood vessels of infected brain parenchyma. The number of 
blood vessels expressing ICAM-I was counted, as described in materials and methods. Sixty 
H.P.F. were counted, per mouse brain and values for each timepoint amalgamated and 
expressed as mean ± SEM. There were significant differences at days 6-11 p.i. between 
B6.Wf and B6.1FN-y-/- values (**p=<0.01 and ****p=<0.001 by ANOVA). Brains from 
mock-infected B6.Wf mice were negative for ICAM-1 whereas B6.IFN-y-/- mice showed 
constitutive expression of ICAM-1. 
respective groups by day 15 p.i (Figure 5.3). These data show that IFN-y does not play a 
critical role in ICAM-1 upregulation in the neurovascular endothelium. Moreover, its 
absence is associated with a massive upregulation of ICAM-1 in WNV encephalitis. 
5.3.2. Expression ofiCAM-1 in microglia 
5.3.2.1. Microglia express ICAM-1 in the absence of IFN-y 
As described earlier in section 5.3.1, lack of IFN-y resulted in massive ICAM-1 
upregulation in blood vessels in B6.1FN-y-/- mice compared to B6.WT. In addition to the 
blood vessels, glial cells were also expressing ICAM-1 in B6.1FN-y-/- mice (Figure 5.4). 
Unlike blood vessels, microglia did not constitutively express ICAM-1 in mock-infected 
brain parenchyma (Figure 5.4 a). After infection, glial cells were positive for ICAM-1 
expression only from day 6 p.i. (Figure 5.4. b) and were observed only in the brainstem at 
this timepoint. On day 11 p.i., an increased number of glial cells were positive for ICAM-1 
as well as showing significantly increased staining intensity (Figure 5.4.c). Nodules were 
also positive for ICAM-1 (Figure 5.4 d). 
It has been reported that both astrocytes and microglia can express ICAM-1 (Lee & 
Benveniste 1999; Zielasek et al. 1993). However, in my model, astrocytes were seldom 
activated, while microglia were highly activated (chapter 4). I speculated that 
ICAM-1-expressing glial cells could be microglia, since the morphology of glial cells 
expressing ICAM-1 was similar to that of microglia. Therefore, double labelling of 
histological sections for both ICAM-1 and GS-lectin were performed to confirm the identity 
of these ICAM-1-expressing glial cells. Almost all ICAM-1-expressing glial cells, as well 
as nodules, co-labelled with GS-lectin, a marker for activated microglia (Figure 5.5 a, b). 
This result confirms that these ICAM-1 expressing cells were activated microglia. 
Although ICAM-1 was expressed in the blood vessels from day 3 p.i. in B6.WT mice 
(section 5.3.1), not all mice expressed ICAM-1 in the blood vessels, initially. However, 
after day 3 p.i. this increased to 100% ICAM-1 expression at day 11 p.i. (Figure 5.6 A). 
Interestingly, no microglia were observed to express ICAM-1 at any timepoint in B6.WT 
(Figure 5.6 B). These results further confirm that lack of IFN-y not only enhanced the 
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Figure: 5.4 Microglia express ICAM-1 only in the absence of IFN-y in WNV encephalitis. 
lmmunoperoxidase labelling was used for the detection of ICAM-1 in mock-infected and 
WNV -infected B6.1FN-y-/- mouse brain. I CAM-I is constitutively expressed only in the 
blood vessels (open arrow) but not in glial cells (a). On day 6 p.i., ICAM-1 was strongly 
expressed both in the blood vessels (open arrows) and glial cells (closed arrows) (b). The 
expression of lCAM-1 was massively increased on day 11 p.i.(c). At this time, nodules 
(closed arrows) were also postive for lCAM-1 labelling (d). Open arrows in all figures show 
ICAM-1 expression in the blood vessels and closed arrows show lCAM-1 expression in the 
glial cells. Scale bar= 50Jtm. 
~ 
~ 
f 
Figure: 5.5 Double labelling of WNV-infected B6.IFN-y-/- mouse brain for ICAM-1 (brown) 
and activated microglia (blue) on day 10 p.i. ICAM-1 was expressed in both microglia and 
blood vessels in B6.1FN-y-/- mice. Astrocytes and microglia both can express ICAM-1. Double 
labelling was performed to confirm the identity of ICAM-1 + glial cells. Nearly all of ICAM-1 + 
microglia were labelled with GS-lectin (a) (solid arrows) confirming that ICAM-1 positive 
glial cells were microglia. Microglial nodules also expressing ICAM-1 (b). Solid arrows in a) 
and b) show double labelled microglia and nodules with GS-lectin and ICAM-1, whereas open 
arrows show blood vessels expressing ICAM-1. Scale bar- 50Jtm. 
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Figure: 5.6 Percentage of mice positive for ICAM-1 expression. Groups, each of 70 mice, 
from B6.WT and B6.1FN-y-/- strains were infected i.p. with 6x104 pfu/mouse. Subgroups of 
mice in each strain were sacrificed from day 3 to 15 p.i. Immunoperoxidase labelling was 
used to detect the expression of ICAM-1 in the brain parenchyma. A) In B6.WT, there was 
no constitutive expression of ICAM-1, but it was expressed on blood vessel endothelium 
from day 3 p.i. in few mice and increased subsequently at later timepoints. In contrast, in 
B6.1FN-y, ICAM-1 was expressed constitutively on endothelium. B) Interestingly, ICAM-1 
was also expressed in microglia in B6.1FN-y-/- from day 6 p.i., the number of mice positive 
for microglial ICAM-1 increasing further in later timepoints. In contrast, no microglia of 
B6.WT were positive for ICAM-1 at any timepoints. 
upregulation of ICAM-1 in the blood vessels in B6.1FN-y-/-, but also that not withstanding 
microglia were induced to express I CAM-I in the absence of IFN-y. 
5.3.2.2. Kinetics of microglial and endothelial/CAM-1 expression in B6.1FN-"fl- mice 
In B6.IFN-y-/- mice, unlike the constitutive expression of !CAM-I in blood vessels, not all 
mice were positive for microglial ICAM-1. A very small percentage of mice was positive 
for microglial ICAM-1 on day 6 p.i. By day II p.i., however, more than 85% mice 
expressed !CAM-I on the microglia (Figure 5.6 B). The number of ICAM-1-positive 
microglia and blood vessels were counted, as described in Materials and Methods. The 
kinetics of ICAM-1-positive blood vessels and ICAM-1-positive microglia are presented in 
figure 5.7. Blood vessels expressing ICAM-1 increased at least 24h before microglia, and 
with much steeper kinetics. The increase in microglial ICAM-1 was slower. Thus, microglia 
and blood vesels express ICAM-1 with different kinetics. 
Although microglial activation was detectable from d7 p.i. by GS-lectin, microglia 
expressed ICAM-1 from day 6 p.i in B6.1FN-y-/- mice. However, the percentage of mice 
expressing microglial ICAM-1 and activation detected by GS-lectin was similar after day 6 
p.i. To evaluate whether there was a significant difference between these cells, the number 
of GS-lectin-positive microglia and ICAM-1-positive microglia were compared. The 
kinetics of microglial ICAM-1 expression and GS-lectin positive microglia can be seen in 
figure 5.8. At the earlier timepoints from day 6-8, a significantly higher number of 
microglia were expressing ICAM-1 (p=<0.05), compared to lectin-positive microglia, 
however, on day 9 and 10 p.i., the numbers of cells expressing both were nearly equal. 
Interestingly, on day II p.i., significantly higher numbers of microglia were expressing 
ICAM-1 (p=<O.OOI), compared to lectin-positive microglia. However, the number of both 
ICAM-1-positive and lectin-positive microglia returned to nearly baseline levels on day 15 
p.i. 
5.3.3. Expression of YCAM-1 on neurovascular endothelium 
Since there was an enhanced ICAM-1 expression in the absence of IFN-y in B6.1FN-y-/-
mice, the status of VCAM-1 expression in the brain parenchyma was assessed, as with 
ICAM-1 expression, in both groups of mice. Unlike I CAM-I expression, VCAM-1 was not 
100 
~lot 
~ 
t;e 
en 
::::l Q) 
u 
Q) 
;:> 
+ 
-I 
::E 
~ 
u 
....... 
8 
4 
0 
A-- ICAM-1 +vc 
blood vessels 
+- ICAM- 1 +\ c 
mtcroglta 
2 4 
n = 70 mice/group 
6 8 10 12 14 16 
Days post inoculation 
Figure: 5.7 ICAM-1 expression in blood vessels and microglia in 86.1FN-y-/- mouse brain. 
Groups, each of 70 mice, from B6.WT and 86.1FN-y-/- strains were infected i.p. with 
6x104 pfu/mouse. Subgroups of mice in each strain were sacrificed from day 3 to 15 p.i. 
Immunoperoxidase labelling was used to detect the expression of ICAM-1 in the brain 
parenchyma. The number of blood vessels and microglia expressing ICAM-1 was counted, 
as described in materials and methods. Expression of ICAM-1 in the blood vessels 
increased earlier than that in the microglia. 
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Figure: 5.8 Comparison between kinetics of ICAM-1 expression in microglia and microglial 
activation in B6.1FN-y-/- mouse brain. Groups, each of 70 B6.1FN-y-/- mice were infected 
i.p. with 6x104 pfu/mouse. Subgroups of mice in each strain were sacrificed from day 3 to 15 
p.i. Immunoperoxidase labelling was used to detect the expression of ICAM-1 and GS-lectin 
was used as a marker to detect the activation of microglia of infected brain parenchyma. The 
numbers of ICAM- 1 expressing microglia and GS-lectin+ microglia were counted, as 
described in materials and methods. Sixty H.P.F. were counted per mouse brain and values 
for each timepoint amalgamated and expressed as mean ± SEM. (* p=<0.05, and 
***p=<0.001 by ANOV A). 
expressed constitutively in either group (Figure 5.9 a, b). Furthermore, after infection, 
VCAM-1 expression was observed only in the blood vessels in both groups (Figure 5.9 c,d). 
The number of blood vessels expressing VCAM-1 was quantitated in both groups, as 
described in Materials and Methods to evaluate whether there was a significant difference 
between the groups. The kinetics of VCAM-1 expression in both groups is presented in 
figure 5.10. In B6.WT mice, VCAM-1 was expressed only from day 5 p.i. It was maximal 
on day 9 and returned to almost baseline levels by day 15 p.i. On the other hand, in 
B6.IFN-y-/- mice, expression of VCAM-1 was detectable from day 3 p.i. Similar to the 
B6.WT, the increasing number of vessels expressing VCAM-1 also peaked on day 9 p.i., at 
approximately 3-fold higher than the B6.WT (]7=<0.001) and returned to almost baseline 
levels by day 15 p.i. The kinetics of VCAM-1 expression was very similar between the 
groups, although it was expressed 24h earlier than B6. WT mice. These data indicate that 
IFN-y is not required for upregulation of VCAM-1 in the CNS blood vessels during WNV 
infection. Moreover, lack of IFN-y is associated with upregulation of VCAM-1 in WNV 
encephalitis. 
5.3.4. Comparison between ICAM-1 and YCAM-1 expression in blood vessels 
Results from preceeding sections show that both ICAM-1 and VCAM-1 were expressed and 
upregulated in WNV encephalitis. Moreover, in both cases it shows that lack of IFN-y was 
associated with enhanced their expression, compared to wild type mice. Comparison 
between the kinetics of ICAM-1 and VCAM-1 expression in the blood vessels of each strain 
were also evaluated. In B6.WT the number of blood vessels expressing ICAM-1 was 
significantly higher (p=<0.001) on day 7, 9 and 11 p.i. than the VCAM-1-expressing blood 
vessels (Figure 5.11 A). Similarly, in B6.IFN-y-/- mice, the number of blood vessels 
expressing ICAM-1 was very much higher from day 6-11 p.i. (p=<0.001) than the VCAM-1 
expressing blood vessels. Thus, greater numbers of blood vessels express ICAM-1 
compared to VCAM-1 in both groups of mice in WNV encephalitis. 
5.4. Discussion 
CNS infection with viruses can result in vigorous inflammatory responses with large 
numbers of leukocytes recruited into the CNS. These are required for the evolution of 
pathological and host-defence processes (Christensen et al. 2001; Weidinger et al. 2000; 
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Figure: 5.9 fmmunoperoxidase labelling of YCAM-1 in the blood vessels of mock-infected 
and WNY-infected mouse brains on day 9 p.i. from both groups. YCAM-1 expression was 
constjtutively negative in the mock-infected brain parenchyma from both B6.WT (a) and 
B6.IFN-y-/- (b). Infected brain parenchyma from B6.WT (c) and B6.IFN-y-/- (d) showing 
YCAM-1 expression. Scale bar=50Jtm. 

Figure: 5.11 Kinetics of ICAM-1 and VCAM-1 upregulation. Groups, each of 70 
mice, from B6. WT and B6.IFN-y-/- strains were infected i.p. with 6x 104 pfu/mouse. 
Subgroups of mice in each strain were sacrificed from day 3 to 15 p.i. 
Immunoperoxidase labelling was used to detect the expression of ICAM-1 and 
VCAM-1 in the blood vessels of infected brain parenchyma. The number of blood 
vessels expressing IGAM-1 and VCAM-1 was counted, as described in Materials 
and Methods. Sixty H.P.F. were counted per mouse brain and values for each 
timepoint amalgamated and expressed as mean± SEM. The number of ICAM-1 
expressing blood vessels was significantly higher than those expressing VCAM-1 in 
both B6.WT (A) and B6.IFN-y-/- (B) mouse brains. (**p=<0.01, ***p=<0.001 by 
AN OVA. Note the change of scale at 5 positive blood vessels/H.P.F. (broken line). 
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Lane et al. 2000; Adler et al. 1999; Noske et al. 1998; Zinkernagel 1992). The unique 
position of the neurovascular endothelial cells at the interface between the blood and the 
brain makes them a principal regulator of peripheral inflammatory cell recruitment into the 
CNS (Rubin 1999). Circulating leukocytes are non-adherent, whereas extravasation requires 
strong adhesion to the endothelial cells. Thus, phenotypic alterations in the neurovascular 
endothelial cells, including expression of CAM are required for extravasation, which is 
induced during inflammation (Irani & Griffin 1996; Engelhardt et al. 1994). ICAM-1 and 
VCAM-1 have emerged as a key players in leukocyte-endothelial cell interactions, since 
they provide firm adhesion via interaction with leukocyte integrins (Carlos & Harlan 1994). 
It was shown in chapter 3 that lack of IFN-y significantly reduced leukocyte recruitment 
into the brain parenchyma in B6.IFN-y-/- mice. Therefore the status of ICAM-1 and 
VCAM-1 expression in the neurovascular endothelial cells was evaluated in this model. 
Animal models of viral encephalitis (Eralinna et al. 1996; Irani & Griffin 1996; Finke et al. 
1995; Sasseville et al. 1992; Soilu-Hanninen et al. 1994) as well as several neurological 
disorders (Dopp et al. 1994; Barten et al. 1994; Brosnan et al. 1995) have shown increased 
expression of both ICAM-1 and VCAM-1 in the neurovascular endothelium, as part of the 
development of CNS inflammation (Raine et al. 1990; Hartung et al. 1993). Deckert-
Schluter et al. (1999) demonstrated that up-regulation of ICAM-1 and VCAM-1 is totally 
dependent on IFN-y in Toxoplasma encephalitis. In contrast, Nansen et al. (1998) showed 
normal induction ofiCAM-1 and VCAM-1 in IFN-y deficient mice in LCMV infection. In 
aggrement with the latter, expression and upregulation of ICAM-1 and VCAM-1 in WNV 
encephalitis has also been shown to be independent of IFN-y in this work (Figure 5.2 and 
5.9). However, unlike the LCMV model, both ICAM-1 and VCAM-1 upregulation, as 
measured both by the number of positive vessels and the intensity of endothelial staining, 
was significantly increased in the absence of IFN-y compared to B6.WT mice. These results 
clearly indicate that upregulation of these adhesion molecules in WNV encephalitis is not 
dependent on IFN-y and indicate that different signaling pathways upregulate these 
molecules in response to particular pathogenetic mechanisms. It has been demonstrated that 
in addition to being inducible by IFN-y, endothelial ICAM-1 and VCAM-1 expression are 
upregulated by other cytokines, IL-1u/j3, TNF and IL4 (Meager 1999; Shen et al. 1997; 
Mickelson et al. 1995; Wong & Dorovini-Zis 1992; Fabry et al. 1992; Masinovsky et al. 
1990). 
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In both groups, the first detectable increases in VCAM-1 expression occurred later than that 
of ICAM-1, although the kinetics of VCAM-1 expression between the groups remained 
similar. The number of vessels showing upregulated VCAM-1 expression in B6.IFN-y-/-
mice was significantly different (p=<0.001) from B6.WT at day 9 p.i. At this timepoint, it 
was approximately 3-fold higher than that of the WT mice. On the other hand, the 
upregulation of ICAM-1 expression in B6.IFN-y-/- mice had different kinetics compared to 
the B6.WT. The increase in number of ICAM-1-positive vessels was significantly different 
(p=<0.001) on days 6-11, at times being >10-fold higher than the corresponding infected 
B6.WT mice. The different kinetics of VCAM-1 expression is presumably due to regulation 
by different cytokines from those inducing ICAM-1. 
Experiments both in vivo and in vitro have demonstrated that glial cells, including both 
astrocytes and microglia are capable of expressing ICAM-1 and VCAM-1 (Weener et al. 
2001; Dallasta et al. 2000; Shrikant et al. 1994; Lee et al. 1999; Lee & Benveniste 1999; 
Zielasek et al. 1993). However in WNV encephalaitis, glial cells expressed only ICAM-1, 
and moreover, only in the absence of IFN-y (Figure 5.4, 5.6 B and 5.9). As mentioned in 
chapter 4, there was little or no activation of astrocytes in B6.IFN-y-/- mice and the 
morphology of ICAM-1-expressing glial cells was similar to the morphology of microglia, 
which suggested that these ICAM-1-expressing glial cells could be microglia. This was 
confirmed by double labelling for ICAM-1 and GS-lectin (Figure 5.5). Nearly almost all 
OS-lectin positive microglia expressed ICAM-1 (Figure 5.5 a), except on day 11 p.i (Figure 
5.8). 
At day 11 p.i., significantly higher numbers (p=<0.001) of microglia were ICAM-1-
positive, compared to GS-lectin-positive microglia (Figure 5.8), however, both parameters 
decreased to nearly baseline levels on day 15 p.i. Expression of ICAM-1 in microglia has 
been reported in many encephalitis models (Deckert-Schluter et al. 1999; Dallasta et al. 
2000; Weissenbock et al. 2000). It has been reported that IFN-y is responsible for the 
induction of ICAM-1 expression in microglia (Zielasek et al. 1993; Deckert-Schluter et al. 
1999). In contrast, my work shows ICAM-1 was expressed in microglia only in the absence 
of IFN-y in WNV encephalitis. Moreover, unlike blood vessels, microglial ICAM-1 was not 
constitutively expressed in B6.IFN-y mice (Figure 5.4 a) and after infection not all mice 
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showed microglial ICAM-1 expression (Figure 5.7 A). Dallasta et al. (2000) suggest that 
microglia expressing ICAM-1 may be involved in the development of neurodegeneration in 
murine retroviral infection. However, neurodegeneration rarely occurred in B6.1FN -y mice. 
Thus these ICAM-1-expressing microglia are unlikely to play a role in neurodegeneration in 
WNV encephalitis. Why there was the discrepancy between the B6.1FN-y mice in terms of 
microglial ICAM-1 expression, and what the functional significance of these ICAM-1 
positive microglia may be, especially since leukocyte recruitment into the brain parenchyma 
is so low, warrant further investigation. 
Endothelial ICAM-1 and VCAM-1 expression are important for the adhesion and migration 
of all leukocyte subsets in vivo and in vitro. Increased expression increases the avidity of 
cell-cell interactions and subsequent transendothelial migration (Bochner et al. 1991; 
Shimizu et al. 1991 ). Deckert-Schluter et a!. (1999) suggested that low levels of CAM 
induction is sufficient to recruit leukocytes into the CNS of IFN-y-deficient mice. However, 
despite markedly higher adhesion molecule expression, significantly lower numbers of 
infiltrating leukocytes were observed in the brain parenchyma of infected B6.IFN-y-/- mice 
compared to B6.WT in WNV encephalitis. Coupled with this, few ICAM-1 and VCAM-1-
positive parenchymal vessels were associated with adjacent inflammatory cell infiltrates 
(Figure 5.2 d). Thus increased expression of endothelial ICAM-1 and VCAM-1 was not 
sufficient to mediate the migration of compensatory numbers of inflammatory leukocytes 
into the brain in WNV encephalitis in the absence of IFN-y. This is similar to the findings of 
other investigators in other model systems (Willenborg et al. 1993; Engelhardt et al. 1994). 
These observations suggest that IFN-y-mediated chemokines may play a role in guiding the 
movement of leukocytes into the brain parenchyma (Lane et al. 2000; Liu et al. 2001). 
It is hypothesized that chemokines, along with CAM play a major role in leukocyte 
reorientation and migration in response to stimuli (Asensio et al. 1999; Lane et al. 2000; 
Ransohoff et al. 1996; Liu et al. 2001; Liu et al. 2000; Godiska et al. 1995). Chemokines 
are synthesized locally at sites of inflammation variously, by leukocytes, endothelial cells 
and CNS resident cells that may localized at or near the endothelial surface. These are 
secreted in association with other molecules, and establish a concentration gradient down 
which target cell populations migrate (Boehm et al. 1997). Recent studies in chemokines 
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have shown that many chemokines that are important for the recruitment of inflammatory 
cells to the CNS are strongly and consistently induced by IFN-y, such as IP-10 (Simpson et 
al. 2000), MCP-1 (McManus et al. 2000), Mig (Liu et al. 2001), RANTES and MIP-1a/~ 
(Boehm et al. 1997). The expression of chemokines in the brain is not the focus of this 
study; however, it can be speculated that these IFN-y inducible chemokines would be poorly 
induced in IFN-y-deficient mice. 
In conclusion, IFN-y is not critical for the induction of ICAM-1 and VCAM-1 in WNV 
encephalitis. In contrast, these molecules were strongly upregulated in the absence of IFN-y 
in WNV encephalitis. Moreover, the greater upregulation of these adhesion molecules was 
not in itself sufficient to facilitate the endothelial transmigration of the high numbers of 
leukocytes into the brain seen in the WNV -infected B6.WT mice. It follows that IFN-y-
mediated chemotactic signals are likely to be required for successful recruitment of 
inflammatory cells before increased ICAM-1 and VCAM-1 expression fulfil their roles in 
leukocyte migration to the sites of WNV infection in the CNS. What the functional 
significance is and which candidate(s) is/are responsible for such massive upregulation of 
ICAM-1 and VCAM-1 in IFN-y-deficient mice in WNV encephalitis is unknown. 
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Chapter-6 
Route of infection determines disease profile in 
WNV encephalitis 
6.1. Introduction 
Several neurotropic viruses regularly produce lethal infections when inoculated into the 
experimental animals via the i.e. route, while peripheral inoculation produces only sub 
lethal infection (Hase et al. 1990; Richards et al. 1981; Nathanson & Cole 1970). 
Neurotropic viruses need to replicate in the peripheral organs before invasion of the CNS, 
when introduced peripherally (Carbone et al. 1987; Monath et al. 1983). Peripheral 
inoculation reflects the usual route of inoculation into the host. It induces host defences 
several days prior to the CNS invasion, leading to the generation of defence mechanisms 
that anticipate and can control the infectious process in the CNS. With the i.e. route of 
inoculation, virus is directly introduced into the brain tissue. Being neurotropic, it quickly 
replicates in neural tissue, often before development of a peripheral immune response. This 
results in fatal encephalitis with 100% mortality. For WNV, the i.e. route of inoculation 
does not reflect natural infection at all; normally the virus enters the body through the bite 
of an insect vector. 
Similar to i.e. inoculation, tbe i.n. route may also result in lethal infection in many animal 
models of viral encephalitis (Thach et al. 2000; Carbone et al. 1987). In i.n. inoculation, 
neurotropic viruses are introduced into the nasal cavity, innervated by both olfactory and 
trigeminal nerves (reviewed in Barnett & Perlman 1993). After i.n. inoculation, virus can 
easily be transported to the CNS via these nerves. Some viruses use the olfactory nerve, 
strictly as a portal of entry into the brain, while some use only the trigeminal nerves. Some 
use both routes (Barnett & Perlman 1993; Plakhov et al. 1995; Babic et al. 1994; Perlman et 
al. 1990). Via peripheral inoculation, neurotropic viruses can get access to the CNS via 
many different pathways. These include the haematogenous route, transmigration of 
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infected immune cells into the brain, endocytosis, axonal migration via spinal cord, etc., 
(see chapter 3). 
Little literature exists about i.n. inoculation of neurotropic viruses in experimental animal 
models, much less about comparative studies between i.p. and i.n. models. To date no one 
has studied the pathogenesis of WNV encephalitis after i.n. inoculation. Nir et al. in 1965 
studied WNV infection in mice with WNV aerosol exposure. However, he used 3-week-old 
mice and did not compare the disease profile with that induced by i.p exposure. Therefore, 
this study was undertaken to understand better the mechanisms involved in the pathogenesis 
of WNV encephalitis comparing these 2 routes of inoculation in the adult mouse as a model. 
The preceding chapters have clearly demonstrated that WNV encephalitis is an 
immunopathological disease, mediated at least in part by IFN-y. To further explore the role 
of IFN-y in survival and its influence in the pathogenesis of disease after i.n. inoculation, 
B6.WT mice and B6.IFN-y-/- mice were infected via both i.p. and i.n. route. 
6.2. Materials and Methods 
6.2.1. Mice 
Female, specific-pathogen free, 8-week-old B6. WT and B6.IFN-y-/- mice, backcrossed to 
C57BL/6, were used. 
6.2.2. Virus infection of mice and tissue preparation 
For the survival study, groups of 36 mice of B6.WT and B6.IFN-y-/- strains were inoculated 
i.p. with 6xl04 pfu/mouse and groups of 20 mice of B6.WT and B6.IFN-y-/- strains were 
inoculated i.n. with 6xl04 pfu/mouse, as described in section 2.2.2.1. The survival rates 
were evaluated, as described in section 2.2.2.1. To determine the kinetics of viral infection, 
leukocyte infiltration and microglial activation in the CNS parenchyma, a time course 
experiment was carried out. Groups of 120 mice/strain were used in the i.p. model and 21 
mice/strain were used in the i.n. model. Tissues, including brains and cervical spinal cords 
were collected and processed as described in section 2.2.2.2. Mice were mock-infected with 
DMEM as controls. 
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6.2.3. HistQpathology 
Serial sections from paraffin-embedded tissues were routinely stained with H and E, and 
examined to evaluate the pathological changes occurring in the brain parenchyma in the i.p. 
and i. n. models. 
6.2.4. DeterminatiQn Qf brain titre 
This was done as described in section 3.2.4. 
6.2.5. Lectin histochemistry and immunQhistQchemistry 
Paraffin-embedded sections were used for both immunohistochemistry and lectin 
histochemistry. 
• Detection of activated microglia by lectin histochemistry 
This was done as described in section 4.2.4. Mock-infected brain sections were used as 
controls for GS-lectin labelling. 
• Detection of WNV antigen 
This was done as described in section 3.2.3. Mock-infected brain sections were used as 
controls for WNV Ag labelling. 
6.2.6. OuantificatiQn Qf cells 
Cells were quantified as described in section 2.3 and figures are mean values ± SEM for the 
total number of fields examined from the indicated number of mice, n. 
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6.3. Results 
6.3.1. Survival after i.p. and i.n. route of WNV inoculation 
Since 40% B6.WT mice survived after i.p. inoculation (section 3.3.1.2.), mice were infected 
i.n. with the same dose of WNV to evaluate the disease profile in WNY encephalitis 
induced via a different route of infection. Therefore, a survival study was undertaken in 
B6.WT mice infected both i.n. and i.p. with 6x104 pfu/mouse. First signs of clinical illness 
were observed from day 6 p.i. in both models. However, there was a difference in the signs 
of clinical illness. In the i.p. model, the clinical signs included ruffled hair, reduced activity, 
hunching, weight loss and/or weakness. Occasionally, CNS symptoms were observed such 
as hindlimb paralysis (0-3% ), tremors and occasionally convulsions (chapter 3). Mortality 
occurred between day 6-11 p.i. In contrast, in the i.n. model, mice were suddenly sick on 
day 6 p.i. They often exihibited a swollen head, hyperactivity and aggressive behaviour. 
This occurred without weight loss or hunching posture, as signs of clinical illness. Mice 
were frequently observed standing on their hind limbs, rocking back and forth. All mice 
were moribund on day 7 p.i. However, none of the mice was paralysed in this model. 
Mortality occurred in 100% of mice between day 6-7 p.i. after i.n. inoculation. The 
cumulative comparative survival after infection in both models is presented in figure 6.1 A. 
Mortality of B6.IFN-y-/- mice was also compared after i.p. and i.n. inoculation. Similar to 
B6.WT, in B6.IFN-y-/- mice, the clinical signs were observed from day 6 p.i. in both i.p. 
and i.n. models and mice exihibited clinical signs in both models similar to those described 
in B6. WT mice. In the i.p. model, mortality occurred in approximately 17% of mice 
bewteen day 6-11 p.i. whereas in the i.n. model, mortality occurred in 100% of mice 
between day 6-7 p.i. The cumulative comparative survival after infection in both models is 
presented in figure 6.1 B. 
Unlike the i.p. model, there was no difference in survival between the groups in the i.n. 
model, which showed 100% mortality in both groups of mice. These data suggest that mice 
are highly susceptible to the i.n. route of infection compared to the i.p. route. Unlike in the 
i.p. model, IFN-y does not play a role in exacerbating disease in the i.n. model. 
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Figure: 6.1 Survival after i.p. and i.n. inoculation of WNV in B6. WT and 
B6.IFN-y-/- mice. Groups of 36 mice/strain were inoculated i.p., 6xl04 pfu/mouse, 
and groups of 20 female mice/strain were inoculated i.n., 6xl04 pfu/mouse. They 
were monitored for signs of illness 3 times per day over 21 days. The percent 
survival at each time point is shown. A) Survival profiles of B6.WT after i.p. and 
i.n. inoculation. B) Survival profiles of B6.1FN-y-/- mice after i.p. and i.n. 
inoculation. Mock-infected mice did not develop signs of illness in either model. 
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6.2.3. Detection of WNV antigen in the brain 
6.3.2.1. Detection of WNV titre in the brain 
Results from the preceding section clearly demonstrated that mice from both strains were 
highly susceptible to infection via the i.n. route of WNV inoculation. Mortality occurred in 
100% of mice within 24h of clinical symptoms appearing, unlike the i.p. model. Therefore, 
the virus load in the brains of these mice was determined as a first approach, using a plaque 
assay. In the i.p. model, groups of 64 mice from B6.WT and B6.IFN-y-/- strains were 
infected i.p. with 6xl04 pfu/mouse. In the i.n. model, groups of 21 mice from B6.WT and 
B6.IFN-y-/- strains were infected i.n. with 6xl04 pfu/mouse. Plaque assay was performed 
from day 1-7 p.i. in the i.n. model and from day 1-11 p.i. in the i.p. model. 
As described in section 3.3.3.3., in B6.WT mice, replicating WNV was detected only from 
day 6 p.i. It increased, peaking on day 8 p.i. and decreased thereafter to become 
undetectable by day 10 p.i. in the i.p. model. The maximum virus titre was 2.23 log10 
pfu/gram on day 8 p.i. in this model. In contrast, replicating virus was detected from day 3 
p.i. (Figure 6.2 A) in the i.n. model in B6.WT. At this timepoint, virus titre was 4.85 log10 
pfu/gram, i.e., 2 log-fold higher than the peak virus titre detected in the i.p. model. Within 
48h of detection, virus titre was increased by a further 2 log-fold in the i.n. model. At the 
time of death, on day 7 p.i., the WNV titre was 9.72log10 pfu/gram. 
Similar to the B6.WT, replicating WNV was detected from day 3 p.i. in B6.IFN-y-/- mice 
after i.n. inoculation of WNV (Figure 6.2 B). Like B6.WT, the virus titre on day 3 p.i. was 
4.98 log10 pfu/mouse and within 48h of detection, the titre was increased almost a further by 
2 log-fold. At the time of death, the virus titre was 9.72 log10 pfu/mouse. In contrast, in the 
i.p. model (section 3.3.3.3). WNV was detected only from day 6 p.i., increased and peaked 
on day 8 p.i. Replicating WNV was undetectable from day 10 p.i. The titre of WNV at the 
peak was 2.22 log10 pfu/gram, which was <2log-fold less than the titre detected on day 3 p.i. 
in the i.n. model. 
Like the i.p. model, the kinetics of WNV growth in the brain parenchyma was similar 
between B6.WT and B6.IFN-y-/- mice in the i.n. model (Figure 2 C). Titres of WNV on day 
110 
Figure: 6.2 Virus titres in the brain after i.p. and i.n. inoculation of WNV in B6.WT 
and B6.IFN-y-/- mice. Groups of 64 mice/strain were inoculated i.p., 6xl04 
pfu/mouse and groups of 21 female mice/strain were inoculated i.n., 6xl04 
pfu/mouse. Brains were collected from day 1-11 p.i. in the i.p. model and from day 
1-7 p.i. in the i.n. model. Virus titres were detected by plaque assay. A) Virus titres 
of B6.WT after i.p. and i.n. WNV inoculation. B) Virus titres of B6.IFN-y-/- mice 
after i.p. and i.n. WNV inoculation. C) Virus titres of B6.WT mice and B6.IFN-y-/-
after i.n. WNV inoculation. No WNV was detected in the mock-infected mice from 
either group in either model. 

3 p.i. were approximately similar between the groups. The titres were also similar at the 
time of death between the groups. These data suggest that death of mice was due to 
overwhelming WNV infection, regardless of the strain of mice in the i.n. model, whereas in 
the i.p. model, death of mice was due to the activity of IFN-y. 
6.3.2.2. Kinetics of WNV progression in the i.n. model 
Since, extremely high virus titres were detected in the i.n. model, brain sections from both 
strains, B6.WT and B6.IFN-y-/- mice, were labelled with anti-WNV Ab and examined for 
progression of infection. In both groups of mice, a few neurones were infected in the 
outermost layer of the OB on day 3 p.i. (Figure 6.3 a). On day 5 p.i., the number of infected 
neurones had markedly increased and WNV Ag was observed in other areas of the OB. 
Many neurones were infected in the base of the OB, front cortex (Figure 6.3 b) and a few 
infected neurones were seen in the base of the brain. At this timepoint few neurones were 
infected in the hippocampus. On day 6 p.i., most of the neurones in the OB and cortex were 
infected (Figure 6.3 C). Most of the neurones in the hippocampus were also infected. 
Similarly, high neuronal infection was observed in the base of the brain, striatum and 
thalamus. Compared to the cortex, fewer neurones were infected in the brainstem but no 
detectable cerebellar infection was observed. On day 7 p.i., nearly all neurones of the OB 
(Figure 6.3 d), cortex, striatum (Figure 6.3 e), hippocampus (Figure 6.3 e and 6.4 c) were 
detectably infected. At this timepoint, many brainstem neurones were also infected (Figure 
6.3 f). In the hippocampus, both pyramidal cells (Figure 6.4 c and d) and granular cells of 
the dentate gyrus (Figure 6.4 c) were highly infected. At the time of death all areas of the 
brain, except cerebellum were heavily infected. Interestingly, only occasional cerebellar 
neurones were infected in both groups of mice (Figure 6.3 g). There was no difference in 
the pattern and kinetics of infection between the groups. These data confirm that WNV is 
highly neurotropic and replicates quickly in neurones if inoculated i.n. These data further 
suggest that death of mice was due to the overwhelming brain infection. Despite such 
extensive and marked brain infection, no infection of glial cells, ependymal cells or 
meninges was observed in either group of mice. Like the i.p. model, WNV was confined to 
the neurones (Figure 6.3 h) and their processes (Figure 6.4 b and d) in the i.n. model, 
possibly suggesting that only neurones have a specific receptors for WNV or reflecting the 
mode of transmission of WNV between cells. However, on day 7 p.i., 1 blood vessel in I 
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Figure: 6.3 WNV-infected B6. WT mouse brain sections labelled with anti-WNV 
antibody showing progression of infection in the i.n. model. WNV antigen first 
appeared in the outermost layer of the olfactory bulb (OB) at day 3 p.i. (a) (solid 
arrows). On day 5 p.i. WNV antigen was observed in other parts of the OB with 
increased numbers of infected neurones (b) (solid arrows). At this timepoint, WNV 
antigen was also found in the OB base (OBB) (Solid arrows) and front cortex (FCO) 
(solid arrow). On day 6 p.i. the number of infected neurones increased in the OB, 
OBB, FCO, striatum (ST) (c) (solid arrows). At the time of death, on day 7 p.i, large 
numbers of neurones were infected in the OB (d) (solid arrows), FCO, ST, 
hippocampus (HIP) (e) (solid arrows). At this timepoint many neurones in the 
thalamus (TH) (e) (solid arrows) and brainstem (f) (solid arrows) were also infected. 
Only occasional neurones were infected in the cerebellum (CB) at the time of death 
(g) (solid arrows). Despite extensive infection, WNV antigen was confined only to 
the neurones (h) (solid arrows). These micrographs are representative of both 
B6.WT and B6.IFN-y-/- mice. Scale bar = 400!-lm from a-f, 100/lm from g-h. 
Anatomic orientation of the brain sections: Right, anterior brain (fore brain), left, 
posterior brain (hind brain). 
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Figure: 6.4 WNV -infected 86. WT brain sections labelled with anti-WNY antibody in the 
i.n. modeL Despite extensive neuronal infection in the i.n. model very little neuronal degen-
eration was found at the time of death (a) (solid arrows). At this timepoint, only one blood 
vessel was found to be infected (b) (solid arrows). WNV antigen was also observed in the 
neuronal processes (open arrow). On day 7 p.i., most of the neurones of the hippocampus 
were infected, including pyramidal and granular cells (c) (solid arrows). WNV antigen can 
be clearly seen in the axons of pyramidal neurones (open arrows). Scale bar= 50~--tm. 
out of 42 mice, was found to be infected (Figure 6.4 b). Very few neurones showed 
abnormal morphology or evidence of degeneration, on day 7 p.i. (Figure 6.4 a), suggesting 
that WNV may interfere with the vital functions of neurones leading to death in the i.n. 
model in both groups of mice. 
6.3.2.3. Route of CNS access by WNV 
Since there was no difference in the survival, virus titres and pattern of brain infection 
between B6.WT and B6.IFN-y-/- mice in the i.n. model, further studies were continued only 
in the B6.WT mice. As described in section 3.3.3., WNV Ag in the i.p. model was 
consistently negative in the OB throughout the timeperiod. It was first detected in the 
brainstem and spread in the cauda-rostral direction. In contrast, in the i.n. model, WNV Ag 
was first detected in the OB on day 3 p.i. (Figure 6.5 b and 6.3 a). In the i.n. model, at this 
timepoint, both brainstem (Figure 6.5 c) and cervical spinal cords (Figure 6.5 d) were 
negative for WNV Ag. The number of infected neurones was increased from day 3 p.i. and 
spread from rostral to caudal (Figure 6.3). These data strongly suggest that WNV get access 
to the brain via olfactory neuroepithelium in the i.n. model, whereas in the i.p. model, WNV 
may get access to the CNS via axonal migration along the spinal cord. 
6.3.3. Histopathology 
The histopathology in the i.n. model was very similar to the i.p. model. Histopathological 
changes in the i.p. model were described in section 3.3.2. Routine H and E staining of brain 
sections from the i.n. model are shown in figure 6.6. Histopathological changes in the i.n. 
model included infiltration of leukocytes consisting of both mononuclear and 
polymorphonuclear cells. Interestingly, infiltrating leukocytes accumulated predominantly 
in the OB (Figure 6.6 b). Very little perivascular cuffing was observed in the brain 
parenchyma at the time of death, despite extremely high neuronal infection in the 
parenchyma. Meningeal infiltration was also observed at this timepoint. Activated microglia 
with rod morphology were observed around the blood vessels. The OB from mock-infected 
mice showed normal histology (Figure 6.6 a). 
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Figure: 6.5 WNV -infected B6. WT brain and cervical spinal cord sections labelled with anti-
WNV antibody in the i.n. model. WNV antigen was first detected in the outermost layer of the 
olfactory bulb on day 3 p.i. (b) (solid arrows). At this timepoint, no WNV antigen was detect-
ed in the brainstem (c). Similarly, WNV antigen was also undetectable in the cervical spinal 
cord at this timepoint (d). No WNV antigen was detected in the olfactory bulb from mock-
infected mouse brain (a). Scale bar= 50~-tm. 
Figure: 6.6 Hand E stained brain sections of B6.WT mice in the i.n. model. Olfactory bulb 
from mock-infected mouse brain showing normal histology (a). Olfactory bulb from infect-
ed mouse showing high infiltration of leukocytes on day 7 p.i. (b) (solid arrows). 
Scale bar= 50Jtm. 
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6.3.4. Kinetics of microglial activation in relation to WNY infection and infiltration 
GS-lectin was used to detect activated microglia in this study. Microglia were activated 
from day 3 p.i., concurrently with the detection of WNV Ag (Figure 6.7 a). At this 
timepoint activated microglia were detected only in the outermost layer of the OB (Figure 
6. 7 b). The number of activated microglia had increased by day 6 (Figure 6.8 c) and was 
highest at the time of deatb on day 7 p.i. (Figure 6.8 d). The detection of activated microglia 
was co-incident with the detection of WNV Ag, occurring in a wave, just ahead of the 
advancing front of WNV-infected neurones. Interestingly, unlike in the OB, relatively few 
microglia were activated in the brain parenchyma and most were found around blood 
vessels, exhibiting amoeboid morphology (Figure 6.8 a and b). Moreover, unlike the i.p. 
model, very few microglial nodules were observed at the time of death. In the i.p. model, 
microglia were highly activated throughout the brain parenchyma with the formation of 
large numbers of nodules. Activated microglia were first observed in the i.p. model within 
24h of WNV Ag detection at or near the sites of neuronal infection (section 4.3.3). 
The number of activated microglia, leukocytes and infected neurones were counted as 
described in Materials and Methods to compare the kinetics. In the i.n. model, the number 
of infected neurones was extremely high, compared to the number of activated microglia. 
The number of leukocytes was near to base line value compared to the number of infected 
neurones (Figure 6.9 A). In contrast, in the i.p. model, tbe reverse was the case. The number 
of activated microglia was extremely high, compared to the number of infected neurones, 
and the number of inflammatory leukocytes was also higher than the number of infected 
neurones in the i.p. model. The number of inflammatory leukocytes and activated microglia 
returned nearly to baseline values once WNV Ag was undetectable (Figure 6.9 B). These 
data suggest that in the i.n. model, the uncontrolled growth of WNV in the brain may be due 
to the low numbers of activated microglia, compared to the number of infected neurones. 
6.4. Discussion 
The i.n. route of WNV inoculation was used to characterize the i.n.-induced disease profile 
and compare it with the i.p. route of WNV inoculation. In the i.p. model, WNV seems to get 
access to the brain via ascending axonal migration along the spinal cord. Therefore, the 
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Figure: 6.7 WNV immunohistochemistry and lectin histochemistry of brain sections of 
B6.WT mice in the i.n. modeL WNV antigen first appeared in the outermost layer of olfac-
tory bulb on day 3 p.i. (a) (solid arrows) . Activated microglia were also detected co-
incidently with the detection of WNV antigen in the outermost layer on day 3 p.i. (b) (solid 
arrows), but no where else in the brain. Scale bar= 50Jtm. 
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Figure: 6.8 WNV-infected B6.WT brain sections in the i.n. model stained with GS-lectin. In 
the brain parenchyma, activated microglia were observed around the blood vessels on day 6 
p.i. (a) and day 7 p.i. (b) exhibiting amoeboid morphology (solid arrows). In the olfactory 
bulb, activated microglia were scattered, exhibiting both amoeboid and intermediate activated 
morphology on day 6 p.i. (c) and day 7 p.i. (d) (solid arrows). Scale bar= lOOJtm. 
Figure: 6.9 Kinetics of WNV infection, microglial activation and leukocyte 
infiltration in B6.WT mice in the i.n. model (A) and i.p. model (B). In the i.n. 
model, extensive neuronal infection was observed in 100% of mice with similar 
pattern throughout and with 100% mortality by day 7 p.i. Therefore, relatively fewer 
numbers of mice were needed in the i.n. model, compared to the i.p. model. Groups 
of 110 mice in the i.p. model and groups of 21 mice in the i.n. model were infected 
with 6x104 pfu/mouse. Subgroups of mice in each strain were sacrificed from day 3 
to 15 p.i. in the i.p. model and from day 1-7 p.i. in the i.n. model. 
Immunoperoxidase labelling was used to detect viral antigen in the brain 
parenchyma of infected mice. H and E stain was used to detect leukocyte infiltration 
in the parenchyma. Lectin-histochemistry was used to detect activated microglia in 
the brain parenchyma. The number of neurones positive for viral antigen, leukocytes 
and activated microglia were counted, as described in Materials and Methods. Sixty 
H.P.F. were counted per mouse brain and values for each timepoint amalgamated 
and expressed as mean ± SEM. 
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route of access to the CNS in the i.n. model was also evaluated in this study. More 
importantly, in the i.p. model, IFN-y clearly exacerbates disease. Therefore, it was important 
to determine in the i.n. model whether IFN-y exerted a similar action to the i.p. model. To 
address these questions, mice were inoculated i.n. and i.p. in both strains of mice with the 
same dose of WNV, 6xl04 pfu/mouse. Their survival rates, clinical symptoms, virus burden 
in the brain, pattern of brain infection, as well as activation of microglia and kinetics of 
leukocyte infiltration were studied. 
As described earlier in section 3.3.1.2., in the i.p. model, there was >2 fold better survival in 
B6.IFN-y mice compared to B6.WT. In contrast, mice inoculated i.n. with WNV became 
sick suddenly and moribund the following day, with mortality rates of 100% in both strains. 
In both strains, mortality occurred between day 6-7 p.i. with identical kinetics (Figure 6.1 A 
and B), indicating that IFN-y does not influence the outcome of disease in this model at this 
dose of virus. Although signs of clinical illness were observed from day 6 p.i. in both 
models in both strains of mice, the clinical signs exhibited by these mice were different 
between the models. In the i.p. model, some of the mice showed hindlimb paralysis whereas 
in the i.n. model, none of the mice from either strain was paralysed. This is supported by the 
early involvement of the spinal cord prior to brain involvement in the i.p. model, while in 
tbe i.n. model the brain was always involved before the spinal cord. These data suggest that 
paralysis is a result of spinal cord involvement, not pathology in the brain. In a study by 
Thach et al. (2000) mice lost up to 30% of their original body weight after i.n. inoculation 
of SBV. In this study, although the infected mice were not weighed during the experiment 
in either model, there was no visually obvious weight loss in the i.n. model, whereas 
inanition was clearly obvious in the i.p. model. 
Since 100% mortality occurred with acute illness in the i.n. model in both strains of mice, 
the replicating virus load was determined by plaque assay. There was a massive difference 
in the titres between the models (Figure 6.2). In the i.p. model in both groups of mice, 
replicating WNV was detected from day 6 p.i. whereas in the i.n. model, replicating WNV 
was observed from day 3 p.i. The maximum titres were approximately 10 log 10 pfu/gram 
brain in both groups of mice. This was >4 log-fold different from the i.p. model and was 
accompanied by 100% mortality. In the i.p. model, detection of WNV in the brain did not 
invariably reflect clinical illness or mortality. In contrast, the extensive growth of WNV in 
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the i.n. model was most likely be the cause of death in both B6.WT and B6.IFN-y-/- mice, 
unlike the i.p. model, where mortality is clearly independent ofWNV. 
Immunoperoxidase labelling was used to determine the types of cells infected, the kinetics 
of disease progression as well as the possible route of WNV entry into the CNS in the i.n. 
and i.p. models. WNV first appeared in the cervical spinal cord 24h before it was detectable 
in the brainstem in the i.p. model. Consistently negative OB neurones and extremely rare 
infection of neurovascular endothelium as well as associated clinical features of hindlimb 
paralysis strongly suggests that WNV enters the brain via ascending axonal migration along 
the spinal cord in this model (section 3.3.3). In contrast, in the i.n. model, WNV first 
appeared in the outermost layer of the OB (Figure 6.3 a and 6.7 a) when both cervical spinal 
cord and brainstem were negative for WNV Ag. WNV spread to other parts of the OB and 
brain in a caudal-to-rostral direction, indicating that in the i.n. model, WNV uses the OB to 
enter the brain. The involvement of the outermost layer of the OB is consistent with the fact 
that this layer contains the incoming axons from the receptor neurones of the 
neuroepithelium. Similar results were also found in other viral encephalitis models using the 
i.n. route of infection, including SBV, VSV, HSV, MHV (Thach et al. 2000; Huneycutt et 
al. 1994; Barnett & Perlman 1993; Barnett et al. 1993; Anderson et al. 1983). These viruses 
use the olfactory nerve to enter the brain from the nasal cavity. However, several 
experiments show that after i.n. inoculation, it is not necessarily the olfactory pathway that 
is used to enter the brain. Shinya et al. (2000) demonstrated that in avian influenza virus 
encephalitis, virus was first detected in the brainstem, not in the OB after i.n. inoculation. 
Similarly, Babic et al. (1994) have shown that pseudorabies virus used 3 different routes, 
including the trigeminal, sympathetic and parasympathetic routes to enter into the CNS after 
i.n. inoculation. These data show that the manner of CNS involvement is clearly dependent 
on the route of inoculation. This in turn influences host survival in viral encephalitis. 
As in the i.p. model, WNV Ag was observed only in the neurones and their processes in the 
i.n. model. However, extremely rarely, blood vessels may be infected (Figure 6.4 b). In the 
i.p. model, relatively localized and restricted infection of neurones were observed 
throughout all timepoints. In contrast, in the i.n. model, WNV spreads very rapidly (Figure 
6.3), infecting almost all neurones of all brain except the cerebellum, demonstrating that 
WNV is highly neurotropic. This suggests either that only neurones have receptors for 
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WNV in vivo (this is clearly not true in vitro) or that WNV spreads from neurone to neurone 
via the axons and dendrites across the synaptic junctions. Very few necrotic neurones were 
observed, despite extensive neuronal infection at the time of death (Figure 6.4 a). WNV in 
the i.n. model regularly infected all the parts of hippocampus (Figure 6.3 e and 6.4 c), 
whereas in the i.p. model, these areas were only rarely infected. This may be due to the 
direct connections between the OB and hippocampus (Barr & Kiernan 1983). Like the i.p. 
model, detectable WNV Ag was rarely observed in the cerebellum, despite extensive 
neuronal infection in the rest of the brain in the i.n. model. This suggests that cerebellar 
neurones are perhaps not as accessible anatomically or are resistant to WNV infection. 
It is clear that viral encephalitis is accompanied by infiltration of leukocytes into the brain 
parenchyma (Liu & Chambers 2001; Christensen et al. 1999; Kimura & Griffin 2000; Liu et 
al. 2001; Lane et al. 2000). In the i.n. model, infiltration of leukocytes was first observed in 
the OB, and increased to a maximum by the time of death. These inflammatory cells include 
both mononuclear and polymorphonuclear leukocytes, although the predominant cell type 
was mononuclear. Despite extensive infection throughout the brain, comparatively few 
leukocytes were observed in the brain parenchyma and very little perivascular cuffing was 
seen. Leukocytes were seen predominantly in the OB (Figure 6.6 b). In the i.p. model, 
infiltrating leukocytes were seen predominantly in the parenchyma, not the OB. Infiltration 
of leukocytes was observed 24h before WNV Ag detection in the brain parenchyma. In 
contrast, in the i.n. model, infiltration of leukocytes was observed 48h after WNV Ag 
detection in the OB. However, WNV spread rapidly throughout tbe brain before infiltration 
of leukocytes increased further (Figure 6.9 A). Interestingly, similar to the i.p. model, 
infiltration of leukocytes was observed from day 5 p.i., suggesting tbat the time required for 
activation of immune system with migration of leukocytes to the brain required at least 4-5 
days in both models and suggests that leukocyte infiltration is part of the adaptive immune 
response, rather than the innate response. 
Since neuronal infection was extensive in the i.n. model, the status of microglial activation 
was also evaluated. Activated microglia first appeared, co-incident with the detection of 
WNV Ag from day 3 p.i. in the OB (Figure 6.7). The number of activated microglia 
increased subsequently and was maximal at the time of deatb (Figure 6.9 A). As in the i.p. 
model, activated microglia showed different activated morphologies, including intermediate 
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and amoeboid forms and were scattered throughout the brain parenchyma and OB (see 
chapter 4). However, in the i.n. model, microglial activation was confined either to the OB 
(Figure 6.8) or found around the blood vessels in the i.n. model with very little nodule 
formation. Microglial activation was much higher in the OB, compared to the rest of the 
brain. Activated microglia are highly motile and mitotic in nature (Dickson et al. 1991). 
They can migrate to the sites of injury (Kreutzberg 1996) in response to chemokines 
(Johnstone et al. 1999; Peterson et al. 1997) they themselves can produce (Persidsky et al. 
1999). The accumulation of activated microglia in the OB begs the question as to why they 
are not migrating to other parts of the brain or being activated in other areas when there is 
such extensive infection in these areas. Evidently high numbers of activated microglia 
migrate towards the early sites of infection in the OB. However, in the i.p. model, activated 
microglia were not concentrated only in the brainstem, but were scattered throughout the 
brain parenchyma, including the brainstem. 
In the i.p. model, extremely high microglial activation was observed after 3-4 days of WNV 
detection in the brain parenchyma (Figure 6.9). This was normalized only after WNV 
antigen was undetectable (See chapter 4 for detail). In contrast, in the i.n. model, despite 
extremely high neuronal infection, significantly fewer microglia were activated after 3-5 
days of WNV detection (Figure 6.9 A). It is known that microglial activation is under the 
strict control of neurones (Neumann 2001). Also, neurones are potential sources of M-CSF 
(Nohava et al. 1992), a potent mitogen for microglial proliferation (Lodge & Sriram 1996). 
Since WNV replicated and spread so quickly through the brain neurones, it is possible that 
these cells were not able to generate the mitogenic and chemoattractant gradient required to 
enable activation and migration of microglia. Further studies of soluble factors production 
by neurones in the i.p. and i.n. models may help to answer this question. 
The responses of microglia in the i.p. model suggests that the control of WNV in the 
neurones may be mediated by activated microglia, since the number of activated microglia 
were extremely high, compared to the number of infected neurones. It is possible that the 
fewer numbers of activated microglia allowed the uncontrolled WNV growth in the brain in 
the i. n. model. 
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In conclusion, the disease profile was completely different, depending on the route of WNV 
inoculation. Mice in the i.n. model were highly susceptible to WNV infection with 100% 
mortality within 7 days p.i. due to acute encephalitis, compared to the mice in the i.p. 
model. In the i.n. model, WNV replicated very quickly and infected almost all neurones in 
most areas of the brain. The virus titres were approximately I 0 log10 pfu/gram at the time of 
death, which is >4 log-fold higher than the peak titres observed in the i.p. model in both 
groups of mice. Unlike in the i.p. model, IFN-y did not influence disease progression in the 
i.n. model. The small amount of neuronal degeneration, despite extensive infection suggests 
that the fatal outcome from i.n. inoculation may be associated with the functional 
insufficiency of the large numbers of WNV -infected neurones in the brain. 
In the i.n. model, WNV used the olfactory pathway to gain access into the brain, whereas in 
the i.p. model WNV probably used the neural pathways through the spinal cord to gain 
entry into the brain. Infiltration of leukocytes occurred 48h after WNV Ag was detected in 
the brain parenchyma, but infiltrating cell numbers were significantly lower than the 
number of neurones infected. In the i.p. model, infiltration of leukocytes occurred 24h 
before WNV Ag was detected and leukocyte numbers were higher than infected neurones. 
Microglia were activated in response to neuronal infection in the i.n. model. However, 
significantly lower numbers of microglia were activated, compared to the number of 
neurones infected. In the i.p. model, extremely high numbers of microglia were activated 
compared to the number of neurones infected. This may contribute to controlling WNV in 
the neurones in the i.p. model. The, i.p., not the i.n. model, exhibits the pathology seen in 
human WNV encephalitis. The i.n. model represents direct neuronal infection whereas the 
i.p. model delays the access of WNV to the CNS, allowing the host to mount an effective 
adaptive immune response. Ironically, this may lead to death from immunopathology in this 
model. 
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Chapter-7 
Role of antibody depends on the route of infection 
in WNV encephalitis 
7.1. Introduction 
The antiviral host defence mechanism is orchestrated by both natural and adaptive immune 
components. The immune mechanisms which mediate natural antiviral defence include 
macrophage activity, IFN-a/~, complement and natural Ab. Those that mediate adaptive 
antiviral defence include cell-mediated and humoral immune responses. Several animal 
models of neurotropic viral infection have shown that cell-mediated immune mechanisms 
play a major role in controlling viral infections in the CNS. This is mediated by T cells, 
either via CTL or by producing antiviral cytokines such as IFN-y or TNF (Binder & Kundig 
1991; Binder & Griffin 2001; Christensen et al. 1999; Harty et al. 2000; Kundig et al. 1993; 
Noske et al. 1998; Stahlman et al. 1998; Weidinger et al. 2000; Geiger et al. 1997; Rossol-
Voth et al. 1991). However, in addition to cell-mediated immunity, humoral immune 
mechanisms also play an important role in controlling viral infection in the CNS and hence 
in disease outcome (Matthews et al. 2001; Wright & Buchmeier 1991; Griffin et al. 1997; 
Levine et al. 1991; Dietzschold et al. 1992; Kapoor et al. 1982). 
Humoral immunity is mediated by Ab which is produced by B cells in both membrane 
bound and secreted forms. Since secreted Ab circulates in the blood, it functions as an 
effector molecule of humoral immunity for terminating primary infection, reducing the level 
of viraemia and may thus prevent disease. Although natural Ab has been shown to play a 
role in controlling viral infections (Ochsenbein et al. 1999; Ochsenbein & Zinkernagel 
2000), most Ab-mediated protection is attributable to specific antiviral Ab (Thach et al. 
2000; Kapoor et al. 1982; Kimura-Kuroda & Yasui 1988; Levine et al. 1991). Antiviral Ab 
can directly bind and neutralize virus particles and this opsonizes them to facilitate 
phagocytosis. Ab can also stimulate Ab-dependent cell cytotoxicity or activate the 
complement cascade (Kuby 1994 ). Antiviral Ab is generated after primary infection, or 
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after viral vaccination, but may also be effective after passive administration of HI or 
specific monoclonal Ab. Antiviral Ab which can neutralize virus infectivity is known as 
neutralizing Ab. Although viruses induce the host to produce both neutralizing and 
non-neutralizing Ab, neutralizing Ab plays a vital role in limiting virus spread and 
preventing disease. Circulating neutralizing Ab is the basis of protection against viral 
reinfection. Increasing evidence shows the importance of Ab in neurotropic viral infection, 
where it is thought to clear infectious virus and viral RNA from neurones (Levine et al. 
1991; Dietzschold et al. 1992; Byrnes et al. 2000). This work is based predominantly on 
passive transfer of HI serum or monoclonal Ab. In the absence of effective antiviral therapy 
for neurotropic virus infection, passive protection with Ab can thus play an important role in 
prophylactic prevention or amelioration of viral infections. However, although Ab is 
important in antiviral defence mechanisms, it has been also postulated that Ab may be 
involved in enhancing disease in viral infections (Gould et al. 1987; Barrett & Gould 1986). 
In WNV encephalitis, in the i.p. model, surviving mice from either strain (B6.WT and 
B6.1FN-y-/-) rechallenged with a 50-fold higher dose of WNV than the original dose 
showed no clinical or histopathological features of encephalitis and 100% of mice survived. 
However, in the i.n. model, fatality was 100% during the primary infection in both groups 
of mice. Although Camenga et al. (1974) have studied the role of Ab in WNV encephalitis 
by passive transfer of HI serum using the i.p. route of WNV inoculation, the role of Ab in 
the i.n. model has not been studied. Therefore, a preliminary investigation was undertaken 
in B6.WT mice to determine the role of Ab in increasing survival and limiting the extent of 
CNS infection in the both i.p. and i.n. model, using passive transfer of HI serum. A 
preliminary study was also carried out in B cell-deficient mice (B6.J.!MT-/-) compared to 
control (B6.WT) mice to further explore the role of Ab in the immune response to WNV. 
7 .2. Materials and Methods 
7.2.1. Mice 
Female, specific-pathogen free, 8-week-old B6.WT and B6.J.!MT-/- mice (deleted J.! chain of 
Ab), backcrossed to C57BL/6 were used. 
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7.2.2. Titration of WNV in the i.n. model 
To determine the sublethal dose of WNV in the i.n. model, WNV was titrated in both 
B6.WT and B6.IFN-y-/-mice. Three different doses were used: 6x104 pfu/mouse, 6x103 
pfu/mouse and 1xl02 pfu/mouse. Groups of 24 mice, each of 8 mice/group/strain were 
inoculated i.n. with different doses of WNV. Their survival rate was evaluated as described 
in section 2.2.2.1. Surviving mice from this titration series were rechallenged i.n. with 6xl04 
pfu/mouse. Their survival rate was evaluated as described in section 2.2.2.1. 
7.2.3. Generation of hyper-immune serum and measurement of efficacy 
HI serum was produced in B6.WT mice and its efficacy, including IgG titre, plaque 
reduction neutralization titre (PRNT) and in vitro efficacy as a neutralizing antibody was 
determined as described in section 2.4. 
7.2.4. Passive transfer of hyper-immune serum and virus infection of mice 
Only B6.WT mice were used for passive transfer experiments in i.n. and i.p. models. 
Groups of 30 mice in each model were treated with 200J.!l of 1:3 diluted serum (HI and 
normal serum) and WNV and their survival rates were evaluated as described in section 
2.4.5. Another group of 10 mice was also treated with 200J.!l of 1:3 diluted HI serum i.p. at 
48h p.i. in the i.p. model. A group of 35 mice was treated with 500J,tl of undiluted serum (HI 
and normal serum) and WNV only in the i.n. model. Infected mice in this group showing 
signs of hindlimb paralysis on day 11 and 13 p.i. were sacrificed for detection of WNV in 
the brain and spinal cord. The survival rate was evaluated as described. Brains and whole 
spinal cords were collected and processed as described in section 2.2.2.2. 
Groups of 20 B6.WT mice and 15 B6.!!MT-/- mice were inoculated i.p. with 6x104 
pfu/mouse and their survival rates were evaluated as described in section 2.2.2.1. Brains and 
cervical spinal cords were collected and processed as described in section 2.2.2.2. 
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7.2.5. Generation of hyper-immune splenocytes 
Hyper-immune splenocytes were obtained from the same HI mice whose sera was used for 
passive transfer experiments, and cells were processed as described in section 2.5.1. 
7.2.6. Adoptive transfer of hyper-immune splenocytes and virus infection of mice 
B6.WT mice were used for adoptive splenocyte transfer experiments only in the i.n. model. 
Groups of 30 mice were treated with 200JL1 containing 5xl07 splenocytes/mouse (HI or 
normal splenocytes) and WNV. Their survival rates were evaluated as described in section 
2.5.2. 
7 .4. 7. Histopathology 
Serial sections from paraffin-embedded tissues were stained with H and E stain, and were 
examined for histopathology. 
7.2.8. WNY immunohistochemistry 
This was done as described in section 3.2.3. Mock-infected brain sections were used as 
controls for WNV Ag labelling. 
7 .3. Results 
7 .3.1. Titration of WNY in the i.n. model 
In the preceeding chapter it was shown that WNV was lethal in B6.WT and B6.IFN-y-/-, 
with 100% mortality in both strains of mice when inoculated i.n. at 6xl04 pfu/mouse. Mice 
from both groups succumbed to extensive neuronal infection. Therefore, WNV was titrated 
in this model to determine the sublethal i.n. dose of WNV. The cumulative comparative 
survival after infection in all groups is presented in figure 7.1. In both strains of mice, 100% 
mortality occurred by day 7 p.i. after inoculation of 6xl04 and 6xl03 pfu/mouse, whereas 
lxl02 pfu/mouse resulted in extended survival in both strains. In mice given lxl02 pfu i.n., 
mortality occurred from day 7 p.i. in both groups and by day 9 p.i. mortality was 85% in 
B6.WT mice and 65% in B6.IFN-y-/-. No further deaths occurred after day 9 p.i. and mice 
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Figure: 7.1 Titration of stock vera-grown WNV in 8-week-old B6.WT (A) and 
B6.IFN-y-/- (B) mice in the i.n. model. Groups of 8 mice/strain/dose were inoculated 
i.n. with different doses of WNV and monitored for signs of illness 3 times a day 
over 21 days. The percent suvival at each timepoint is shown. Mock-infected mice 
did not develop signs of illness. 
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appeared healthy. Surviving mice from both strains were rechallenged with a 600-fold 
higher dose of WNV than the original dose, i.e., 6xl04 pfu/mouse. This showed 100% 
protection from disease. These data suggest that the lethality of WNV is dose-dependent in 
the i.n. model and similar to the i.p. model, secondary immunity can be generated in the i.n. 
model. 
7 .3.2. Measurement of Hyper-immune serum efficiency in vitro 
Before passive transfer of HI or normal sera into naive mice, their antiviral activity was 
measured by 2 different methods. The IgG titre was determined by direct ELISA. The titre 
was determined as the dilution of serum where the optical density of HI and normal sera 
were equal. HI serum had an IgG titre of log 4.8 (Figure 7 .2). The log of the highest dilution 
reducing 100 WNV plaques on vero cells by 50% was considered to be the PRNT or 
neutralizing titre50 (NT 50). HI serum had a NT 50 of log 5.4 (Figure 7.3). The efficacy of HI 
serum was further confirmed by its ability to neutralize WNV released from vero cell 
monolayers into the supernatant. In this assay, the presence of replicative WNV in the 
culture supernatant was determined after 48h infection in the presence of undiluted HI 
serum. It was found that undiluted HI serum could completely neutralize all supernatant 
WNV released from vero cells by 48h and this was dose-dependent, whereas undiluted 
normal sera had no effect on WNV released from infected vero cells (Figure 7.4 ). These 
data indicate that mice develop high levels of neutralizing Ab upon exposure to WNV. 
7.3.3. Effect of passively transferred hyper-immune serum on survival 
After analyzing the efficiency of HI serum in vitro, 200J.!l of 1:3 diluted HI and normal sera 
were passively transferred i.p., as described in Materials and Methods. This dose of HI 
serum could completely neutralize 6xl04 pfu in vitro. Another group of mice was treated 
with the same dose of HI serum at 48h p.i. in the i.p. model. Mice were observed for 2 
weeks for clinical signs of illness. 
In the i.p. model, mice passively transferred with normal serum or untreated and infected 
with WNV showed signs of clinical illness by day 6-10 p.i. with 60-70% mortality. In 
contrast, mice passively transferred with HI serum on p.i. day-1 or p.i. day+2 did not show 
any signs of clinical illness for 14 days p.i and appeared completely healthy (Figure 7.5 A). 
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Figure: 7.2 Detection of IgG titre in hyper-immune serum: IgG titre in the hyper-
immune serum was determined by ELISA as described in Materials and Methods. 
IgG titre was defined as the Jog dilution of the serum where the optical density of 
hyper-immune and normal serum were equal. 
Figure: 7.3 Kinetics of WNV neutralization by hyper-immune serum. Plaque 
reduction neutralization titre or neutralizing titre50 was determined as described in 
Materials and Methods. The highest dilution of the hyper-immune serum that 
reduced plaques by 50% was regarded as the plaque reduction neutralizing titre. 
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Figure: 7.4/n vitro efficacy of neutralizing antibody: The efficacy of neutralizing antibody 
was performed in an in vitro culture system, as described in materials and methods. In this 
assay, the effect of neutralizing antibody on WNV released from infected vero cells into the 
supernatant was measured. Nonnal serum was used as a control for hyper-immune serum 
and untreated infected vero cells were used as a control for both immune and nonnal sera. 
Undiluted nonnal serum could not inhibit WNV released from infected vero cells. Undilut-
ed hyper-immune serum completely inhibited WNV released from infected vero cells into 
supernatant and no WNV plaques were detected by plaque assay of the supernatant. This 
effect was dose-dependent. 
After 14 days p.i., 50% of mice were sacrificed, sera were pooled and assessed. 
Interestingly, 100 J.ll of this serum could still neutralize 6xl04 pfu, the dose originally given 
to infect these mice. The remaining 50% mice were rechallenged with a 50-fold higher dose 
of WNV than the original dose and observed for 14 days. No signs of clinical illness was 
observed in this time period (data not shown). 
In contrast, in the i.n. model, mice passively transferred with HI or normal sera or left 
untreated, showed signs of clinical illness by day 6 p.i. and had all died by day 7 p.i. (Figure 
7.5 B). It was speculated that the amount of serum given to the naive mice may not have 
been enough to protect mice in this model. Therefore, 500J.ll undiluted HI or normal serum, 
i.e., 750-fold higher than the neutralizing dose in the first experiment, was passively 
transferred, as described, one day prior to WNV infection. It was found that this dose of HI 
serum could extend the survival of mice in this model (Figure 7 .6). However only 13% mice 
survived until day 14 p.i., when they were sacrificed. Interestingly, one mouse on each of 
days 11 and 13 p.i. showed hindlimb paralysis. Mice passively transferred with 500J.ll of 
undiluted normal serum, succumbed by day 7 p.i. with 100% mortality, similar to untreated 
mice. These data indicate that passive transfer of HI serum both pre and post infection can 
abrogate encephalitis in the naive mice in the i.p. model, but not in the i.n. model. Very high 
dose immune serum is required to extend the life of naive mice in the i.n. model. 
7 .3.4. Effect of adoptively transferred hyper-immune splenocytes on survival 
It was demonstrated that passive protection with HI serum was effective in the i.p. model 
and not in the i.n. model. Thus, the question arises as to whether these i.n. mice would be 
protected if adoptively transferred with splenocytes from HI mice. Therefore, naive mice 
were adoptively transferred i.p. with 5xl07 splenocytes/mouse only in the i.n. model, as 
described in Materials and Methods, to determine whether passive protection occur via 
these cells in the i.n. model. Similar to the passive transfer of HI serum, adoptive transfer of 
immune splenocytes experiment was undertaken in B6.WT mice. Mice treated with HI or 
normal splenocytes or left untreated showed signs of clinical illness by day 6 p.i. and had all 
died by day 7 p.i. (Figure 7 .7). Thus HI splenocytes were unable to protect mice inoculated 
by the i.n. route despite being given 24h before WNV inoculation. 
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Figure: 7.5 Survival of B6.WT mice passively transferred with hyper-immune or 
normal sera or left untreated and infected either i.p. or i.n. with WNV. Groups of 30 
mice in each model, 10 mice/group were used in both i.p. and i.n. models. One 
group was treated with hyper-immune serum, one group was treated with normal 
serum and one group was left untreated in both models. Sera were diluted 1:3 and 
200!LI was injected i.p. 24h before infection in both models. All groups of mice were 
inoculated with 6xl04 pfu/mouse as decribed, and monitored for signs of illness 3 
times/day over 14 days. The percent survival at each time point is shown. Figure A 
shows survival profiles of B6.WT mice passively transferred with sera and infected 
via the i.p. route. Figure B shows the survival profiles of of B6.WT mice passively 
transferred with sera and infected via the i.n. route. 
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Figure: 7.6 Survival of B6.WT mice passively transferred with 500pl undiluted sera and 
infected i.n. with WNV. Groups of 35 naive mice were used. One group (n=15) was treated 
with hyper-immune serum, one group (n=lO) was treated with normal serum and one group 
(n=10) was left untreated. Five hundred microlitres undiluted sera were passively transferred 
i.p. 24h before i.n. infection. All groups of mice were then inoculated i.n. with 6x104 
pfu/mouse as described in materials and methods. Groups of i.n. WNV-immune mice (n=8) 
were also rechallenged i.n. with 600-fold higher dose of WNV than the original dose, i.e., 
6xl04 pfu/mouse. They were monitored for signs of illness 3 times a day over 14 days. The 
percent survival at each timepoint is shown. 
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Figure: 7.7 Survival of B6.WT mice adoptively transferred with 5xl07 splenocytes/mouse 
and infected i.n. with WNV. Groups of 30 naive mice, 10 mice/group were used. One group 
was treated with hyper-immune splenocytes, one group was treated with normal splenocytes 
and one group was left untreated. Splenocytes were transferred 24h before infection and all 
groups of mice were then inoculated i.n. with 6x104 pfulmouse as described in materials and 
methods. They were monitored for signs of illness 3 times a day over 7 days. The percent 
survival at each timepoint is shown. 
7 .3.5. Effect of passively transferred sera on WNY antigen distribution in the CNS 
Since none of the mice passively transferred with HI serum showed clinical illness and 
100% survived in the i.p. model, the brains and spinal cords were analysed for WNV Ag on 
day 7 and 8 p.i. No WNV Ag was detected and the brain and spinal cords of these mice 
showed normal histology (data not shown). In contrast, in the i.n. model, all mice treated 
with low dose (200J.!l of I :3 diluted) HI serum showed widespread neuronal infection at the 
time of death, on day 7 p.i, similar to that of normal serum-treated and untreated mice. 
Since high dose HI serum extended survival in the i.n. model and since a few mice were 
paralysed on day 11 and 13 p.i., it was necessary to see the pattern and extent of WNV Ag 
distribution in the brain and spinal cords of these mice. Mice passively transferred with a 
high dose of normal serum showed widespread neuronal infection in the OB (Figure 7.8 b), 
front cortex (Figure 7.8 a) and other parts of the brain by day 7 p.i., similar to untreated 
mice. Interestingly, no WNV Ag was detected in the OB of mice passively transferred with 
high dose HI serum on day 8 p.i. (Figure 7.8 c), but it was detected in a few neurones in the 
front cortex (Figure 7.8 d). No WNV Ag was detected in the OB on day 11 p.i. either 
(Figure 7.8 e), but infected neurones were observed in the cervical (Figure 7.8 f) and lumbar 
spinal cord on day 13 p.i. (Figure 7.8 h). At this time, also very few infected neurones were 
seen in the front cortex (Figure 7.8 g), compared to normal serum-treated mice (Figure 7.8 
a). Histology showed high activation of microglia with formation of nodules throughout the 
brain. These data indicate that low dose HI serum is insufficient to abrogate direct infection 
via the olfactory neuroepithelium and suggest that mice died due to overwhelming neuronal 
infection. In contrast, high dose HI serum can extend survival. 
Mice adoptively transferred with splenocytes showed very similar signs of clinical illness 
and mortality to that of normal splenocyte-transferred or untreated mice. Therefore, 
histopathology and WNV detection were not studied in these mice. 
7 .3.6. Survival after i.p. route of WNY inoculation in B6.uMT -1- mice 
To further explore the role of Ab in WNV encephalitis, B6.J.!MT-/- mice were used in this 
study. In the i.n. model, although high dose HI serum extended survival it could not protect 
mice. Therefore, in B6.J.!MT-/- mice a survival study was performed using the i.p. route of 
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Figure: 7.8 Brain sections from B6. WT mice, passively transferred with 500JL1 
undiluted hyper-immune or normal serum and WNV -infected, labelled with anti-
WNV antibody in the i.n. model. Mice treated with normal serum showed extremely 
high neuronal infection in the front cortex (a) (solid arrows) and olfactory bulb (b) 
(solid arrows) at day 7 p.i. Mice pretreated with hyper-immune serum showed no 
detectable neuronal infection in the olfactory bulb (c) but very few infected neurones 
were observed in the front cortex (d) at day 8 p.i. Mice pretreated with 
hyper-immune serum also showed no detectable neuronal infection in the olfactory 
bulb at day I I p.i (e) but WNV Ag was detected in the cervical spinal cord neurons 
at this timepoint (f) (solid arrows). On day 13 p.i. these mice showed very few 
infected neurones in the front cortex (g) (solid arrows). Infected neurones were also 
observed in the lumbar spinal cord (h) (solid arrows) at this timepoint. Scale bar= 
IOOJlm from a-e, g-h and 50JLm f. 
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WNV inoculation, and compared to wild type mice. Like B6.WT, in B6.J.!MT-/- mice the 
first signs of clinical illness was observed from day 6 p.i. similar to those described for 
B6.WT in chapter 3 and 6. In B6.J.!MT-/- mice mortality occurred between day 6-9 p.i. with 
100% mortality compared to B6.WT mice (Figure 7.9), suggesting that B6.J.!MT-/- mice are 
highly susceptible to WNV infection. 
7.3.7. HistQpathology in B6.uMT-/- mice 
H and E staining was used to evaluate the histopathological changes in B6.J.!MT-/- mice 
mice (Figure 7.10). Since this is a preliminary study, tissues from these mice were examined 
at the time of death, on day 9 p.i. Like B6.WT mice, histopathological changes were 
observed in B6.J.!MT -I- mice, including infiltration of leukocytes, occasionally perivascular 
cuffs and microglial activation (Figure 7.10 a). Interestingly, despite extensive neuronal 
infection, very few infiltrating leukocytes were observed in the brain-parenchyma on day 9 
p.i. Interestingly, unlike B6.WT, many degenerating neurones were observed in the 
pyramidal cells of the hippocampus (Figure 7.10 c and d). The hippocampus from mock-
infected B6.J.!MT -I- mice showed normal histology (Figure 7.10 b). 
7 .3.8. Detection Qf WNY antigen in B6.uMT -/- mice 
The pattern and extent of WNV Ag in the brain and spinal cord was determined by 
immunoperoxidase labelling. No WNV Ag was detected in the brain parenchyma from 
mock-infected B6.J.!MT-/- mice (Figure 7.11 a). On day 9 p.i., WNV Ag was detected 
throughout the brain parenchyma and cervical spinal cord. Like B6.WT, WNV Ag was 
confined only to the neuronal cytoplasm and processes (Figure 7 .II b, d and e). Very large 
numbers of neurones were infected in the brainstem (Figure 7.11 b), cortex, hippocampus 
(Figure 7.11 c and d) and also in the cervical spinal cord, with both motor (Figure 7.11 e) 
and sensory neurones (Figure 7 .II f) infected. These data indicate that CNS infection is 
more extensive and spreads at a significantly higher rate throughout the brain in the genetic 
absence of functional Ab. 
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Figure: 7.9 Survival after i.p. inoculation of WNV in B6.Wf and B6.jtMT -1- mice. Groups of 
20 mice from B6.Wf and 15 mice from B6.jtMT-1- mice were inoculated i.p with 6x104 
pfu/mouse. They were monitored for signs of illness 3 times a day over 21 days. The percent 
survival at each time point is shown. Mock-infected mice did not develop signs of illness in 
either group. 
Figure: 7.10 Hand E stained brain sections of mock-infected and WNV-infected B6.JlMT-/-
mice on day 9 p.i. Infected brain parenchyma showed infiltration of leukocytes with perivascu-
lar cuffing (a) (solid arrow), activation of microglia (a) (open arrows) and extensive neuronal 
degeneration in the hippocampus (c) and (d) (solid arrows). The hippocampus from mock-
infected mice showed normal histology (b) (solid arrows). Scale bar= 100 f..tm. 
Figure: 7.11 WNV-infected B6.J.!MT-/- mouse brain sections labelled with anti-
WNV antibody on day 9 p.i. No WNV antigen was detected in the mock-infected 
brain parenchyma (a). On day 9 p.i., extensive neuronal infection was observed 
throughout the brain, including brainstem (b) (solid arrows), cortex (c) (solid 
arrows) and hippocampus (c) (open arrows). In the hippocampus, all neurones were 
infected (d) (solid arrows). At this timepoint, high numbers of infected motor 
neurones (e) (solid arrows) and sensory neurones (f) (solid arrows) were observed in 
the cervical spinal cord. Scale bar= 50~-tm a-b, d and e-f and 300J.!m c. 
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7 .4. Discussion 
Data presented in the previous chapter demonstrated that WNV was lethal, with I 00% 
mortality when inoculated i.n. in both strains of mice, but the same dose of WNV caused 
only 60% mortality in B6.WT and approximately 17% mortality in B6.IFN-y-/- mice. 
Therefore, WNV was titrated in both strains of mice in the i.n. model to determine a 
sublethal dose of WNV for this route of inoculation. Mice from both groups were highly 
susceptible to 6xl04 pfu/mouse and 6xl03 pfu/mouse, with 100% mortality, but showed 
extended survival when inoculated with lxl02 pfu/mouse (Figure 7.1). Thus B6.WT showed 
85% mortality and B6.IFN-y-/- showed 65% mortality. Surviving mice appeared healthy 
These data indicate that in the i.n. model as well, disease outcome is dependent on dose of 
WNV. Previously, it was demonstrated (chapter 3) that mice surviving primary infection 
completely abrogate encephalitis upon rechallenge with 50-fold the original dose of WNV. 
Thus, surviving mice from either group in the i.n. model primarily infected with the lowest 
dose of WNV were also rechallenged i.n. with a 600-fold higher dose WNV. Interestingly, 
these mice also completely abrogate encephalitis. This data further confirms that, as in the 
i.p. model, IFN-y is not required for the generation of primary or secondary immunity 
against WNV in the i.n. model. 
To investigate whether the generation of secondary immunity is mediated via immune cells 
or Ab or both, naive mice were adoptively transferred with HI serum or splenocytes in these 
models. The role of Ab in WNV encephalitis was further confirmed by using B6./lMT-/-
mice compared to the corresponding wild type mice. Before passively transferring HI or 
normal sera the IgG titre and efficacy was determined using PRNT, as an in vitro test for the 
efficacy of neutralization. Twenty four hours after passive transfer of sera or splenocytes 
into naive mice, they were infected either i.p. or i.n. with WNV at 6xl04 pfu/mouse. Mice 
were monitored for signs of clinical illness, survival and histopathology, as well as WNV 
Ag in the CNS. 
It is clear that Ab plays an important role in controlling neurotropic viral infections. Most 
previous studies on neurotropic viral encephalitis is based on passive transfer of either 
monoclonal or polyclonal Ab. In HSV infection, passive transfer of HI serum protected 
mice from death and neurological diseases compared to control mice treated with normal 
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serum (McKendall et al. 1979). Experiments with flaviviruses also showed that passive 
transfer of immune Ab can protect mice from lethal infection (Kimura-Kuroda & Y asui 
1988; Chiba et al. 1999; Kreil and Eible 1997). Antibody also plays an important role in 
alphavirus infection. SBV infection in mice is perhaps the most extensively studied model 
in the evaluation of the role of Ab in neurotropic viral infections. Genetic absence of either 
IFN-a/[3 or IFN-a/f3 receptor makes mice highly susceptible to a number of viral infections 
(Muller et al. 1994; Durbin et al. 2000). However, this susceptibility can be overcome by 
passive transfer of Ab. Thus passive transfer of monoclonal Ab was found to protect mice 
completely in the absence of IFN-a/f3 in SBV infection (Byrnes et al. 2000). Moreover, 
passive transfer of HI serum could also protect mice from SBV infection in the complete 
absence ofT and B cells, as shown by Levine et al. (1991). 
In the i.p. model of WNV encephalitis, mice passively transferred with HI serum 24h before 
infection were completely protected and appeared healthy until 14 days p.i., compared to 
mice passively transferred with normal serum or left untreated prior to WNV infection 
(Figure 7.6 A). Kimura-Kuroda & Yasui (1988) showed that passive administration of 
monoclonal Ab 24h before i.v. inoculation of JE virus increased protection, but the same 
Ab, if transferred 24h after infection, showed lower protection from lethal JE infection. In 
contrast, in TBE infection, passive transfer of Ab was effective at both 24h before and after 
peripheral infection, but not 48h after TBE infection (Chiba et al. 1999). Interestingly, in 
the i.p. model of WNV encephalitis, complete protection was observed even after passive 
transfer of HI serum 48h p.i. (Figure 7.5 A). The brain parenchyma of HI serum-treated 
mice showed normal histology and no WNV Ag was found on day 7 and 8 p.i. Moreover, 
these mice were completely protected upon rechallenge with a 50-fold more WNV than the 
original dose. It is not known whether this denotes the development of adaptive immunity, 
or whether the passively transferred Ab continued to be efficacious in these mice. Although 
Peiris & Porterfield (1979) showed Ab-dependent enhancement of infection in an in vitro 
culture system, this was not observed in WNV encephalitis. 
WNV encephalitis in the i.p. model reflects immunopathology. Results from this chapter 
showed that passive transfer of HI serum 24h before and 48h after infection can completely 
abrogate IFN-y-mediated immunopathology in the i.p. model. Similar results were also 
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found in LCMV infection (Wright & Buchmeier 1991). LCMV infection is a T-een-
mediated immunopathological disease (Zinkernagel 1992). Wright & Buchmeier (1991) 
showed that passive transfer of monoclonal Ab one or two days before infection completely 
protected mice from lethal LCMV immunopathological disease. In their model, LCMV was 
inoculated i.e. after passive transfer of Ab. They found both suppressed viral replication and 
a specific cytotoxic T-cell response in surviving mice. 
Interestingly, unlike the i.p. model, in the i.n. model, mice passively transferred with the 
same dose of HI did not protect mice from disease. All mice treated with HI serum died by 
day 7 p.i., similar to normal serum-treated or untreated mice (Figure 7.5 B). 
Immunohistochemistry showed extremely high brain infection, similar to the normal 
serum-treated or untreated mice, suggesting that HI serum does not provide passive 
protection against the i.n. route of WNV inoculation. Dietzschold et al. (1992) have shown 
that passive transfer of monoclonal Ab protected rats against lethal rabies virus infection 
after i.n. inoculation. In control rats, rabies virus RNA was observed in the OB and front 
cortex after 6-12h p.i. respectively, but was not detected in Ab-treated mice even after 30 
days p.i. HI serum can also passively protect mice against i.e. challenge (Chaturvedi et al. 
1977; Byrnes et al. 2000; Wright & Buchmeier 1991). 
It was speculated that in the i.n. model of WNV encephalitis, a higher dose of neutralizing 
Ab may be required to protect mice from lethal WNV infection. Therefore, a 750-fold 
higher dose of HI serum than the original neutralizing dose was transferred into naive mice 
24h before i.n. inoculation of WNV. Mice thus treated survived longer, compared to control 
mice treated with a 750-fold higher dose normal serum (Figure 7.6). However, only 13% of 
mice were able to survive until day 14 p.i. when they were sacrificed. Moreover, some of 
the surviving mice showed hindlimb paralysis, which was not previously observed in the 
i.n. model. More interestingly, on day 8 p.i. the brain parenchyma of moribund mice that 
had been treated with high dose HI serum showed very few infected neurones (Figure 7.8 d) 
in the front cortex. Surprisingly, none of the neurones in the OB and hippocampus showed 
detectable WNV infection, while mice treated with normal serum or left untreated showed 
extensive neuronal infection in the OB and front cortex at the time of death (Figure 7.8 a 
and b). 
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These data suggest that high dose HI serum-treated mice are not dying due to brain infection 
as in normal serum-treated or untreated mice, which died due to overwhelming brain 
infection. The mice that survived on day 11 and 13 p.i. showed infection of motor neurones 
in lumbar, thoracic and cervical spinal cord, but no detectable neuronal infection in the OB. 
Very few infected neurones were observed in the front cortex at day 13 p.i. (Figure 7.8). 
Highly activated microglia were observed throughout the brain, but not in the OB. Thus, 
entry of WNV via the olfactory route seems unlikely in these mice. These data indicate that 
passive transfer of high-dose HI serum extends survival in the i.n. model but suggests that it 
may also alter the route of WNV entry into the CNS. However, it is not clear how and why 
this route is altered in the presence of high dose Ab. 
Since passive transfer of high-dose HI serum was unable to completely protect mice in the 
i.n. model, I speculated that effective immunity against WNV might occur via immune cells 
in the i.n. model. Therefore, mice were adoptively transferred with HI splenocytes 
5xl07/mouse 24h before i.n. infection. Mice adoptively transferred with HI splenocytes 
showed the same disease outcome, with 100% mortality, by day 7 p.i. as that of normal 
splenocytes-treated and untreated mice (Figure 7.7). However, i.n. WNV-immune mice can 
abrogate encephalitis and death even with a 600-fold higher dose of WNV than the original 
dose. This data raises the question of whether the brain needs to be infected to become 
immune. Murali-Krishna and Manjunath (1996) have shown that adoptive transfer of 
JE-specific CD8+ T cells when co-inoculated with JE virus via i.e. protected mice from 
lethal JE, but the same CD8+ T cells were unable to protect mice when adoptively 
transferred via i.p. or i.v. in this model. Thus, adoptive transfer of splenocytes via i.e. before 
infection or at the time of i.n. infection could answer the question of whether these cells can 
abrogate encephalitis in the i.n. model. Unfortunately, HI splenocytes were not used as a 
positive control in the i. p. model. It is therefore possible that this experiment may not have 
worked for technical reasons. This will be addressed in future experiments in this 
laboratory. 
Complete passive protection was observed in the i.p. model with HI Ab administered either 
before and after infection. Therefore, the role of Ab in the i.p. model was further 
investigated using B6.!lMT-I- mice, compared to B6.WT mice to determine whether Ab is 
critically important in the normal immune response to WNV infection. As expected, it was 
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found that B6.~tMT -I- mice were highly susceptible to WNV infection, with 100% mortality 
within 6-9 days p.i., compared to B6.WT (Figure 7 .9). A similar result was found by Liu 
and Chambers (2001) in YF virus infection and by Beland et al. (1999) in HSV 
encephalomyelitis. On day 9 p.i., many neurones had degenerated in the hippocampus 
(Figure 7 .I 0 c and d). At this timepoint, WNV Ag was observed throughout the brain 
parenchyma. Extremely high neuronal infection was observed both in the brain and spinal 
cord (Figure 7.11 ), suggesting that Ab plays an important role in restricting WNV spread in 
in vivo. This can be acquired either via passive transfer of HI serum or monoclonal Ab 
(Matthews et al. 2001; Levine et al. 1991; Dietzschold et al. 1992) or local production of 
Ab in the CNS (Tyor & Griffin 1993; Hatalski et al. 1998). However, depending on the 
route of infection, Ab may not be enough to control WNV infection of the CNS. 
In conclusion, complete protection via passive transfer of HI serum was observed only in 
the i.p. model. In contrast, in the i.n. model, the same dose of HI serum as given to the nai:ve 
mice in the i.p. model, failed to protect mice from lethal WNV encephalitis. Extensive brain 
infection was observed in these mice, similar to the normal serum-treated or untreated mice. 
Very high dose HI serum was required to extend survival in the i.n. model, however, even 
this was still unable to protect the majority of mice, although a few survived, at least until 
day 14 p.i., when they were sacrificed. Some of the surviving mice in this model exihibited 
paralysis. In normal serum-treated mice, WNV used the olfactory route to enter the brain. 
But HI serum-treated moribund mice, on day 8 p.i. showed no infection of OB and very 
little neuronal infection in the front cortex. More interestingly, WNV Ag was detected in the 
spinal cords of surviving mice on day 11 and day 13 p.i. These data indicate that mortality, 
as well as disease profile, can be changed in the presence of high dose HI serum in the i.n. 
model. In the i.n. model, the adoptive transfer of HI splenocytes also completely failed to 
protect mice. B cell-deficient mice were highly susceptible to WNV infection. Extensive 
neuronal infection and extensive neuronal degeneration occurred in the absence of Ab. 
Taken together, these data show that Ab plays an important role in protecting mice from 
WNV infection. In the absence of functional Ab, the CNS is highly vulnerable to the 
uncontrolled spread of WNV infection, which leads to death. 
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Chapter-S 
General Discussion 
WNV encephalitis is one of the emerging mosquito-borne flaviviral diseases in the new 
world. Periodically, unusal epidemic outbreaks of WNV encephalitis occur in the world 
with high morbidity and mortality. Although WNV has been isolated since 1937 (Smithbum 
et at. 1940), little is known about the pathogenesis of encephalitis caused by this virus. Most 
of the previous work with flaviviruses has been done in neonatal or young mouse models. 
Encephalitis develops more readily and is more severe in young mice due to the immature 
immune system and less completely developed BBB. Therefore, an adult murine model was 
developed in this project to understand better the mechanisms of pathogenesis of WNV 
encephalitis in adult mice. The results reported in this thesis highlight the role of IFN-y in 
survival and development of disease in WNV encephalitis acquired by peripheral routes. A 
plausible antiviral role for microglia was also observed in this study. In addition, the role of 
immune Ab in protecting mice against disease was clearly found to depend on the route of 
original infection. A summary of the pathogenesis of disease in i.p. and i.n. models is 
presented in figure 8.1 and 8.2, respectively. 
8.1. Pathogenesis of WNV encephalitis after i.p. inoculation 
8.1.1. WNV encephalitis is an immunopathological disease 
IFN-y is produced predominantly by T cells and NK cells (Harty 2000; Salazar-Mather et 
at. 2000; Christensen et at. 1999) and is one of the most important cytokines regulating 
immune and inflammatory events (Benveniste 1998; Boehm et at. 1997). It inhibits viral 
replication, either directly (Kohonen-Corish et at. 1990) or by activating other antiviral 
defences, including those mediated by CTL, NK cells and macrophages (Billiau 1996; 
Munoz-Fernandez & Fresno 1998). Thus, it plays an important role in the generation of 
immunity in a number of viral infections (Nansen et at. 1998; Huang et at. 1993; Bouley et 
at. 1995; Karupiah et at. 1990). Data presented in this thesis clearly demonstrate that IFN-y 
is not required for survival or generation of immunity against WNV infection after i.p. 
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inoculation. On the contrary, genetic absence of IFN-y significantly reduced mortality from 
WNV encephalitis (see figure 3.2). Therefore, this data indicates a role for IFN-y in the 
generation of immune-mediated pathology or immunopathology leading to death from 
WNV encephalitis. 
The incidence of flaviviral encephalitis remains a serious health problem in the tropical and 
subtropical areas of the world. These viruses predominantly infect neurones in the brain. 
They either directly kill or damage neurones (Despres et al. 199S; Hase et al. 1990) or 
infection is accompanied by a vigorous immune response within the CNS which in itself 
causes severe damage to the host (Andrews et al. 1999; Zinkernagel 1992). The presence of 
the BBB, which normally prevents entry of protein and limits entry of immune cells to that 
of activated T cells (Hickey et al. 1991), the low or absent expression of MHC molecules 
and the nonreplacable nature of neurones, make the CNS a unique organ system for the 
study of immunopathogenesis (Griffin et al. 1992). The mechanisms involved in causation 
of immunopathology in viral encephalitis include immune cytolysis, delayed-type 
hypersensitivity reactions, formation of immune complexes and autoimmune reactions. 
These result in lysis of infected cells, necrosis, demyelination, tissue destruction, 
haemorrhage and functional alteration of CNS resident cells, especially neurones (Lohler 
19SS). 
Lymphocytic choriomeningitis has been extensively studied as an animal model of virus-
induced immunopathological disease (Zinkernagel 1999). In this model, severe 
inflammation, mediated especially by MHC-I-restricted cos• T cells, results in an acute 
neurological disease leading to death, which can be prevented by depletion of cos• T cells 
(Doherty & Zinkernagel 1974). In contrast, in Borna disease, MHC-II restricted CD4+ T 
cells cause neurological disease in the rat model. The adoptive transfer of the MHC-II 
restricted T cell line NM1, specific for Borna disease virus, can also result in a progressive 
meningoencephlomyelitis (Richt et al. 19S9). Although pathology was associated with 
severe inflammation in these models, none could satisfactorily explain the exact cause of 
death. In LCMV infection, despite severe infiltration of T cells in meninges, ependyma and 
choroid plexus, only a low level of cell damage could be seen in these areas under both light 
and electron microscopy. This was not thought to be enough to explain the cause of death 
(reviewed by Lohler 19SS). In addition to these areas, cos• T cells were also detected in 
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the brainstem and cervical spinal cord in this model, but the absence of significant neuronal 
destruction or degeneration makes it hard to believe that CTL lysis is the cause of death in 
LCMV infection (reviewed by Lohler 1988). Besides cytolysis, CD8+ T cells can also exert 
antiviral functions via secretion of IFN-y (Harty et al. 2000; Klavinskis et al. 1989). 
Increasing evidence suggests that in the absence of IFN-y, CD8+ T cells can not clear virus, 
despite their potent CTL activity in LCMV infection (Bartholdy et al. 2000; Von Herrath et 
al. 1997). Furthermore, it has been reported that treatment of mice with sheep anti-IFN-y 
protected mice from fatal LCMV infection, despite enhanced virus replication in the CNS 
(Leist et al. 1989). Therefore, it can be argued that generation of immunopathology by 
CD8+ T cells in LCMV infection, as well as virus clearance, may be mediated via increased 
secretion of IFN-y. 
The disease-promoting role of IFN-y emerged from work in MS in the 1980s, when IFN-y 
was used as a therapeutic agent for MS. MS is a chronic inflammatory neurological disease 
of humans, characterized by infiltration of leukocytes into the CNS with localized myelin 
destruction and loss of oligodendrocytes and axons (Al-Omaishi et al. 1999). A small 
clinical trial using IFN-y for treating MS patients showed a worsening of disease after 
administration of IFN-y in these patients (Popko et al. 1997). This study opened the door to 
the further understanding of the role of IFN-y in disease progression. Detection of increased 
numbers of IFN-y-secreting T cells in the CSF of MS patients and IFN-y in postmortem 
samples (Billiau 1996) further provided evidence for the involvement of IFN-y in the 
progress of disease. Moreover, adoptive transfer of IFN-y-secreting T cells isolated from 
animals affected by EAE, induced EAE in the adoptive host animals. In EAE also, increased 
numbers of IFN-y-secreting T cells were observed in the CNS shortly before the onset of 
clinical signs. These signs could be inhibited by treatment with anti-IFN-y Ab (Olsson 
1995). 
The role of IFN-y in MS and EAE clearly suggests that IFN-y can also play an 
immunopathological role in viral encephalitis. In the CNS, the source of IFN-y seems 
almost exclusively to depend upon infiltrating T cells (Binder & Griffin 2001; Hammarberg 
et al. 2000; Finke et al. 1995; Cantin et al. 1995; Krakowski & Owens 1996), although CNS 
resident cells are also capable of producing IFN-y upon stimulation (Mori et al. 2001; 
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Morris & Esiri 1998). Since T cells generally do not enter into the CNS due to the presence 
of the BBB, IFN-y is generally not present in the normal CNS. However, during CNS 
infection and neurological disorders, increased numbers of these cells immigrate into the 
CNS and produce large amounts of IFN-y there. In this manner CNS resident cells are 
exposed to the potent effect of IFN-y. Moreover, IFN-y plays a key role in leukocyte 
recruitment into the CNS (Liu & Chambers 2001; Baumgarth & Kelso 1996) by inducing 
several different chemokines (Simpson et al. 2000; McManus et al. 2000; Liu et al. 2001; 
Boehm et al. 1997). They are synthesized locally at sites of inflammation by different cell 
populations, including leukocytes, endothelial cells and CNS resident cells and may be 
located at or near the endothelial surface in association with other molecules to establish a 
concentration gradient. Leukocytes then transmigrate into the CNS in a concentration-
dependent manner (Boehm et al. 1997). 
The data presented in this thesis demonstrate that in WNV encephalitis significant numbers 
of leukocytes infiltrate into the brain parenchyma of wild type mice, compared to 
IFN-y-deficient mice. Thus there was approximately 4-fold difference in the number of 
infiltrating leukocytes in the brain parenchyma on day 7 p.i. between the groups (see figure 
3.1 0). This finding correlated with disease outcome in wild type mice. Significantly higher 
mortality occurred in wild type mice compared to IFN-y-deficient mice (see figure 3.2), 
despite there being no significant difference in the number of neurones infected (see figure 
3.9) or virus titres (see figure 3.8) in the brain between the strains. These data indicate that 
the cause of death in adult mice is not due to WNV by itself in this model. The paucity of 
significant neuronal death, despite high leukocyte infiltration in the brain parenchyma of 
wild type mice (see chapter 4 ), makes death mediated by cos+ T cells via cytolysis 
unlikely. Therefore, it seems likely that the cause of death in wild type mice was attributable 
to infiltrating T cells via increased secretion of IFN-y. However, which subset of leukocytes 
is linked to this in immunopathogenesis is not yet clear. 
Although chemokines play an important role in guiding leukocyte migration towards the 
site of inflammation, the process of transmigration is thought to begin with activation of 
endothelial cells. Endothelial cells are activated by proinflammatory cytokines leading to 
increased expression of CAM such as selectins and the immunoglobulin superfamily CAM 
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(Meager 1999; Imhof & Dunon 1995). Strong adhesion to the endothelial cells is required 
for extravasation of circulating leukocytes. Therefore, phenotypic alteration in the 
neurovascular endothelial cells with expression of CAM is required for extravasation. 
Selectins are involved in initial attachment and rolling of leukocytes along the vessel wall, 
whereas ICAM-1 and VCAM-1 provide firm adhesion by interacting with leukocyte 
integrins, LFA-1 and VLA-4, respectively. These integrins are constitutively expressed on 
the surface of leukocytes. Therefore, expression of ICAM-1 and VCAM-1 on the 
neurovascular endothelium is crucial for transmigration of leukocytes into the CNS 
parenchyma. These molecules are absent or expressed at low levels under normal conditions 
(Matyszak 1998). However, they are induced and upregulated during inflammation to 
recruit inflammatory leukocytes into the CNS. This initiates a cascade of inflammation in 
the CNS (Irani & Griffin 1996; Engelhardt et al. 1994; Lassmann 1997). 
It has been shown that IFN-y is responsible for induction of these molecules in both in vivo 
and in vitro culture systems (Deckert-Schluter eta! 1999; Zielasek et al. 1993; Lee et al. 
1999; Campbell et al. 1989). However, data presented in this thesis show that upregulation 
of ICAM-1 and VCAM-1 in WNV encephalitis is independent of IFN-y. Besides IFN-y, 
other cytokines, eg., IL-la/P, TNF and IIA can also induce upregulated expression of 
these molecules (Meager 1999; Shen et al. 1997; Mickelson et al. 1995; Wong & Dorovini-
Zis 1992; Fabry et al. 1992; Masinovsky et al. 1990). It is likely that one or more of these 
cytokinesis responsible for the induction of high levels of ICAM-1 and VCAM-1 in IFN-y-
deficient mice in WNV encephalitis. 
It has been suggested that low levels of ICAM-1 and VCAM-1 expression are sufficient to 
recruit leukocytes into the CNS of IFN-y-deficient mice (Deckert-Schluter et a! 1999). 
Increased expression of these molecules increases the avidity of cell-cell interactions and 
subsequent migration (Bochner et al. 1991; Shimizu et al. 1991). However, data presented 
in this thesis show that despite extremely high expression of ICAM-1 and VCAM-1 in IFN-
y-deficient mice compared to wild type mice (see chapter 5), significantly lower numbers of 
leukocytes were observed to infiltrate into the brain in WNV encephalitis in IFN-y-deficient 
mice (see chapter 3). Greater upregulation of these molecules was not sufficient in itself to 
enable the migration of large numbers of leukocytes into the brain parenchyma of IFN-y-
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deficient mice. This suggests that recruitment of greater numbers of inflammatory cells into 
the brain parenchyma may require IFN-y-induced chemokines, in addition to increased 
ICAM-1 and VCAM-1 expression. The data also show that in addition to increased 
endothelial cell expression, increased levels of ICAM-1 was also observed on the microglia 
in the absence of IFN-y. The actual role of ICAM-1 expression in glial cells has not been 
elucidated, however, it is assumed that they may involved in guiding infiltrating leukocytes 
into and through the CNS parenchyma (Merrill & Benveniste 1996). They are also involved 
in neuronal degeneration (Dallasta et al. 2000). However, the absence of neuronal 
degeneration in IFN-y-deficient mice, despite high microglial ICAM-1 expression suggests 
there may be some other role for this molecule on microglia in WNV encephalitis. More 
detailed investigation is required to address these issues. 
The mechanism by which IFN -y exacerbates disease in MS and EAE is still unresolved. It is 
thought to be associated with demyelination occurring with the death of oligodendrocytes 
due to the cytotoxic effects of activating macrophage/microglia. This decreases 
demyelination and axonal necrosis in MS and EAE (Popko et al. 1997). IFN-y is a potent 
inducer of IDO and NOS2 (Karupiah et al. 1993; Takikawa et al. 1990) and can contribute 
to immunopathology by inducing these molecules within the CNS (Maloney et a/. 2000; 
Lane et a/. 1999). For example, increased induction of IDO can significantly decrease the 
levels of tryptophan within the CNS, which is highly correlated with serotonin. Serotonin is 
a neurotransmitter; decreases in tryptophan levels can significantly alter CNS function and 
lead to death (Maloney et al. 2000). IDO expression was evaluated in this project to 
determine whether IFN-y contributes to immunopathology via induction of IDO in the brain 
parenchyma. This study showed that expression of IDO was hardly detectable within the 
CNS in wild type mice (data not shown). This suggests that the immunopathological role of 
IFN-y via the induction of IDO is unlikely in WNV encephalitis. Alternatively, NOS2 may 
be involved in the progression of disease via the production of reactive nitrogen species 
such as NO in WNV encephalitis. NOS2 associated with the progression of disease in many 
other neurotropic viral infections (Rose et a/. 1998; Lane et al. 1999; Andrews et al. 1999). 
In these models, neutralization of NOS2 by aminoguanidine significantly reduced mortality 
and disease. Therefore, an experiment was set up to neutralize NOS2 using aminoguanidine 
in wild type mice. Amino guanidine is a selective inhibitor of NOS2 (reviewed in Cross et 
al. 1994 ). This study showed that there was no difference in mortality between 
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aminoguanidine-treated and untreated animals (data not shown), suggesting that progression 
of disease by IFN-y via induction of NOS2 is also unlikely. Due to the lack of significant 
IDO induction, neuronal death as well as negligible role of NOS2 in these mice, alteration 
in vital functions of neurones mediated by IFN-y may be the only other alternative to 
explain the cause of such a fatal disease in WNV encephalitis. However, how IFN-y may be 
involved in altering neuronal function or how it exerts its action in the CNS in WNV 
encephalitis is not resolved. 
8.1.2. Is a clearance of WNV from brain mediated via microglia? 
Mice deficient in IFN-y exhibit increased neuronal infection in many neurotropic viral 
infections, suggesting a role for IFN-y in termination of both acute and persistent infection 
in the CNS (Bartholdy et al. 2000; Christensen et al. 1999; Geiger et al. 1997; 
Lewandowski et al. 1998; Tishon et al. 1995). However, data presented in this thesis show 
that clearance of WNV from the CNS is independent of IFN-y (see chapter 3). WNV was 
cleared from the brain parenchyma in the complete absence of IFN-y, although a greater 
percentage of IFN-y-deficient mice had neuronal infection compared to wild type mice (see 
figure 3.7). It is therefore possible that CNS resident cells, in particular astrocytes and 
microglia participate in controlling viral infection in the CNS in an IFN-y-independent 
manner .. 
Microglia and astrocytes are important glial cells which provide physical and metabolic 
support, as well as protection of neurones from subtle changes in the CNS environment, 
thus helping to maintain neuronal function (Afifi & Bergman 1998). These glial cells also 
respond to various infectious and inflammatory stimuli by producing a range of different 
cytokines, chemokines, cytotoxic metabolites and growth factors, as well as upregulating or 
expressing de novo various immune receptor molecules. These molecules enable immune 
function in conjunction with the peripheral immune system within the CNS (Chao et al. 
1994; Merrill et al. 1996; Brodie et al. 1997; Dallasta et al. 2000; Glabinski et al. 1999; 
Grzybicki et al. 1997; Benveniste 1992; Schijns et al. 1991; Persidsky et al. 1999; Sauder et 
al. 2000; Asensio et al. 1999). Thus, these cells are regarded as immunocompetent cells of 
the CNS, able themselves to mount immune responses. 
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Astrocyte activation, astrogliosis, has been demonstrated in many viral infections both in 
vivo and in vitro (Weissenbock et al. 2000; Schoneboom et al. 1999; Bi et al. 1995; Chen et 
al. 2000; Liu et al. 1989; Medana et al. 1996) and is thought to be mediated by IFN-y 
(Balasingam et al. 1994; Yong et al. 1991). Data from this project show that in WNV 
encephalitis astrocytes were very rarely activated in either group of mice. Thus the presence 
or absence of IFN-y neither induced astroglial activation nor reduced its activation (see 
chapter 4). These data indicate that astrocytes do not usually play a role in WNV 
encephalitis. 
Although astrocytes act as immunocompetent cells of the CNS, immune defence within the 
CNS is predominantly provided by microglia (Cross & Woodroofe 2001; Mori et al. 2001; 
Chao et al. 1994 ). Therefore, microglia are seen as the first line of defence in the CNS in 
inflammation, infectious diseases, brain tumors, neurodegeneration, etc., (Kreutzberg 1996). 
Once activated, they can destroy invading microorganisms, remove cell debris, as well as 
enhance neuronal survival by secreting many different neurotrophic factors. They thus 
facilitate a return to normal tissue homeostasis (Kreutzberg 1996, Nakajima & Kohsaka 
1998). Microglia in the normal adult brain display ramified morphology with small somata 
and numerous thin processes (Ling & Wong 1993) and in the resting state either do not 
express or express low levels of immune molecules (Streit et al. 1999; Raivich et al. 1999). 
Microglia are of monocyte origin and exhibit macrophage-like activity upon activation 
(Davis et al. 1994 ). Activation occurs in a graded fashion, as seen by the alteration of 
morphology from resting to activated and then reactive forms. Activated microglia have 
large cell bodies with shorter, stouter processes and are non-phagocytic, whereas reactive 
microglia no longer display any processes and exhibit a pleomorphic morphology, 
commonly including spherical and rod shapes. Reactive microglia are also known as 
amoeboid microglia and are phagocytic in nature (Raivich et al. 1999; Streit et al. 1999). 
Reactive microglia are involved in the formation of nodules which is a prominent feature of 
viral encephalitis (Dickson et al. 1991 ). 
There are several schools of thought about microglial activation. One suggests that 
microglial activation is mediated by stressed neurones (Sudo et al. 1998). Another proposes 
their activation is mediated by IFN-y (Grau et al. 1997; Meda et al. 1995; Sethna et al. 
1991) or infiltrating leukocytes (Langford & Masiah 2001; Gehrmann et al. 1993, Aloisi et 
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al. 2000; Sedgwick et al. 1998; Bauer et al. 1995). Data from this project show that 
microglia were highly activated in both WNV-infected wild type and IFN-y-deficient mice, 
displaying both activated and amoeboid morphology in both strains (see chapter 4). Thus, 
this study indicates that microglial activation can be independent of IFN-y. The data 
presented in this thesis also show that infiltration of leukocytes was observed 48h before 
activation of microglia (Figure 4.4). It is possible therefore, that their activation may have 
been mediated by these infiltrating leukocytes. However, data from mice inoculated i.n. 
with WNV demonstrated that microglia were activated 48h before infiltration of leukocytes 
in the brain (see chapter 4 and 6), indicating that microglial activation is independent of 
infiltrating leukocytes in the CNS in WNV encephalitis. Indeed, it could be argued that in 
the i.p. model leukocyte infiltration delayed microglial activation, although it may enhance 
activation in other models (Aloisi et al. 2000). 
The facial-nerve transection model shows that microglia activate in response to stressed 
neurones (Kreutzberg 1996). The data presented in this thesis show that microglia were 
activated within 24h of WNV Ag detection in the brain parenchyma only at or near the sites 
of demonstrable neuronal infection in both groups of mice in the i.p. model. The number of 
activated microglia subsequently increased showing various morphologies, as well as 
nodule formation. The numbers of activated microglia declined and their morphology 
returned to the resting ramified state after WNV Ag was undetectable in the brain 
parenchyma in both groups of mice (see chapter 4 ). Thus, these data strongly suggest that 
microglial activation was induced by infected neurones and that these cells may be involved 
in clearing WNV from neurones. The appearance of increased numbers of microglial 
nodules with little evidence of neuronal death (see chapter 4) also indicates that the 
presence of microglial nodules does not equate with neuronal death. 
Recently, the antiviral capcity of microglia has been demonstrated in viral infection in an in 
vitro culture system (Cheeran et al. 2001). These microglia were found to produce antiviral 
cytokines like TNF, soon after CMV infection. These cells were able to control infection of 
astrocytes when co-cultured in vitro. In addition to this, microglia have also been shown to 
produce other potent antiviral cytokines like IFN-a and espress their receptors (Yamada et 
al. 1994; Akiyama et al. 1994; Yamada & Yamanaka 1995). These antiviral cytokines can 
dramatically reduce viral gene expression in the CNS (Akwa eta! 1998; Carr et al. 1998; 
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Schijns et al. 1991 ). Although, a cytokine study was not done in this project, it can be 
postulated that such high numbers of activated microglia would produce one or more 
antiviral cytokines in WNV encephalitis and thus may help to clear WNV from the infected 
neurones. Besides the production of anti viral cytokines, activated microglia can upregulate 
de novo expression of FeR and CR3 receptors on their surface (Nakajima & Kohsaka 1998). 
Thus, they might be involved in controlling WNV in conjunction with antibody produced 
locally by infiltrating leukocytes in the brain via non-cytotoxic mechanisms. Further study 
of microglia in these systems will help us to understand better the role of microglia in 
controlling WNV in the CNS. 
Data presented in this thesis show that more than 85% of surviving mice from both groups 
showed significantly high microglial activation in the absence of neuronal degeneration. 
Therefore, although microglia have been reported to be cytotoxic in the CNS (Banati et al. 
1993), data from this thesis do not support such a role in WNV encephalitis. On the 
contrary, activated microglia may have a protective role. They can produce several different 
kinds of neurotrophic growth factors, including NGF, BDNF, basic fibroblast growth factor, 
thrombospondin, plasminogen, IL-6, IL-l, IL-11), TGF-13 and IL-3, etc,. These molecules 
are involved in survival, regulation and regeneration of neurones as well as remyelination 
(Soontomniyomkikj et al. 1998; Chamak et al. 1994; Mason et al. 2001; Hama et al. 1989; 
Kamegai et al. 1990; Frei et al. 1989; Giulian et al. 1994; Pratt & McPherson 1997; Elkabes 
et al. 1996; Mallat et al. 1989; Shimojo et al. 1991; Nakajima et al. 1992). A possible 
protective role for microglia is supported by the ischaemic lesion model in CSF-1-deficient 
mice. CSF-1 acts as a potent mitogen for microglia and its absence resulted in abnormal 
microglial activation, associated with increased neuronal susceptibility to ischaemia 
(Berezovskaya et al. 1995). 
In the CNS, microglia represent the local APC (Shrikant 1996), although MHC-II is 
normally absent or expressed at low levels on these cells (Griffin et al. 1992). The induction 
of MHC-II is required to present Ag to CD4+ T cells. Similar to MHC-II induction in 
peripheral cells, IFN-y is also a potent inducer of MHC-II in microglia (Deckert-Schluter et 
al. 1999; Pazmany et al. 2000; Aloisi et al. 1998) and increased expression in microglia has 
been observed in many neurological disorders and encephalitic models (Bo et al. 1994; 
Song & Jia 1999; Schmitt et al. 1998; Morioka et al. 1992; Caplazi & Ehrensperger 1998; 
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Figure: 8.1 Kinetics of WNV antigen detection, microglial activation and leukocyte 
infiltration in the i.p. model in B6.WT mice. WNV antigen (open arrows) in the 
neurones was first detected in the brainstem parenchyma on day 6 p.i. (a) with 
infiltrating leukocytes (k) (open arrow). No microglial activation was observed at 
this timepoint (f). Microglial activation (open arrows) was detected within 24h of 
neuronal infection, i.e., from day 7 p.i., with the formation of small nodules (solid 
arrows) (g). The number of infected neurones was increased (b) (open arrows) 
followed by increased leukocyte infiltration (I) (open arrows) at this timepoint. On 
day 11 p.i., very few infected neurones were detected (c) (open arrow) with 
significantly reduced leukocytes (m) (open arrows) (solid arrows show microglial 
nodules). At this timepoint microglia were still highly activated (h) (solid arrows). 
The morphology of activated microglia reverted almost to the ramified state (i) 
(open arrows) after WNV antigen was undetectable (d) in the brain parenchyma on 
day 15 p.i. Only the occasional leukocyte was detected at this timepoint (n), Some 
rod shaped microglia can be seen in H and E stained brain sections (n) (solid 
arrows). These stained faintly with GS-lectin (i). On day 30 p.i. activated microglia 
had completely reverted to the normal ramified state Gl. At this timepoint no WNV 
antigen (e) and leucocytes ( o) were detected. Scale bar = 40!lm for all pictures. 
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Gehrmann et al. 1993). Data presented in this thesis show that despite full activation in 
WNV encephalitis, not all microglia expressed MHC-11 in either group and the presence or 
absence of IFN-y did not influence levels of MHC-11 expression or the numbers of microglia 
expressing it (see chapter 4). Thus MHC-11 induction in microglia is not dependent on 
IFN-y in WNV encephalitis. 
8.2. Pathogenesis of WNV encephalitis via the i.n. route of inoculation 
Disease outcome often depends upon route of virus inoculation into the host. In neurotropic 
viral infections i.e. inoculation usually results in a fatal outcome, whereas peripheral 
inoculation produces sublethal disease (Hase et al. 1990; Richards et al. 1981; Nathanson & 
Cole 1970). Similar to i.e. inoculation, most neurotropic viruses also produce fatal disease 
when inoculated i.n., compared to peripheral inoculation (Carbone et al. 1987; Thach et al. 
2000). The data presented in this thesis also show that mice were highly susceptible to i.n. 
WNV inoculation, compared to i.p. inoculation in both wild type and IFN-y-deficient mice 
(see chapter 6). 
The pathogenesis of WNV encephalitis in the i.n. model was completely different from that 
of the i.p. model. After i.n. inoculation all mice died within 7 days p.i. (see figure 6.1). 
Virus titres in this model were nearly 5 log-fold higher in both groups of mice at the time of 
death, compared to peak titres detected in the i.p. model (see figure 6.2). Immunoperoxidase 
staining revealed widespread brain infection in both groups of mice in the i.n. model. 
However, despite far more extensive brain infection, than the i.p. model, WNV was 
restricted, like the i.p. model, only to the cytoplasm and major dendrites of neurones in both 
groups of mice. Although microglia were activated concurrently with the appearance of 
WNV Ag in the i.n. model, numbers of activated microglia were significantly fewer than 
infected neurones. Similarly, infiltration of leukocytes occurred 48h after detection of WNV 
Ag and the number of infiltrating leukocytes were significantly fewer than the number of 
infected neurones (see figure 6.9). Thus, this was the reverse of what was observed in the 
i.p. model. 
In the i.n. route of inoculation, WNV replicated very quickly in the brain, presumably 
before the development of an effective peripheral immune response could control it. These 
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Figure: 8.2 Kinetics of WNV antigen detection and microglial activation in the i.n. 
model in B6.WT mice. WNV antigen was first detected in the outermost layer of 
olfactory bulb (OB) neurones on day 3 p.i. (a) (open arrows) with concurrent 
activation of microglia at the site of neuronal infection (e) (open arrows). The 
number of infected neurones increased on day 5 p.i. (b) (open arrows) with 
concommitantly increased microglial activation (f) (open arrows). At this timepoint, 
both WNV antigen and activated microglia were observed in other areas of the 
(OB). On day 6 p.i. the number of infected neurones increased significantly (c) 
(open arrows) followed by high microglial activation (g) (open arrows). At the time 
of death, on day 7 p.i, almost all neurones were infected in the OB (d) (open arrows) 
with massive microglial activation, predominantly of the phagocytic form (h) (open 
arrows). Scale bar= 200J.!m for all pictures. 
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data suggest that extensive neuronal infection causes death in both groups of mice and that, 
unlike the i.p. model, IFN-y is not involved in the progression of disease in the i.n. model. 
In the absence of significant neuronal degeneration, despite extremely high WNV 
replication in the neurones, death may be associated with neuronal dysfunction in this 
model. Since 100% mortality occurred in the i.n. model with the chosen i.p. dose, WNV 
was titrated in the i.n. model to determine the sublethal dose in both strains of mice. It was 
found that the fatality was dose-dependent. Mortalities of 85% in B6.WT and 65% in 
B6.IFN-y-/- mice occurred with 100 pfu/mouse (see figure 7.1). This data further confirmed 
that WNV is highly neurotropic in mice when inoculated i.n. The surviving mice in both 
groups, when rechallenged with a 600-fold higher dose than the original dose, were 
completely protected. 
8.3. Portal of WNV entry into the CNS depends upon route of inoculation 
Neurotropic viruses can invade the CNS by haematogenous, olfactory or neural routes after 
peripheral inoculation. The haematogenous route has been observed in many neurotropic 
viruses. These viruses either infect neurovascular endothelial cells, or are transported 
through the endothelial cells without replication (Wisniewski et al. 1983; Coffin & Lu 
1957; Liou & Hsu 1998). Some viruses get access into the brain via diapedesis of infected 
leukocytes or by destruction of the BBB (Dallasta et al. 1999; Soilu-Hanninen et al. 1994; 
Johnson 1964). Data presented in this thesis show that WNV Ag was detected in brain 
neurones in the presence of an intact BBB and without neurovascular endothelial cell 
infection in the i.p. model. Similarly, none of the infiltrating leukocytes in the brain 
parenchyma was infected (see chapter 3). These data suggest that WNV does not use the 
haemtogenous route to invade CNS. Further studies by electron microscopy is required to 
exclude the possibility of neurovascular transendothelial transport of WNV into the brain in 
this model. 
Besides the haematogenous route, the olfactory neuroepithelium is obviously a portal of 
entry into the CNS after peripheral inoculation in several neurotropic viruses, including 
some flaviviruses (Monath et al. 1983; Albrecht 1962; McMinn et al. 1996; Vogel et al. 
1996; Charles et al. 1995; Reinacher et al. 1983). However, data from this project also show 
that the OB was not infected after i.p. inoculation of WNV at any time during the period 
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investigated. Therefore, WNV entry into the CNS via olfactory route seems unlikely (see 
chapter 3). 
Some neurotropic viruses, like rabies, human poliovirus and Barna disease virus, use 
pheripheral nerves as a route of CNS invasion from the periphery (Tang et al. 1999; 
Murphy et al. 1973; Nathanson & Bodian 1961; Carbone et al. 1987). These viruses 
replicate within nerves and are moved through the host via axonal transport. Data presented 
in this thesis show that WNV Ag was first detectable in the spinal cord motor neurones 24h 
before it was detected in the brainstem (see figure 3.4 and 3.6). Since these data were 
derived from an adult mouse model, another experiment was set up using 3-week-old mice 
to confirm these results. Interestingly, this study also showed a similar pattern of WNV Ag 
detection to that observed in the adult model (see figure 3.5). Specimens from postmortem 
human cases also revealed WNV Ag in the brainstem and spinal cords (Shieh et al. 2000). 
These data strongly suggest that WNV infects the spinal cord via retrograde axonal 
transport along motor nerves supplied by infected striated muscle after i.p. inoculation, and 
then invade brain parenchyma via transneuronal pathways. This study also shows that there 
was no difference in the route of CNS invasion in both wild type and IFN-y-deficient mice, 
indicating that IFN-y does not alter the route of CNS invasion. 
Similarly, neurotropic viruses can also invade the CNS by different routes after i.n. 
inoculation. In i.n. inoculation, viruses are introduced into the nasal cavity, which is 
innervated by both olfactory and trigeminal nerves (reviewed in Barnett & Perlman 1993). 
The receptor neurones of the neuroepithelium of the nasal cavity send axons to the brain 
where they first synapse with neurones of the OB. Many viruses use this route for brain 
invasion (Barnett & Perlman 1993; Plakhov et al. 1995; Charles et al. 1995). Some viruses 
use the trigeminal nerve. They infect the trigeminal ganglion initially, followed by 
anterograde transneuronal transfer to the spinal trigeminal nucleus (Perlman et al. 1989), 
with subsequent invasion of the rest of the brain. It has been also observed that some viruses 
use both olfactory and trigeminal routes (Esiri & Tomlinson 1984). In addition to these, 
viruses like pseudorabies use 3 different routes after i.n. inoculation to invade the CNS. 
These include the trigeminal, sympathetic and parasympathetic, but not olfactory routes to 
enter the brain (Babic et al. 1994 ). Data from this project show that WNV Ag was first 
detected only in the outermost layer of the OB (see figure 6.3 and 6.7) after i.n. inoculation 
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whereas no WNV Ag was detected in the cervical spinal cord and brainstem at this 
timepoint. After this WNV Ag was detected in other parts of the OB and brain proper, 
spreading in a rostral-to-caudal direction. Therefore these data strongly suggest that WNV 
uses the olfactory route to enter into the CNS after i.n. inoculation. Similar results have 
been found in other encephalitis models (Thach et al. 2000; Huneycutt et al. 1994; Barnett 
et al. 1993; Anderson et al. 1983). In conclusion, data presented in this thesis suggest that 
CNS involvement is influenced by the route of WNV inoculation and this determines the 
portal of entry into the CNS. 
Although WNV uses the olfactory route as a portal of entry into the CNS in the i.n. model, 
this route can be altered. In the preliminary study reported here on passive transfer of 
high-dose HI serum 24h before i.n. infection resulted in a pattern of disease pathogenesis 
similar to the i.p. model (see chapter 7). Here, WNV Ag was not detected in the OB, 
although a few infected neurones were observed in the front cortex of moribund mice on 
day 8 p.i. Surviving mice on days 11 and 13 p.i. showed infection of motor neurones in the 
cervical and lumbar spinal cord, respectively. However, WNV Ag was not detected in the 
OB at this timepoint (see figure 7 .8). Therefore, these data suggest that route of WNV entry 
into the CNS can be altered in the presence of high dose HI serum. However, how HI serum 
is involved is not known. 
8.4. The role of antibody in WNV encephalitis induced by different routes 
of WNV inoculation 
Although cell-mediated immunity makes a major contribution to controlling viral infections 
in the CNS (Binder & Kundig 1991; Binder & Griffin 2001; Christensen et al. 1999; Harty 
et al. 2000; Noske et al. 1998; Stohlman et al. 1998; Weidinger et al. 2000; Geiger et al. 
1997), humoral immunity also plays an important role in neurotropic viral infections 
(Matthews et al. 2001; Wright & Buchmeier 1991; Griffin et al. 1997; Levine et al. 1991; 
Dietzschold et al. 1992; Kapoor et al. 1982). Circulating Ab, especially antiviral Ab, 
functions to terminate primary infection and reduce the level of viraemia. This reduces or 
prevents disease and acts as a basis for protection against viral reinfection. Ab can be 
acquired after primary infection or by passive administration of HI or monoclonal Ab. 
Circulating antiviral Ab includes both neutralizing and non-neutralizing Ab (Griffin et al. 
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1997). Neutralizing Ab plays an important role in controlling infectious virus spread, as 
well as clearing viral RNA from neurones (Levine et al. 1991; Dietzschold et al. 1992; 
McKendall et al. 1979; Byrnes et al. 2000). The role of Ab in neurotropic viral infection has 
been extensively studied using passive transfer of HI serum (Chiba et al. 1999; Kreil & Eibl 
1997; Kimura-Kuroda & Yasui 1988; Wright & Buchmeier 1991). 
In this project preliminary studies were undertaken to evaluate the role of Ab by using 2 
approaches. These included passive transfer of HI serum in the i.p. and i.n. models and the 
use of J.LMT-1- mice. Mice surviving i.p. inoculation of WNV, when rechallenged with a 
50-fold higher dose of WNV than the original dose showed no clinical or histopathological 
signs of encephalitis. Moreover, passive transfer of low-dose HI serum into naive wild type 
mice 24h before or 48h after i. p. inoculation of WNV also resulted in the complete 
abrogation of encephalitis with 100% survival (see figure 7.6). These data indicate that 
passive transfer of HI serum can protect naive mice from IFN-y-mediated 
immunopathological disease in WNV encephalitis. It has been similarly shown that passive 
transfer of monoclonal Ab one or two days before infection completely protected mice from 
lethal LCMV immunopathological disease (Wright & Buchmeier 1991). 
Passive transfer of monoclonal Ab can inhibit rabies viral RNA after i.n. inoculation and 
thus protect rats completely from lethal rabies disease (Dietzschold et al. 1992). However, 
work presented here shows that passive transfer of the same dose of HI serum as that given 
in the i.p. model, into naive mice before i.n. inoculation did not protect mice from lethal 
WNV encephalitis. Indeed, all mice died with extensive neuronal infection (see figure 7.5). 
Since it was possible that the amount of Ab given was not sufficient to protect from lethal 
WNV encephalitis in this model, a 750-fold higher dose of HI than the original was 
transferred passively into naive mice 24h before i.n. infection. These mice survived longer 
compared to mice treated with low-dose HI serum, however only 13% mice survived until 
day 14 p.i. (see figure 7.6). Interestingly, mice surviving low-dose WNV i.n. inoculation, 
when rechallenged with a 600-fold higher dose of WNV than the original dose showed 
100% survival. It has been suggested that adoptive transfer of immune splenic cells can 
protect naive mice from lethal flaviviral encephalitis (Jacoby et al. 1980). Therefore, it was 
speculated that in the i.n. model, the protection may be mediated via T cells. Data presented 
in this thesis show that adoptive transfer of hyper-immune splenocytes, 5x107 splenocytes 
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per mouse 24h before i.n. infection also completely failed to protect mice from lethal WNV 
encephalitis (see figure 7.7). These data raise the question that whether brain need to be 
pre-infected to become "immune'' in the i.n. model. Further studies are required to address 
this question. In conclusion, data presented here indicate that the efficacy of passive 
protection depends upon the route of WNV inoculation. 
Use of !lMT-1- mice further emphasize the role of Ab in viral encephalitis. These mice are 
highly susceptible to neurotropic viral infections (Liu and Chambers 2001; Beland et al. 
1999). The preliminary study in !lMT-1- mice reported here also shows that these mice were 
highly susceptible to WNV infection, with 100% mortality by day 9 p.i., compared to wild 
type mice (see figure 7 .9). This study showed an extremely high number of neurones to be 
infected throughout the brain parenchyma and cervical spinal cord at this timepoint, as well 
as extensive neuronal degeneration in the hippocampus (see figure 7.10 and 7 .11). 
Therefore, Ab may play a role in WNV encephalitis by restricting WNV spread through the 
CNS, and by limiting the growth of virus in neurones, thereby protecting them from death. 
However, detailed studies are required to investigate this further. 
8.5. Conclusions and further perspectives 
The data presented in this study have demonstrated that IFN-y is not important for survival 
in primary WNV infection or generation of secondary anti-WNV immunity. It does not play 
a crucial role in the clearance of WNV from the CNS. However, it is critically involved in 
disease progression in the i.p. model. The precise mechanism by which IFN-y exerts its 
action in the CNS is not resolved. However, understanding these mechanisms may enable 
therapeutic approaches to treatment in the acute disease, since this model exhibits similar 
pathology to that observed in the human. 
This thesis also shows that ICAM-1 and VCAM-1 upregulation is independent of IFN-y. 
Extremely high expression of these adhesion molecules on neurovascular endothelium was 
unable to facilitate the infiltration of compensatory numbers of leukocytes into the brain. 
ICAM-1 was also expressed at high concentration on microglia in the absence of IFN-y. 
However, the functional significance of such high levels of adhesion molecule expression 
on these cells in WNV encephalitis in the absence of IFN-y is not clear. 
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This work shows that microglial activation is independent of IFN-y. The activation and 
normalization of activated microglia directly correlated with the appearance and 
disappearance, respectively, of WNV Ag from the brain. Absence of significant neuronal 
apoptosis despite substantial high microglial activation and nodule formation suggest that 
these microglia may be involved directly or indirectly in the clearance of WNV from 
neurones. However, how this occurs is unknown. Further study, both in vivo and in vitro, is 
required to understand the mechanisms by which microglia may be efectively antiviral in 
WNV encephalitis. 
Antibody plays an important role in WNV encephalitis. In the absence of effective antiviral 
therapy for WNV infection, passive protection with Ab could play an important role in 
prophylactic prevention or in reduction of WNV infection following peripheral inoculation. 
However, the failure to protect mice after i.n. inoculation of WNV, even with passive 
transfer of high-dose of HI serum in the i.n. model indicates a more complex involvement of 
Ab in this disease than was previously thought. Moreover, adoptive transfer of HI 
splenocytes was also unable to protect mice from lethal WNV encephalitis in the i.n. model. 
More detailed investigation using passive transfer of high dose HI before and after infection 
and adoptive transfer of splenocytes and lymphocytes subsets via i.e. and other routes will 
be required to understand these complex mechanisms. 
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Appendix 
A) Tris-buffer, pH 7.6 
Tris (Tris hydroxymethyl aminomethane) 
Distilled water 
1 N hydrochloric acid 
24.4g 
1800ml 
74ml 
Dissolve Tris in 1800ml distilled water. Add hydrochloric acid and adjust pH dilute to 7.6 
with cone. HCL and make upto 2L. 
To 2L of O.IM Tris buffer add 
Sodium chloride 
Tween 20 
B) Citrate buffer, pH 6.0 
Citric acid 
Distilled water 
17.54g 
lml 
2.1g 
900ml 
Dissolve citric acid in 900ml distilled water. Adjust pH to 6.0 with NaOH and make up to 
IL. 
C) Carbonate buffer pH 9.1 
Sodium carbonate (Na2C03) 5.72g 
Sodium hydrogen carbonate (NaHC03) 15.12g 
Distilled water 2L 
Dissolve sodium salt in 1800 ml distilled water. Adjust pH to 9.1 with NaOH or HCl and 
make up to 2L. 
D) RBC lysis buffer, pH 7.4 
Ammonium chloride (NH4Cl) 
Potassium hydrogen carbonate (KHC03) 
Sodium Ethylenediaminetetraacetic acid (Na2EDTA 
Distilled water 
8.29g 
1 g 
37.2 mg 
900ml 
Dissolve above contents in 900 ml water and adjust pH to 7.4 with 1M HCl and make up to 
IL. Filter sterilize through a 0.2~tm filter and store at room temperature. 
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